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LIST OF ABBREVIATIONS
a-IgE goat anti rat IgE
[3-hex (3-hexosaminidase
BMMC(s) bone marrow-derived mast cell(s)
BSA bovine serum albumin
CTMC connective tissue mast cell
CRAC calcium release activated calcium current
DAG diacylglycerol
DIDS 4,4' -diisothiocyano-2,2' -stilbenedisulfonate
DNP dinitrophenyl
ELISA enzyme-linked immunosorbent assay
ELISPOT enzyme-linked immunospot
FACS fluorescent-activated cell sorter
FceRI high affinity receptor for IgE
FCS foetal calf serum
FITC fluorescein isothiocyanate




IMDM Iscove's modified Dulbecco's medium
IP3 inositol 1,4,5-trisphosphate
I/V current/voltage
IRk inwardly rectifying potassium current
kDa kilodaltons
LNCM lymph node conditioned medium
LT leukotriene
MMC mucosal mast cell
MMCP mouse mast cell protease
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MW molecular weight
NGF nerve growth factor
NGS normal goat serum
O.D. optical density
ORCi outwardly rectifying chloride current
PBS phosphate buffered saline
PLC phospholipase-C
PKC protein kinase C
PG prostaglandin
P/S penicillin/streptomycin
RBL rat basophilic leukaemia
RMCP-I rat mast cell protease-I
RMCP-II rat mast cell protease-II
RPMC rat peritoneal mast cell
RT room temperature
rhSCF recombinant human stem cell factor
rrSCF recombinant rat stem cell factor
SCF stem cell factor
s.d. standard deviation
s.e.m. standard error of the mean
TB Tyrode's buffer
TB+ Tyrode's buffer + 1 mM Ca2+/lmM Mg
TTL transistor transistor logic
WCR whole-cell recording
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ELECTROPHYSIOLOGICAL TERMS AND UNITS
Current (I) - Amperes (A)
1 mA 1 x 10~3 Amps
1 ^A 1 x 10~6 Amps
1 nA 1 x 10~9 Amps
1 pA 1 x 10~12 Amps
Voltage(V) - Volts (V)
1 mV 1 x 10 3 Volts
Resistance (R) - Ohms (£2)
1 k£2 1 x 103 Ohms
1 MS 1 x 106 Ohms
1 GS 1 x 109 Ohms
Conductance (G) - Siemens (S)
1 nS 1 x 10"9 Siemens
1 pS 1 x 10"12 Siemens
1 fS 1 x 10~15 Siemens
Capacitance (C) - Farads (F)
1 pF 1 x 10~12 Farads
Ohm's Law
V = IxR (IV = lAx IS)
Relationship between resistance and conductance
R = 1/G (IS = 1/S)
The Nernst Equation
Relates the equilibrium potential to the concentration and valence of a particular ion
e.g. for potassium ions, EK = RT/zF In [K]0/[K]; or 2.303 x RT/zF logI0 [K]0/[K]j
where E = the equilibrium (reversal) potential
R = gas constant
T = absolute temperature
z = valence of ion
[K]0 = concentration of potassium ions outside (extracellular)
[K]j = concentration of potassium ions inside (intracellular)
RT/F = 25.26 at 20°C, 26.12 at 30°C and 26.73 at 37°C
N.B. For anions such as CI" ions, the intracellular concentration is divided by the
extracellular concentration.
Current Notations
In this thesis, the standard current notation is adopted i.e. outward currents are
displayed upwards and inward currents are displayed downwards. Note that an
outward current can be caused by movement ofpositive ions out of the cell, or
negative ions into the cell.
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ABSTRACT
Based on biochemical and functional characteristics, mast cells are broadly classified
into mucosal and connective tissue phenotypes. Both types may be effector cells in
the pathogenesis of allergic diseases, but intestinal mucosal mast cells (MMCs) are
also involved in the immune response against intestinal nematodes. Rat bone
marrow-derived mast cells (BMMCs), cultured in the presence of a T lymphocyte
conditioned medium, are analogous to MMCs as defined by the granule content of
the soluble chymase, rat mast cell protease-II (RMCP-II); by the granule
proteoglycan chondroitin sulphate; and by their secretory characteristics. To
investigate the secretory response of BMMCs to IgE-dependent stimulation, a
sensitive, specific and repeatable enzyme-linked immunospot (ELISPOT) assay was
developed to detect the release of RMCP-II from individual cells. Within
populations of BMMCs, only 6-24% of the cells responded to challenge with either
anti-IgE or specific antigen, leaving a large residual refractory population. Pre¬
incubation of mature BMMCs with the multi-functional cytokine, stem cell factor
(SCF), significantly increased (~ 2-fold) the proportion of cells responding to IgE-
dependent stimulation without directly causing mediator release. Furthermore, SCF
enhanced the total percentage release of RMCP-II and (3-hexosaminidase from
populations of mature BMMCs in association with an increased proportion of cells
secreting RMCP-II as detected by ELISPOT. These results suggest that SCF
augments IgE-dependent secretion from rat BMMCs primarily by activating
previously unresponsive cells.
To further characterise the functional phenoiype of rat BMMCs, the
electrophysiological properties of the cells were investigated using the whole-cell
configuration of the patch-clamp technique. Rat BMMCs had a mean membrane
potential of -28.5 mV and a mean whole-cell capacitance of 4.8 pF. With the
amphotericin B perforated-patch technique, both inwardly rectifying (IR) and
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outwardly rectifying (OR) currents were observed in rat BMMCs. The reversal
potential and conductance of the IR current depended on the extracellular K+
concentration, indicating that the channel was K+ selective. The OR current was
reversibly decreased both by lowering the extracellular CI" concentration and by the
CI" channel blocker DIDS, indicating a CI" conductance. The IRK current could also
be detected in the majority of BMMCs using the conventional whole-cell recording
technique at room temperature. In contrast, the activity of the ORu current was
dependent on temperature and the maintenance of cytoplasmic integrity. The ORc,
current may be involved in voltage control of the cell during degranulation.
However, in addition, the ORa current was influenced by changes in extracellular
osmolality, suggesting a possible role in volume control.
These studies provide further insight into the regulation of secretion in rat BMMCs,





Mast cells were first observed by Von Recklinghausen in 1863 but were named by
the German medical student Paul Ehrlich in 1878 (Foreman, 1993). He called the
cells "mastzellan" (well-fed cells) because of the large number of prominent granules
in the cytoplasm which he thought represented phagocytosed material. The granules
took up blue aniline dyes in histological sections, but stained a pinkish-purplish
colour, a process Ehrlich called metachromasia. However, it was subsequently
shown that the granules contained stores of inflammatory mediators such as
histamine which are released during immunological stimulation of the cells (Riley
and West, 1953). This release of inflammatory mediators constitutes the main
functional role of the mast cell in inflammation and allergic reactions.
FUNCTIONAL IMPORTANCE OF MAST CELLS
Although a full review of the role of mast cells in physiological and pathological
processes is beyond the scope of this introduction, a summary of proposed mast cell
functions is provided to emphasise the importance of these cells in immunological
responses.
Mast cells are most commonly regarded as key effector cells in the pathogenesis of
allergic diseases such as asthma, rhinitis, atopic dermatitis, urticaria, anaphylaxis,
and food allergy (Brostoff and Hall, 1993; Miller, 1993b). In these type I
hypersensitivity reactions, mast cells are classically activated by cross-linking of
receptor-bound IgE by multivalent antigen, resulting in the release of a variety of
pre-formed and newly synthesised inflammatory mediators (Table 1.1).
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Preformed Granule Mediators
Mediator Type Mediators Proposed Functions
Biogenic amines Histamine
Serotonin
Permeabilise venules, dilate arterioles
contract bronchial and intestinal smooth




kallikrein, stabilise tryptase, neutralise
major basic protein, stabilise the granule
matrix, modulate cell adhesion
Neutral Proteases Tryptase Degrades fibrinogen, generates C3a from
C3, activates collagenase, increases
pulmonary smooth muscle response to
histamine, degrades VIP
Chymases Generate angiotensin, degrade basement
membranes, activate IL-1 (3 precursor,
stimulate glandular mucus secretion,
degrade substance P
Newly Generated Mediators
Mediator Type Mediator Proposed Functions
Leukotrienes ltc4 Permeabilises venules, augments mucus
secretion, contracts intestinal and
bronchial smooth muscle
ltb4 Upregulates neutrophil adhesion and
chemotaxis, augments mucus secretion,
modulates cell growth and differentiation
Prostaglandins pgd2 Vasodilation, inhibits platelet
aggregation, augments airway reactivity
Phospholipid PAF Activation of platelets, activation of
neutrophils, contraction of intestinal and
bronchial smooth muscle, increases
vasopermeability, chemotactic for
eosinophils
Table 1.1 - Mast cell-derived mediators and their proposed functions (modified from
(Harvima and Schwartz, 1993; Schwartz, 1994). The mediators listed are present to
varying extents in mast cells from different species and different locations. For
example, the chymases represent a number of distinct serine proteases of which
specific types are restricted to certain mast cell subsets (see section on mast cell
heterogeneity in this chapter for further details). The proposed functions of the
mediators have been largely determined in vitro, and in restricted species. VIP =
vasoactive intestinal peptide; PAF = platelet activating factor.
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An exciting development in the study of mast cell biology was the discovery that
mast cells can generate or release various cytokines in addition to the above
mediators (Plaut et al, 1989; Burd et al, 1989; and see Table 1.2). Cytokine
synthesis typically occurs hours after mast cell activation in contrast to the release of
mediators and the generation of arachidonic acid metabolites, which begin within
seconds and last for up to 30 minutes (Harvima and Schwartz, 1993). The
production of these cytokines indicates that mast cells are not only stores of
inflammatory mediators, but also important regulatory cells in the immune response.
Hence, in addition to their role in mediating allergic diseases, mast cell mediators
and cytokines are involved in diverse pathophysiological processes such as chronic
inflammatory responses, wound healing, fibrosis, and the acute sunburn response
(Harvima and Schwartz, 1993; Schwartz, 1994; Gordon et al, 1990; Walsh, 1995).
Despite playing a detrimental role in allergic reactions, mast cells have a number of
important protective functions. For example, TNF-a production by mast cells was
critical for the neutrophilic response and bacterial clearance seen in murine models of
septic peritonitis and pneumonia (Echtenacher et al, 1996; Malaviya et al, 1996).
However, perhaps the most important protective role of mast cells is the defence of
the host against gastrointestinal nematodes. The epithelial and mucosal changes
occurring during intestinal nematode infections have many features that are
characteristic of allergic inflammation, including production of IgE, recruitment of
mast cells, basophils and eosinophils, and altered epithelial secretion (Miller, 1993a).
In rodent models, infection with nematode parasites such as Nippostrongylus
brasiliensis and Trichinella spiralis results in a marked hyperplasia of the intestinal
mast cell population, and these cells are functionally active during spontaneous
expulsion of A. brasiliensis in rats (Woodbury et al, 1984). Furthermore, release of
inflammatory mediators such as histamine, serotonin, prostaglandins, leukotrienes,
platelet-activating factor and chymases have all been quantified during intestinal
responses to parasite infections (Miller, 1993a; Moqbel et al, 1986; MacDonald,
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1994; Miller et al, 1983). Hence, in addition to performing a protective role, mast
cell responses in the gut represent a model for the study of allergic reactions.
Table 1.2 - Cytokines produced by mast cells
Cytokine Type Cytokine Proposed Functions




IL-3* Multilineage (including mast cell) colony
stimulating factor
IL-4* B cell growth factor, isotype switching to
IgE and IgGl, mast cell growth cofactor
IL-5 B cell growth and differentiation factor,
IgA selection, eosinophil differentiation
factor
IL-6* B cell differentiation, induces acute phase
proteins
IL-8 Chemotactic for neutrophils and
basophils
Other factors TNF-a* Activation of macrophages, granulocytes
and cytotoxic cells, increases
leukocyte/endothelial cell adhesion,
induction of acute phase proteins,
stimulation of angiogenesis, enhanced
MHC class I production
TGF-p Stimulates connective tissue growth and
collagen formation, inhibitory to most
immune functions
GM-CSF Proliferation of granulocyte and
macrophage precursors and activators
Table 1.2 - Cytokine production by rodent mast cells (information derived from
(Harvima and Schwartz, 1993; Schwartz, 1994; Gordon et al, 1990; Plautet al, 1989;
Burd et al, 1989; Roitt et al, 1993). The cytokines marked with an asterisk have been
demonstrated in protein form. The expression of the other cytokines has only been
detected as mRNA. TNF-a and IL-4 production has also been demonstrated in
human mast cells.
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ORIGIN AND DEVELOPMENT OF MAST CELLS
Mast cells are normal residents of connective tissue and are found in highest numbers
in areas of the body that interface with the environment, such as the skin, lung and
gastrointestinal tract (Foreman, 1993). However, the origin of mast cells and how
they arise in these tissues is a question that has only recently been resolved. Early
investigators considered many cell types to be mast cell precursors including
fibrocytes, emigrated leukocytes, plasma cells, muscle cells, endothelial cells,
degenerate eosinophils or undifferentiated mesenchymal cells (reviewed in Michels,
1963). Subsequent investigators suggested that mast cells might arise from T
lymphocytes (Guy-Grand et al, 1978; Burnet, 1977). Mast cells also show many
similarities to blood basophils (a circulating granulocyte) including the presence of
cytoplasmic granules containing histamine and proteoglycan, and the presence of
high affinity receptors for IgE on their surfaces. This similarity led to the suggestion
that basophils might be the precursor of mast cells. However, mast cells are not
identical to basophils and can be distinguished morphologically (Galli, 1990),
especially in electron microscopic studies (Dvorak et al, 1983). Mast cells also have
different immunological surface markers to basophils, showing a profile more similar
to macrophages than granulocytes (Valent et al, 1990b). In addition, no studies have
shown that mature basophils can either proliferate or differentiate into mast cells, and
basophils did not lead to mast cell colonies when grown in methylcellulose cultures
(Seder et al, 1991). It is therefore now generally accepted that basophils are
terminally differentiated granulocytes and are not mast cell precursors (Galli, 1990;
Kitamura et al, 1993).
Evidence that mast cells originated from haematopoietic cells was first provided by
studies of beige mice by Kitamura et al. (1977). Beige mice possess two mutant
alleles at the bg locus and are characterised by the presence of giant granules in
various cell types including melanocytes, neutrophils and mast cells (Chi and
Lagunoff, 1975). Transplantation of bone marrow cells from 57BL/6-Z?g,//&(g^, beige
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mice to lethally irradiated +/+ mice resulted in the development of mast cells with
giant granules in the recipient (Kitamura et al, 1977). The haematopoietic cell origin
of mast cells was confirmed in a number of other studies in which mast cells were
grown in culture from bone marrow using factors derived from T lymphocytes
(Nabelefa/, 1981; Nagao et al, 1981; Razin et al, 1981; Schrader et al, 1981; Tertian
et al, 1981; Nakahata et al, 1982). Mast cells were subsequently shown to originate
from multipotential haematopoietic stem cells in studies by Kitamura et al. (1981)
and Nakahata and Ogawa (1982) in which colony forming units resulted in the
formation of other haematopoietic cells in addition to mast cells.
In contrast to other cells of the haematopoietic stem cell lineage, which differentiate
in the bone marrow before being released into the circulation, mast cells do not
circulate as mature cells. Morphologically unidentifiable precursors migrate in the
blood (Kitamura et al, 1979; Sonoda et al, 1982; Zucker-Franklin et al, 1981) and
invade connective or mucosal tissues where they proliferate and differentiate into
mature mast cells (Kitamura et al, 1979; Kasugai et al, 1995). The committed
precursor of the mast cell lineage was recently isolated from murine foetal blood and
was characterised as a cell possessing Thy-l'° c-kithl markers, cytoplasmic granules,
RNAs encoding mast cell proteases, but lacking expression of the IgE receptor
(Rodewald et al, 1996). These cells generated functionally competent mast cells in
vitro, but lacked developmental potential for other haematopoietic lineages.
Mast Cell Development in Laboratory Animals
1. Non T-cell dependent
The use ofmutant mice
The study of mast cell development has been aided by the use of strains of mutant
mice, especially the W/Wv mutant and the Sl/Sf1 mutant. Mice with two mutant
alleles at the W locus on chromosome 5 suffer from a combination of defects
including macrocytic anaemia, sterility, lack of hair pigmentation and deficiency of
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mast cells (Kitamura et al, 1978). The same set of defects are seen in mice with a
double gene dose of mutant alleles at the SI (steel) locus on chromosome 10
(Kitamura and Go, 1979). The reduction in erythrocytes, germ cells, melanocytes
and mast cells in W mutant mice is due to a defect in the cells themselves or their
precursors (Kitamura et al, 1993). Hence, the number of mast cells in WAV" mice
can be normalised by transplanting bone marrow cells from normal (+/+) mice
(Kitamura et al, 1978; Galli and Kitamura, 1987). In contrast, the precursor cells of
SUSf* mice are normal and transplantation of bone marrow cells from Sl/St* mice to
WAV" mice can also reverse the deficiency in mast cells (Kitamura and Go, 1979),
suggesting that the defect in S//Sf mice was a deficiency in a growth factor. When
skin from WAVv mice was grafted onto normal (+/+) mice or Sl/Sf mice, mast cells
appeared in the graft suggesting that normal precursor cells from the host had
differentiated into mast cells within the graft microenvironment. However, when
skin from S//Sf mice was grafted onto normal (+/+) mice or WAV1' mice, no mast
cells developed in the graft, indicating that the deficiency in mast cells in S//Sf mice
was due to a deficiency in the skin microenvironment (Kitamura and Go, 1979;
Matsuda and Kitamura, 1981).
Analysis of the W locus
Molecular analysis of the W locus has revealed it to be identical to the c-kit proto-
oncogene (Chabot et al, 1988; Geissler et al, 1988) which encodes a transmembrane
tyrosine kinase receptor (Chabot et al, 1988; Yarden et al, 1987). The c-kit receptor
is structurally similar to the receptors for colony stimulating factor and platelet-
derived growth factor, having an extracellular domain with five immunoglobulin-like
repeats and a tyrosine kinase split into two domains by an insert sequence of variable
length (Yarden et al, 1987; Qiu et al, 1988; and see Figure 1.1). The rat c-kit protein
contains a 522 amino acid extracellular domain, a 25 amino acid transmembrane
domain, and a 432 amino acid intracellular domain, although the structure and amino
acid sequence is well preserved in both rats and humans (Kitamura et al, 1993). The
19
various mutations at the W locus cause a number of abnormalities in the c-kit
receptor including absence of the transmembrane domain, absence of kinase activity
or reduced expression of the extracellular domain (Nocka et al, 1990b; Tan et al,
1990).
In rats, homozygous mutants at the "white spotting locus" (WsAVs) had a similar
phenotype to W/Wv mice, including anemia and deficiency in mast cells (Niwa et al,
1991). Analysis of the Ws locus revealed that the abnormalities were due to a 12






















Figure 1.1 - Schematic representation of the rat c-kit receptor (modified from
(Kitamura et al, 1993 and Girault, 1994). The receptor has an extracellular domain
with five immunoglobulin-like repeats and an intracellular tyrosine kinase split into
two domains by an insert sequence. The numbers in brackets show the amino acid
sequence. The autophosphorylation site is a tyrosine residue (amino acid 824).
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Analysis of the SI locus
Molecular analysis has shown that the steel (S/) locus encodes the ligand for the c-kit
tyrosine kinase receptor (Copeland et al, 1990; Huang et al, 1990; Zsebo et al,
1990a) which was variably termed stem cell factor (Zsebo et al, 1990b), mast cell
growth factor (Williams et al, 1990), and kit ligand (Flanagan and Leder, 1990;
Huang et al, 1990; Nocka et al, 1990a) by the investigators who first described it.
The ligand is also occasionally referred to as steel factor (Kitamura et al, 1993). In
this thesis, the currently favoured term, stem cell factor (SCF), is used. The
purification of stem cell factor was initially based on its ability to stimulate the
growth of mouse bone marrow-derived mast cells (Nocka et al, 1990a) and
established mast cell lines (Williams et al, 1990). It is an extensively and
heterogeneously glycosylated protein with a molecular weight of 28 - 35 kDa (Zsebo
et al, 1990b). Injection of soluble SCF into Sl/Sf mice reversed the characteristic
macrocytic anaemia and mast cell deficiency (Zsebo et al, 1990a), indicating that
these mutants were deficient in active SCF. The main sources of SCF in vivo are
fibroblasts (Nocka et al, 1990a; Flanagan and Leder, 1990) and bone marrow stromal
cells (Williams et al, 1990), but the molecule has been cloned and exists in
membrane bound and soluble forms, both of which are biologically active (Anderson
et al, 1990). The membrane bound form is produced by alternative splicing and is
missing in the Sf mutant (Flanagan et al, 1991) suggesting that this form may be
more important in the intact organism. Hence, analysis of the gene products of the W
and SI loci has explained the identical clinical syndromes seen in W/Wv and Sl/Sf*
mice, and led to the identification of SCF, a new mast cell growth factor.
Effects offibroblasts and SCF on mast cell development in vivo
The inter-relationship between fibroblasts and mouse bone marrow-derived mast
cells (BMMCs) was demonstrated in studies using diffusion chambers (Ru et al,
1990). When BMMCs from normal (+/+) mice were injected into the peritoneal
cavity of W/Wv mice (which lack c-kit but express SCF), the cells survived (Nakano
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et al, 1985). In contrast, normal BMMCs injected into the peritoneal cavity in
diffusion chambers did not survive in WAVv mice, suggesting a cell-bound survival
factor could not gain access to the cells (Ru et al, 1990). When 3T3 fibroblasts were
included in the diffusion chambers, the BMMCs proliferated, indicating that the
survival factor was present on the surface of the fibroblasts.
Further evidence for the role of SCF in mast cell proliferation was obtained from
studies in which the soluble form of the cytokine was injected into normal animals.
Subcutaneous injection of recombinant rat SCF164 (a biologically active, soluble form
of SCF expressed in E-coli) into normal mice induced the development of mast cells
in the skin, and systemic administration of rrSCF164 to rats resulted in a striking
expansion of the mast cell population in the skin, lung, liver, spleen, stomach and
small intestine (Tsai et al, 1991a). A similar, reversible, expansion of the mast cell
population was seen in baboons and cynomolgus monkeys after subcutaneous
injections with recombinant human SCF (Galli et al, 1993), and rhSCF also induced
cutaneous mast cell hyperplasia in humans (Costa et al, 1996).
SCFIc-kit interactions were also shown to contribute to the intestinal mastocytosis
that accompanies intestinal nematode infections in laboratory rodents. Treatment of
mice with a monoclonal antibody to c-kit (Grencis et al, 1993) or SCF (Donaldson et
al, 1996), or rats with a polyclonal sheep anti rat SCF antibody (Newlands et al,
1995) significantly decreased the mast cell hyperplasia in response to infections with
Trichinella spiralis (Grencis et al, 1993; Donaldson et al, 1996; Newlands et al,
1995) or Nippostrongylus brasiliensis (Newlands et al, 1995).
Effects offibroblasts and SCF on mast cell development in vitro
The inter-relationship between fibroblasts and mouse BMMCs was investigated in
vitro by co-culturing BMMCs from normal (+/+), WAV1 and S//Sf mice with
NIH/3T3 fibroblasts (reviewed in Kitamura et al, 1993). The BMMCs from normal
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and Sl/Sf1 mice proliferated, but the cells from the WAVv mice (which lack the c-kit
receptor) disappeared. In addition, fibroblasts derived from Sl/St1 mice (which lack
SCF) were unable to support BMMCs from normal mice. These results suggested
that interaction between SCF and the c-kit receptor was essential for fibroblast-
dependent proliferation of BMMCs.
In accord with in vivo studies, SCF also promoted the proliferation of both mouse
(Tsai et al, 1991b; Takagi et al, 1992) and rat (Haig et al, 1994) BMMCs and
peritoneal mast cells in vitro. However, when used alone, SCF could not stimulate
the development of mast cells from primitive mast cell progenitors, suggesting that
its effect was probably dependent both on other cofactors and the degree of
maturation of the cells (Rennick et al, 1995; Lantz and Huff, 1995a).
In addition to stimulating the development and proliferation of mast cells, SCF also
possesses a number of other important functional properties. SCF was shown to be a
chemotactic agent for mast cells (Blumejensen et al, 1991; Meininger et al, 1992),
and the interaction between SCF and c-kit could regulate the adhesion of mast cells
to fibroblasts (Adachi et al, 1992) or extracellular matrix components such as
fibronectin (Dastych and Metcalfe, 1994; Kinashi and Springer, 1994). These
functions could be important for controlling the migration of mast cells into
appropriate tissues. Furthermore, recent studies have demonstrated that SCF can also
influence the secretory function of mast cells. Treatment with SCF in isolation
directly induced mediator release from mouse peritoneal mast cells (Coleman et al,
1993), rat peritoneal mast cells (Nakajima et al, 1992; Koike et al, 1993; Taylor et al,
1996), mouse skin mast cells (Wershil et al, 1992) and human skin mast cells (Costa
et al, 1996) without the need for IgE receptor activation. SCF also upregulated IgE-
dependent mediator release in a number of connective tissue and mucosal mast cell
types. For example, brief preincubations (10 - 15 minutes) with the cytokine
enhanced IgE-dependent mediator release from human skin, lung and intestinal mast
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cells (Columbo et al, 1992; Bischoff and Dahinden, 1992; Bischoff et al, 1996).
These important observations suggest that SCF may be directly involved in the
regulation of immune responses by modulating mast cell secretory function, and will
be discussed in more detail in chapter 4.
2. T-cell dependent mast cell development
Infection of normal mice and rats with intestinal nematodes such as Nippostrongylus
brasiliensis or Trichinella spiralis results in a massive hyperplasia of mast cells in
the intestinal lamina propria (Miller and Jarrett, 1971; Befus and Bienenstock, 1979).
A similar, but reduced, response was also seen in Ws/Ws rats, normally deficient in
intestinal mast cells (Arizono et al, 1993), although mast cells in connective tissue
sites were not increased. This intestinal mastocytosis was shown to be T cell-
dependent in studies using congenitally athymic mice (Ruitenberg and Elgersma,
1976), thymectomised rats (Mayrhofer and Fisher, 1979), and adoptive transfer of
primed T cells followed by nematode challenge in rats (Nawa and Miller, 1979). The
importance of T-cell derived factors for mast cell development was also shown when
mast cells were grown in liquid culture from hematopoietic cells of the rat (Haig et
al, 1982) or mouse (Hasthorpe, 1980; Nabel et al, 1981; Nagao et al, 1981; Razin et
al, 1981; Schrader et al, 1981; Tertian et al, 1981). Five of these six groups used
growth factors derived from stimulated T cells, but Nagao et al. used a culture
medium from a mouse leukemia cell line (WEHI-3). The mast cell growth factor in
WEHI-3 medium was subsequently purified and designated interleukin 3 (IL-3) (Ihle
et al, 1983). However, other T cell derived cytokines, including IL-4, IL-9 and IL-
10, have subsequently been shown to influence mast cell development either in vivo
and/or in vitro (Kitamura et al, 1993).
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Effects of interleukins on mast cell development in vivo
Repetitive administration of purified IL-3 to nude athymic mice resulted in a 30-fold
increase in intestinal mucosal mast cells (Abe et al, 1988), and restored the host's
ability to develop a mastocytosis in response to the intestinal nematode Strongyloses
ratti (Abe and Nawa, 1988). In addition, perfusion with IL-3 resulted in the
development of mast cells in the skin of W/W1' mice (Ody et al, 1990). However, as
these mice are capable of producing IL-3, the significance of this finding in vivo is
not known. Further evidence for the role of IL-3, and additionally IL-4, in mast cell
development is provided by experiments showing the effect of antibodies directed
against the two cytokines on Nippostrongylus brasiliensis-induced mastocytosis in
mice (Madden et al, 1991). Administration of either antibody caused 40-50%
inhibition of mast cell numbers, but concurrent administration of both antibodies
suppressed the mast cell response by 85-90%, suggesting that the cytokines may act
synergistically. A reduced intestinal mast cell response to the nematode Trichuris
muris was also seen in mice treated with a monoclonal antibody to the IL-4 receptor,
again suggesting a role for this cytokine in vivo (Else et al, 1994).
Effects of interleukins on mast cell development in vitro
When mouse (Chiu and Burrall, 1990; Razin et al, 1984; Ihle et al, 1983) or rat (Haig
et al, 1988) bone marrow cells are cultured in the presence of IL-3, large numbers of
mast cells can be generated as virtually a pure population. In both systems, other cell
types (neutrophils, eosinophils and macrophages) proliferate initially in response to
IL-3, but the response is not sustained and the cells die out (Kitamura et al, 1993).
IL-3 also supported the survival of mouse peritoneal mast cells in methylcellulose
cultures (Tsuji et al, 1990) and stimulated the growth of rat peritoneal mast cells
(Haig et al, 1994). However, IL-3 did not promote mast cell colony formation when
used to stimulate highly purified c-kiC cells derived from the peritoneal cavity or
mesenteric lymph nodes of Nippostrongylus brasiliensis infected mice, suggesting
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that the effect of the cytokine was dependent on the degree of maturation of the cells
(Lantz and Huff, 1995a).
IL-4 did not sustain the long term growth of bone marrow-derived mast cells, but
acted synergistically with IL-3 in the stimulation of mouse BMMCs (Schmitt et al,
1987), neoplastic mast cell lines (Smith and Renwick, 1986), and peritoneal cells
(Tsuji et al, 1990). When used in combination with SCF, IL-4 also caused the
initiation and proliferation of mast cell colonies from primitive progenitors derived
from mesenteric lymph node cells (Rennick et al, 1995).
IL-9 prolonged the survival of mouse BMMCs and in conjunction with IL-3,
synergistically enhanced the growth of primary bone marrow cultures (Moeller et al,
1989) and IL-3 dependent mast cell lines (Hultner et al, 1989; Hultner et al, 1990).
The effects of IL-10 on mast cell growth were investigated by Thompson-Snipes et
al. (1991). IL-10 alone did not support the proliferation of mast cell lines, but it
markedly enhanced their growth when used in combination with IL-3 and IL-4. In
fact, the combination of IL-10 and IL-4 was as effective at stimulating mast cell
growth as IL-3 alone, but optimum conditions were provided by the three cytokines
together. When used in combination with SCF, IL-10 was also an efficient
differentiation and maturation factor for mast cells derived from primitive
progenitors in mesenteric lymph node cells (Rennick et al, 1995).
Other factors affecting mast cell development
Another fibrobiast-derived factor, nerve growth factor (NGF), was shown to increase
the number of mast cells in neonatal rats (Aloe and Levi-Montalcini, 1977), and
acted synergistically with IL-3 to stimulate the growth of mouse BMMCs in vitro
(Matsuda et al, 1991). NGF also enhanced the survival of rat peritoneal mast cells
placed in culture in the absence of other cytokines (Horigome et al, 1994), but did
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not lead to proliferation of these cells. Immunoglobulin E (IgE) was also reported to
act in combination with IL-3 to promote mast cell differentiation (Kawanashi, 1986),
and IgE immune complexes could stimulate the development of mast cell committed
progenitors from normal mouse bone marrow (Ashman et al, 1991).
Interferon y (IFN-y) was shown to inhibit the development of IL-3-stimulated mouse
BMMCs, but did not affect the proliferation of mature cells, suggesting an action on
mast cell precursors (Nafziger et al, 1990). IFN-y also inhibited the proliferation of
mouse peritoneal mast cells in cultures containing IL-3 and IL-4 (Takagi et al, 1990).
The IL-3-dependent proliferation of mouse BMMCs was also suppressed by
transforming growth factor-(31 (Broideetal, 1989).
Mast Cell Development in Humans
In the rodent systems described above, both fibroblast-dependent and T-cell
dependent mechanisms for stimulating mast cell development were established. In
the human system, mast cells (analogous to skin mast cells) developed when
umbilical cord blood cells were co-cultured with 3T3 fibroblasts (Furitsu et al, 1989).
Recombinant human SCF also stimulated the growth of mast cells from their
progenitors in human bone marrow (Valent et al, 1992; Kirshenbaum et al, 1992),
peripheral blood (Valent et al, 1992), foetal liver (Irani et al, 1992), and umbilical
cord blood (Mitsui et al, 1993). The circulating mast cell progenitor in humans has
now been characterised as a c-kit+, CD34+ colony forming cell (Kirshenbaum et al,
1991; Agis et al, 1993). In addition to SCF, nerve growth factor has also been shown
to have mast cell growth promoting properties in human haematopoietic cultures
(Matsuda et al, 1988a; Matsudaefa/, 1988b).
In humans, IL-3 appears to be the principal growth factor that induces development
of basophils from bone marrow (Kirshenbaum et al, 1989; Valent et al, 1989), cord
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blood (Dvorak et al, 1989), or fetal liver cells (Irani et al, 1992). In contrast to mice
and rats, IL-3 does not promote the development of mast cells from human bone
marrow or cord blood (Mitsui et al, 1993), although it generally increases the total
number of mast cells in cultures stimulated with SCF. However, the proportion of
mast cells in IL-3 containing cultures was comparable to that seen with SCF alone,
suggesting that the effect is not selective for mast cells (Ishizaka et al, 1993). In
addition, IL-3 receptors could not be detected on human lung mast cells (Valent et al,
1990a).
Yanagida et al (1995) examined the effects of T-helper 2-type cytokines on the
survival of human mast cells grown to 100% purity from cord blood in the presence
of SCF and IL-6 (Yanagida et al, 1995). After withdrawal of the cytokines, the mast
cells underwent apoptosis within 2 to 6 days. However, addition of SCF, IL-3, IL-4,
IL-5 or IL-6 prolonged their survival in a dose-dependent manner, whereas other
cytokines such as IL-2, IL-9, IL-10, IL-11, TNF-a, TGF-|31, or NGF had no
survival-promoting effect (Yanagida et al, 1995). IL-6 was also shown to enhance
SCF-dependent growth and maturation of mast cells derived from umbilical cord
blood mononuclear cells (Saito et al, 1996). In other studies, neither IL-4 nor IL-9
appeared to have any growth promoting activity for human mast cells (Kirshenbaum
et al, 1989; Valent et al, 1992), but IL-4 was shown to down-regulate the c-kit
receptor on human bone marrow progenitor cells and neoplastic mast cell lines
(Sillaber et al, 1991).
MAST CELL HETEROGENEITY
It has been increasingly recognised over the last 15-20 years that mast cells from
different tissues exhibit considerable variations in their morphological, biochemical
and functional characteristics (reviewed in Galli, 1990). This heterogeneity was first
observed in the rat in which mast cells of the intestinal mucosa were distinguished
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from those in the skin by virtue of their histochemical and secretory properties
(Enerback, 1966c; Enerback, 1966b; Enerback, 1966a). This led to the common
usage of the terms "mucosal mast cells" (MMCs) and "connective tissue mast cells"
(CTMCs) to describe the two subpopulations. Mast cell heterogeneity is now well
documented in the rat, mouse, sheep and humans, and is defined in terms of
histochemical characteristics, the content of granule mediators, and functional
properties (Barrett and Pearce, 1993).
Histochemical characteristics
Enerback (1966) reported that, in contrast to mast cells in rat skin, mast cells in the
intestinal mucosa were sensitive to routine formalin fixation and could not be
identified in standard histological sections. However, following appropriate fixation
and sequential staining with alcian blue and safranin, the MMCs stained blue in
comparison to the CTMCs which stained with safranin and were predominantly red
(Enerback, 1966b). This staining sequence has been widely used to characterise mast
cells from various origins, tissues or species as either mucosal or connective tissue
types respectively. Hence, rat BMMCs, rat basophilic leukaemia (RBL-2H3) cells,
mouse MMCs, mouse BMMCs and human lung mast cells stain with alcian blue,
whereas rat and mouse peritoneal mast cells stain with safranin (Katz et al, 1985).
Unfortunately, this method is not a totally reliable indicator of mast cell subsets
because immature CTMCs stain with alcian blue (Combs et al, 1963) and CTMCs
from different connective tissue locations in the rat show marked differences in
safranin staining depending on the site of origin (Tainsh and Pearce, 1992).
Differences in histologic staining characteristics between mast cell subpopulations
are aiso seen with beibeiine sulphate which forms a strong fluorescent complex with
heparin in rat CTMCs, but does not bind to rat MMCs (Enerback, 1974) or rat
BMMCs (MacDonald, 1994). This variation in dye binding properties reflects the
presence of different proteoglycans in the two subpopulations (see below).
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Heterogeneity of Granule Mediators
Proteoglycan heterogeneity
Proteoglycans are a major granular constituent of all mast cells, but the predominant
type varies among subpopulations. Each class of proteoglycan has distinctive
glycosaminoglycans with characteristic negative-charge densities conferred by the
degree of sulphation of the dissacharides. Rat peritoneal and skin mast cells contain
heparin (Schiller and Dorfman, 1959; Horner, 1971; Yurt et al, 1977), whereas
intestinal MMCs (Stevens et al, 1986), BMMCs (Broide et al, 1988) and rat
basophilic leukaemia cells (Seldin et al, 1985) contain predominantly chondroitin
sulphate di-B. Subsequent work indicated that intestinal MMCs from rats infected
with Nippostrongylus brasiliensis contained chondroitin sulphate E and dermatan
sulphate (Kusche et al, 1988). In the mouse, CTMCs contain heparin whereas
BMMCs contain chondroitin sulphate E (Razin et al, 1982). Mouse intestinal MMCs
have not been purified to date, but the non-heparin nature of their proteoglycan has
been implied by their inability to stain with berberine sulphate (Nakano et al, 1985)
and their alcian blue+ / safranin" staining characteristics (Crowle and Phillips, 1983).
In humans, cutaneous mast cells contain heparin (Metcalfe et al, 1980), whereas
intestinal mucosal mast cells contain chondroitin sulphate E (Eliakim et al, 1986;
Gilead et al, 1987). Human lung mast cells, considered to be a mucosal phenotype
on the basis of their alcian blue and berberine sulphate staining (Flint et al, 1985)
appear to represent an intermediate form, containing both heparin and chondroitin
sulphate E (Stevens et al, 1988; Thompson et al, 1988).
Protease heterogeneity
Mast cell subpopulations can also be defined on the basis of their content of serine
proteases. Two antigenically distinct serine proteases, of chymotryptic specificity,
have been isolated from rat mast cells. These chymases have been designated rat
mast cell protease I (RMCP-I) and rat mast cell protease II (RMCP-II) (Katanuma et
al, 1975; Woodbury et al, 1978; Woodbury et al, 1978a; Woodbury and Neurath,
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1980). Although these chymases have similar substrate specificity (Yoshida et al,
1980), they can be distinguished on the basis of their physico-chemical and
immunological properties (Woodbury et al, 1978; Woodbury et al, 1978a; Woodbury
et al, 1978b). In contrast to RMCP-II, which is highly soluble (Woodbury and
Neurath, 1980), RMCP-I is insoluble in physiological buffers and remains heparin-
bound both in the granule and following secretion (Schwartz et al, 1981).
Specific antibodies raised against these enzymes have been used to characterise the
protease phenotype of rat mast cells in different locations. Mast cells in the skin,
tongue, intestinal serosa and lung parenchyma, which by histochemical techniques
have been identified as CTMCs, contained only RMCP-I (Gibson and Miller, 1986).
Cells in the jejunal lamina propia and bronchial epithelium, previously classified as
MMCs, contained RMCP-II exclusively (Gibson and Miller, 1986). In a more
detailed study of the gastrointestinal tract (Gibson et al, 1987), the distribution of
mast cells staining with alcian blue (MMCs) or safranin (CTMCs) correlated closely
with the distribution of cells staining for the presence of RMCP-II or RMCP-I
respectively. Hence, the presence of RMCP-II or RMCP-I can be used to identify rat
mast cells as either MMCs or CTMCs. However, using paired immunofluorescence,
Huntley et al. (1990a) showed that 17 - 23% of the mast cells in the gastric
submucosa, liver, and peribronchial regions of the lung were identified as possessing
both RMCP-I and RMCP-II, but the significance of this finding was not determined.
Rat BMMCs, which can be grown to homogeneity from normal rat bone marrow
using an IL-3-rich T cell-conditioned medium (Haig et al, 1982; Haig et al, 1988),
possessed exclusively RMCP-II on immunohistochemical analysis, thus
demonstrating their identity with intestinal mucosal mast cells (McMenamin et al,
1987). Similarly, RBL-1 cells (an earlier passage of the tumour used to produce
RBL-2H3 cells) possessed exclusively RMCP-II, suggesting homology between
these cells and rat mucosal mast cells (Seldin et al, 1985). Protease heterogeneity in
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rat mast cells also extended to tryptase, which was only detected in CTMCs (Chen et
al, 1993).
In the mouse, five mast cell chymases (MMCP-1, -2, -3, -4, -5), two tryptases
(MMCP-6 and -7), and one carboxypeptidase have been reported (Reynolds et al,
1990; Schwartz, 1994). MMCPs-3, -4, -5 and -6 and mast cell carboxypeptidase are
present in CTMCs, whereas MMCP-1 and -2 are present in MMCs (Schwartz, 1994).
However, in contrast to the rat, mouse BMMCs show immunoreactivity to both
CTMC and MMC proteases (Newlands et al, 1991). They can not, therefore, be
definitively categorised as a mucosal phenotypc based on protease expression, and
may represent the immature stages of both MMCs and CTMCs.
In humans, the differentiation of mast cells into mucosal or connective tissue
phenotypes is less clear cut than in rodents. Two mast cell proteases, chymase and
tryptase, have been isolated along with a carboxypeptidase and a cathepsin G-like
protease (Schwartz, 1994). Schwartz et al. defined two types of human mast cell
based on the presence or absence of chymase (Irani et al, 1986; Schwartz et al,
1987). Cells containing only tryptase (MCT) were predominant in the lungs, and
represented essentially all of the cells in the intestinal mucosa (Irani et al, 1986).
Mast cells containing both tryptase and chymase, along with carboxypeptidase and
cathepsin G-like protease (MCtc), were predominant in the skin and intestinal
submucosa (Irani et al, 1986; Schwartz, 1994). Mast cells derived from cord blood
in the presence of SCF were recently shown to be of the MCtc phenotype (Nilsson et
al, 1996). Using the rodent classification, MCT cells could be loosely regarded as
MMC phenotype and MCtc cells as CTMC phenotype. However, the notation can
not be rigidly applied as shown by the equal numbers of MCT and MCtc cells found
in the nasal mucosa (Schwartz, 1994).
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Heterogeneity ofother mediators
Variation in the content, or generation, of other mast cell mediators also occurs
between the subpopulations. Rat peritoneal mast cells contain, on average, 20 pg
histamine per cell, whereas rat cutaneous and intestinal mast cells contain 4 and 1
pg/cell respectively (Barrett et al, 1985; Befus et al, 1982). Rat BMMCs contained a
mean of 2.7 pg histamine per cell (MacDonald, 1994).
The generation of leukotrienes and prostaglandins also vary in CTMCs and MMCs.
Following activation with anti-IgE, rat peritoneal mast cells generated exclusively
prostaglandin D2 (PGD2) (Lewis et al, 1982), whereas intestinal MMCs and BMMCs
synthesised approximately equal quantities of PGD2 and leukotriene C4 (LTC4)
(Heaveyefa/, 1988; Broide et al, 1988).
Functional heterogeneity
The most important aspect of mast cell heterogeneity, in terms of clinical relevance,
is the variation in functional characteristics seen between mast cell subpopulations.
This is manifested experimentally as variations in susceptibility to secretagogues or
anti-allergic drugs (Barrett and Pearce, 1993). The first example of functional
heterogeneity was provided by Enerback (1966) who found that compound 48/80, a
known secretagogue for rat CTMCs, failed to cause degranulation of intestinal
MMCs in situ (Enerback, 1966a; Enerback, 1974). Subsequent studies confirmed
that, in contrast to rat peritoneal CTMCs, neither isolated intestinal rat MMCs (Befus
et al, 1982) nor rat BMMCs (Broide et al, 1988) responded to compound 48/80.
Rat intestinal MMCs also showed a minimal or complete lack of response to a range
of neuropeptides including somatostatin, vasoactive intestinal peptide, neurotensin
and bradykinin (Shanahan et al, 1985). In contrast, these compounds were potent
secretagogues for rat peritoneal mast cells. Substance P triggered histamine release
from both populations of cells, but the response in MMCs was only 33% of that in
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peritoneal mast cells (Shanahan et al, 1985). Broide et al. (1988) found that rat
BMMCs were unresponsive to both somatostatin and substance P.
Rat intestinal MMCs and peritoneal CTMCs also differ in their response to the anti¬
allergic drugs disodium cromoglycate and theophylline (Pearce et al, 1982). These
drugs effectively inhibited IgE-mediated histamine secretion from peritoneal mast
cells, but were without effect on isolated intestinal MMCs (Pearce et al, 1982).
Likewise, disodium cromoglycate failed to inhibit IgE-dependent mediator release
from rat BMMCs (Broide et al, 1988).
Despite these apparently clear differences in functional characteristics between
mucosal and connective tissue type mast cells in the rat, variations occur within
subpopulations both in the same animal, and between species. For example, rat
cutaneous mast cells were less responsive to compound 48/80 than rat peritoneal
mast cells (Barrett et al, 1985), and mouse cutaneous mast cells showed different
kinetics of histamine release than that of peritoneal mast cells (He et al, 1990).
Marked differences in the response to secretagogues were also seen when rat CTMCs
from various locations (peritoneal cavity, skin, mesentery and lung) were compared
(Tainsh and Pearce, 1992). In addition, mouse peritoneal mast cells are less
responsive to compound 48/80 than rat peritoneal mast cells (Barrett and Pearce,
1983), and are not stabilised by disodium cromoglycate (Leung et al, 1984).
In humans, it is not possible to predict the functional phenotype of a mast cell from
its proteoglycan or protease composition. Human skin mast cells (MCtc) respond to
compound 48/80 (Lawrence et al, 1987; Benyon et al, 1989), whereas colonic
submucosal mast cells (also MCtc) do not (Rees et al, 1988; Liu et al, 1990).
Similarly, disodium cromoglycate does not inhibit IgE-dependent histamine release
from human skin mast cells (Clegg et al, 1985; Lowman et al, 1988), but has a
partial effect on colonic submucosal mast cells (Liu et al, 1990).
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The functional heterogeneity of rat mast cells also extends to their
electrophysiological properties (Lindau and Fernandez, 1986b), but this will be the
subject of a more detailed review at the end of this chapter.
Regulation ofmast cell phenotypes
The studies described in the previous sections clearly show that proliferation of
MMCs is dependent on T cell-derived cytokines and that development of CTMCs
requires the interaction between stem cell factor and the c-kit receptor. However, this
simplistic distinction does not fully explain the derivation of the two phenotypes.
WAV1' and Sl/Slrf mice (which lack the c-kit receptor and SCF respectively) lack both
CTMCs and MMCs, suggesting that SCF is required for the development of both cell
types in vivo. In addition, systemic administration of SCF to normal rats resulted in
expansion of both the CTMC and MMC populations (Tsai et al, 1991a). SCF could
also prevent apoptosis of IL-3-dependent mouse mast cells following removal of the
IL-3 (Mekori et al, 1993). However, pure mast cell populations can be grown from
both mouse (Ihle et al, 1983)and rat (Haig et al, 1988) bone marrow in the presence
of IL-3 alone, and systemic administration of IL-3 to WAVv mice increased the
number of cutaneous mast cells (Tsai et al, 1991a). Hence, some degree of overlap
appears to exist between the two signalling systems, and deficiencies in one can be
partially overcome by additional provision of the other, at least in experimental
systems.
The mechanisms governing the development of mast cell phenotypes are complex, as
highlighted by numerous studies which document the capacity of mouse mast cell
populations to change phenotype from MMC to CTMC, or vice versa. When cloned
mouse peritoneal mast cells were injected into WAVv mice, they gave rise to both
connective tissue and mucosal mast cells in the appropriate tissue locations
(Kobayashi et al, 1986). Mouse peritoneal mast cells also produced berberine
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sulphate-negative mast cells when cultured in methylcellulose with IL-3 and IL-4,
but injection of these "MMCs" back into the peritoneum of WAV1" mice resulted in a
reversion to the CTMC phenotype (Kanakura et al, 1988). Similarly, when mouse
BMMCs were co-cultured with 3T3 fibroblasts, the cells acquired the characteristics
of CTMCs including a marked increase in histamine content, de novo synthesis of
heparin, positive staining with safranin, and an increase in the granule content of
carboxypeptidase A (Levi-Schaffer et al, 1986; Dayton et al, 1988). In addition,
injection of IL-3-dependent cultured mouse mast cells into the peritoneal cavity, skin
or gastrointestinal mucosa of WAV1 mice replenished both the connective tissue and
mucosal mast cell pools (Nakano et al, 1985). Mouse BMMCs treated with either
nerve growth factor (NGF) (Matsuda et al, 1991) or SCF (Tsai et al, 1991b) also
acquired connective tissue type characteristics such as increased histamine and
heparin, and staining with safranin and berberine sulphate. Taken together, these
experiments suggested that mouse mast cells could "transdifferentiate" between
phenotypes (Barrett and Pearce, 1993). However, as already stated, mouse BMMCs
do not have the same protease expression as intestinal MMCs and can not be
regarded as mature mucosal mast cells. It is likely, therefore, that mouse BMMCs
represent an immature phenotype with the ability to further differentiate into
connective tissue or mucosal types if placed in the appropriate microenvironment.
Gurish et al. (1995) provided further evidence for tissue regulated differentiation and
maturation by injecting v-abl immortalized mast cell lines into normal mice. These
cells have a protease phenotype analogous to mouse BMMCs, but following
infiltration into the liver, spleen and intestine they underwent progressive
differentiation and maturation, eventually expressing the same proteases as the
indigenous mast cells of the specific organs (Gurish et al, 1995).
In contrast to the above studies, rat BMMCs, which on biochemical and functional
analysis appear to be identical to rat MMCs, did not develop a CTMC phenotype
when co-cultured with 3T3 fibroblasts, as assessed by the levels of RMCP-I and -II
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and berberine sulphate staining (MacDonald et al, 1996). However, when mast cells
were cultured from the bone marrow of Ws/Ws rats in the presence of either SCF
alone, or concanavalin A-stimulated spleen cell conditioned medium and fibroblasts,
a proportion of the cells developed a mixed phenotype containing both RMCP-I and
RMCP-II (Tei et al, 1994). Small crystalline structures staining weakly for RMCP-I
were also seen when BMMCs derived from normal rats were incubated in the
presence of SCF (Haig et al, 1994). Hence, in the rat, SCF can induce some
characteristics of CTMCs in developing BMMCs, but complete transdifferentiation,
as seen in the mouse, does not appear possible.
In human patients with severe immunodeficiency or HIV infection there are
markedly decreased numbers of MMCs in the intestinal mucosa, but normal numbers
of CTMCs in the submucosa (Irani et al, 1987). These observations indicate not only
the T-cell dependency of mucosal mast cells, but also suggest that CTMCs in man
are terminally differentiated and do not have the capacity to dramatically change
phenotype.
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STIMULUS-SECRETION COUPLING IN MAST CELLS
The main biological function of mast cells is the release of inflammatory mediators
and cytokines. Although this process can be triggered by a variety of immunological
and non-immunological stimuli, the most important signalling pathway in vivo is by
aggregation of surface bound immunoglobulin E (IgE) by specific antigen. In this
section, the activation of mast cells via the IgE pathway is reviewed.
The high-affinity IgE receptor
Mast cells and basophils express on their surface a protein that binds the Fc region of
IgE with high specificity and affinity (Alber and Metzger, 1993). The IgE receptor,
known as FceRl, is a tetrameric complex of non-covalently attached subunits,
consisting of one a (45 kDa), one (3 (33 kDa) and two y (9 kDa) subunits, designated
af3y2 (Alber and Metzger, 1993, and see Figure 1.2A). The genes for the a and y
subunits are situated close together at the distal end of chromosome 1 in mice (Huppi
et al, 1988; Huppi et al, 1989) and humans (LeConiat et al, 1990). The gene for the
(3 subunit is located on mouse chromosome 19 (Huppi et al, 1989). During
assembly, the a subunit associates first with the (3 subunit, and subsequently with the
y subunits (Alber and Metzger, 1993).
The a subunit contains 245, 250 and 260 amino acids in rat, mouse and human
respectively (Kinet et al, 1987; Alber and Metzger, 1993). It possesses a single
transmembrane domain and an extracellular domain that carries the high-affinity
binding site for IgE (Kinet, 1990; Riske et al, 1991; Hulett et al, 1993). The (3
subunit of the rat and mouse contains 243 and 235 amino acids respectively (Kinet et
al, 1988; Ra et al, 1989; Aiber and Metzger, 1993). It has four transmembrane
domains, with both the N- and C- termini protruding into the cytoplasm (Kinet et al,
1988). The y subunit is virtually identical in rat, mice and humans and contains 67
amino acids (Blank et al, 1989; Ra et al, 1989; Kuster et al, 1990). It has a single
transmembrane domain, and an extracellular region containing only 5 amino acids.
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In the plasma membrane, the y subunits exist as covalently cross-linked dimers,
joined by a disulphide bond (Varin-BIank and Metzger, 1990). In contrast to the a
subunit, which is responsible for binding IgE, the (3 and 7 subunits of the IgE receptor
are concerned with signal transduction (see below).
Binding of IgE to FceRl
The IgE receptor can only bind one molecule of IgE at a time (Mendoza and
Metzger, 1976) and it does so with an affinity of = 109"10 M"1 (Kulczycki and
Metzger, 1974). The binding of IgE to FceRl can not be inhibited by massive
excesses of IgG or other immunoglobulins, so isotype specificity is almost absolute
(Alber and Metzger, 1993). Numerous studies have shown that the IgE molecule
binds to the a subunit of the IgE receptor via the Ce3 domain in the Fc region of the
immunoglobulin heavy chain (Weetall et al, 1990; Nissim and Eshhar, 1992; Nissim
et al, 1991). This results in a bent conformation of the antibody, with the Fab arms
projecting up and the Fc region projecting laterally (Figure 1.2B, modified from





Figure 1.2 - A: Schematic representation of the tetrameric IgE receptor (FceRI,
modified from Kinet, 1990). Each circle represents one amino acid residue. The
receptor consists of one a chain, one [3 chain and two y chains. The large
extracellular portion of the a chain contains the IgE binding site. The (3 subunit
possesses four transmembrane domains and, with the 7 su'bunits, is involved in signal
transduction. The solid circles show the position of amino acid residues in the a and
7 chains that are identical in rat, mouse and human.
B: Model for the binding of IgE to the IgE receptor (modified from Baird et al,
1989). The IgE molecule (dark striations) binds via the Ce3 domain in the Fc region
of the immunoglobulin heavy chain, resulting in a bent conformation with the Fab











Aggregation of IgE receptors
It has been known for many years that binding of single IgE molecules to FceRl
receptors does not lead to activation of the signal transduction pathway. Early
studies showed that aggregation of surface bound IgE was required for antigen-
induced activation of mast cells (Alber and Metzger, 1993). Subsequent studies
revealed that bivalent antibodies to the IgE receptor, but not their monovalent Fab
fragments, could trigger mediator release from RBL-2H3 cells, even in the absence
of IgE (Ishizaka and Ishizaka, 1978; Isersky et al, 1978). These studies demonstrated
that aggregation of the receptor itself was the critical stimulus for mast cell
activation.
Rat and mouse peritoneal mast cells possess approximately 2-3 x 105 IgE receptors
per cell (Sterk and Ishizaka, 1982; Conrad et al, 1975), whereas RBL-2H3 cells
express approximately twice this number (Conrad et al, 1975). Rat intestinal
mucosal mast cells possessed 3 x 104 IgE receptors per cell (Lee et al, 1985b), and
based on molecular weight, had a different receptor profile than peritoneal mast cells,
providing further evidence of heterogeneity (Swieter et al, 1989). These receptors
diffuse over the surface of the cell like other plasma membrane proteins, but when
their bound IgE is aggregated by antigen or anti-IgE, they are rapidly immobilized
(Schlessinger et al, 1976; Wolf et al, 1980; Mao et al, 1991; Tamir et al, 1996).
Immuno-gold labelling studies of IgE receptors demonstrate a change in distribution
from a diffuse pattern in resting cells to patched or capped aggregated forms after
challenge (Stump et al, 1989). Receptor immobilization may occur because of
interactions with the underlying cytoskeleton (Mao et al, 1991).
Signal transduction
The events following aggregation of FceRl receptors that culminate in exocytosis are
complex and not fully understood, and the mechanisms underlying this process are a
current focus of mast cell research (Beaven and Metzger, 1993). Most of the recent
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progress in elucidating these mechanisms has resulted from studies of five main
areas: tyrosine kinases; G proteins; the inositol trisphosphate pathway; calcium
signalling; and electrophysiology.
Tyrosine kinases
Phosphorylation is a post-translational covalent modification used by cells to regulate
the properties of a wide variety of proteins including enzymes, receptors, ion
channels and regulatory or structural proteins (Alberts et al, 1994). Protein kinases
are phosphotransferases which catalyse the transfer of the phosphoryl group of ATP
to an amino acid side chain in the presence of Mg2+ (Girault, 1994). Phosphoryl
acceptors include serine, threonine and the phenol group of tyrosine. Tyrosine
kinases exist in two forms: as transmembrane receptors (such as the c-kit receptor),
and as non-receptor tyrosine kinases (Girault, 1994). The latter group comprises a
large number of enzymes includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Csk, Tec, Abl,
Fes, Fer, Syk, Fak, Tyk and Jak tyrosine kinases. Most, but not all, of these enzymes
are characterized by the presence of SH2 domains which bind to phosphorylated
tyrosines and are important regions for protein-protein interactions (Girault, 1994).
At least two families of cytoplasmic tyrosine kinases are activated on cross-linking of
FceRI: the Src family tyrosine kinases c-Src, Lyn and c-Yes (Eiseman and Bolen,
1992); and the syk (p72syc) tyrosine kinase (Benhamou et al, 1993; Shiue et al,
1995). Tyrosine phosphorylation of several proteins is one of the earliest signalling
events in mast cells following FceRI cross-linking (Benhamou et al, 1990; Connelly
et al, 1991; Yu et al, 1991; Li et al, 1992a; Benhamou et al, 1992; Paolini et al,
1992; Kawakami et al, 1992). Substrates identified to date include the (3 and y
subunits of the IgE receptor, which are phosphorylated within 5 seconds of receptor
aggregation (Paolini et al, 1991; Li et al, 1992a); phospholipase C-yl (Park et al,
1991; Schneider et al, 1992; Fukamachi et al, 1992; Li et al, 1992a); a proto-
oncogene product p93iav (Margolis et al, 1992); a MAP kinase (Fukamachi et al,
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1993); an SH2 and SH3-containing protein, Nek (Li et al, 1992b); and protein
SPY75 (Fukamachi et al, 1994).
The (3 and y subunits of the IgE receptor act as the signalling units between the
receptor and cytoplasm (Paolini et al, 1991). Recent studies have suggested that
triggering of the IgE receptor activates Lyn (already associated with the (3 subunit)
which phosphorylates both the (3 and y subunits (Jouvin et al, 1994). This induces
the activation of Syk which phosphorylates and activates phospholipase C-yl (Jouvin
et al, 1994), an important enzyme in the generation of inositol triphosphate (see
below). In this scheme, the (3 subunit is thought to act as an amplifier of the signal
generated by the y subunit (Lin et al, 1996). The critical role of Syk in FceRI
signalling was recently confirmed in a variant of the RBL-2H3 cell line that was
deficient in Syk (Zhang et al, 1996). In these cells, aggregation of the IgE receptor
induced no tyrosine phosphorylation of phospholipase C, no increase in cytosolic
Ca2+ concentration, and no histamine release. However, following transfection,
cloned lines were established with stable expression of Syk, and all these responses
were restored (Zhang et al, 1996).
The activation of MAP kinases and the vav protein by Syk may be involved in the
activation of phospholipase A2 (Hirasawa et al, 1995; Hirasawa et al, 1995) which
contributes to the release of arachidonic acid (Ishimoto et al, 1994), whereas
activation of the Nek protein may be involved in stimulation of cell activation and
growth (Li et al, 1992b). Although the function of the SPY75 protein is currently
unknown, it contains an SH3 domain which is a common feature of signalling
molecules and cytoskeletal proteins (Fukamachi et al, 1994).
The critical role of tyrosine kinases in FcsRI signalling has also been demonstrated
using tyrosine kinase inhibitors. A number of inhibitors including genistein
(Kawakami et al, 1992), lavendustin A (Kawakami et al, 1992), methyl 2,5
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dihydroxycinnamate (Lavens et al, 1992), and piceatannol, a syk-selective inhibitor
(Oliver et al, 1994), prevented not only tyrosine phosphorylation, but also mediator
release.
G-proteins
The second common intracellular mechanism for regulating the function of proteins
is the binding and subsequent hydrolysis of GTP (Alberts et al, 1994). These so-
called G-proteins are activated when bound GDP is exchanged for GTP, and
inactivated when the phosphate is removed by hydrolysis (Sagi-Eisenberg, 1993).
The similarities between this mechanism and that described above for protein kinases
is obvious; both systems rely on the addition and removal of phosphate to modulate
protein function. A subfamily of G-proteins called the heterotrimeric G-proteins are
involved in transmembrane signalling by coupling receptors to their effector systems
(Sagi-Eisenberg, 1993).
The involvement of G-proteins in mast cell activation was first demonstrated when
non-hydrolysable analogues of GTP (such as GTP-y-S) were introduced into the
cytoplasm of mast cells that had been temporarily permeabilised with ATP
(Gomperts, 1983). These analogues directly activate G-proteins and, in the presence
of extracellular Ca2+, caused mast cell degranulation (Gomperts, 1983). Subsequent
studies showed that treatment of RBL-2H3 cells with mvcophenolic acid, which
decreases endogenous GTP levels, resulted in inhibition of IgE receptor-mediated
secretion and Ca2+ influx, but the response could be restored by replenishing the GTP
pool (Wilson et al, 1989). In contrast, treatment of RBL-2H3 cells with cholera
toxin, which causes prolonged activation of the Gs protein, resulted in enhanced
formation of inositol-trisphosphate, Ca2+ influx and secretion (Knoop and Thomas,
1984; McCloskey, 1988; Narashimhan et al, 1988). Further studies indicated that
activation of G-proteins by GTP-y-S led to a concomitant activation of phospholipase
C (Sagi-Eisenberg, 1993). Taken together, the results of these studies suggest that
45
two main mechanisms are involved in the activation of phospholipase C and the
inositol-trisphosphate pathway in mast cells and RBL-2H3 cells: the first is the
activation of phospholipase C by tyrosine phosphorylation; and the second involves
the coupling of the receptor to the enzyme by G-proteins.
Evidence that a second G-protein may be involved in the direct stimulation of mast
cell secretion came from the observation that in patch-clamped or permeabilised
cells, GTP-y-S could elicit degranulation in the absence of Ca2+, and independent of
phospholipase C activation (Fernandez et al, 1984; Neher, 1988; Barrowman et al,
1986). This latter pertussis toxin-sensitive G-protein, termed GE, is probably
responsible for direct triggering of exocytosis following stimulation of the cells with
basic secretagogues such as compound 48/80 or substance P (reviewed in Sagi-
Eisenberg, 1993). Aridor et al demonstrated that GE is likely to be the heterotrimeric
G-protein Gai3 (Aridor et al, 1993). A similar dependency of the secretory response
on G-proteins was seen in human and rat cutaneous mast cells stimulated with the
peptides mastoparan and neuropeptide Y (Emadikhiav et al, 1995). However, the
role of this pathway in vivo following aggregation of the IgE receptor is not known.
The inositol trisphosphate pathway
Hydrolysis of phosphatidylinositol 4,5-bisphosphate to inositol trisphosphate and
diacylglycerol is a universal signal transduction mechanism used for controlling a
variety of cellular processes including secretion, metabolism and cell proliferation
(reviewed in Berridge and Irvine, 1984). The key enzymes in this reaction are the
phospholipase Cs, which can be divided into four types (a, (3, y, and 6) based on their
molecular sizes and amino acid sequences (Rhee et al, 1989). Each type of
phospholipase C comprises a family of isoenzymes such as yl and y2. As discussed
earlier, crosslinking of the IgE receptor can lead to activation of phospholipase C-yl
by both tyrosine phosphorylation and G-protein coupling.
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The hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C yields
two intracellular second messengers with different functions (reviewed in Sagi-
Eisenberg, 1993). Inositol 1,4,5-trisphosphate (IP3) triggers the IP3 receptor on the
endoplasmic reticulum, resulting in release of Ca2+ from intracellular stores (Streb et
al, 1983; Spat et al, 1986; Spat et al, 1986). The other second messenger,
diacylglycerol (DAG), activates a family of serine/threonine kinases collectively
known as protein kinase C (Dekker and Parker, 1994).
The role of IP3 and DAG in signal transduction in RBL-2H3 cells was investigated
using the phorbol ester 12-0-tetradeconylphorbyl-13-acetate (TPA) (Gat-Yablonski
and Sagi-Eisenberg, 1990). TPA blocked the breakdown of phosphatidylinositol 4,5-
bisphosphate to IP3, and also inhibited the rise in intracellular Ca2+ induced by
antigen (Gat-Yablonski and Sagi-Eisenberg, 1990). However, TPA did not inhibit
secretion at concentrations that completely blocked IP3 formation, suggesting that IP3
formation was involved in Ca2+ mobilization, but was not essential for exocytosis.
More recent studies have suggested that the IP3 signal induced by FceRI crosslinking
is not sufficient to explain the Ca2+ signal in RBL-2H3 cells, and that sphingosine-1-
phosphate, an alternative second messenger for intracellular mobilization, is more
important (Choi et al, 1996).
A number of studies have documented the importance of protein kinase C in the
secretory process and proliferation of mast cells (Ozawa et al, 1993a; Ozawa et al,
1993b; Barane and Razin, 1991; Chaikin et al, 1994). Secretion in RBL-2H3 cells
could be abolished by inhibiting protein kinase C, but the response was restored by
addition of the |3 and 6 isoenzymes, suggesting that these were critical for exocytosis
(Ozawa et al, 1993a; Ozawa et al, 1993b). One possible substrate for protein kinase
C in RBL-2H3 cells is myosin (Ludowyke et al, 1989). Both myosin light and heavy
chains were phosphorylated by protein kinase C in RBL-2H3 cells in vivo, and the
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time course and extent of the reaction were correlated with histamine secretion
(Ludowyke et al, 1989).
Ca2+ signalling
It has been known for many years that Ca2+ plays an important role in exocytosis in
mast cells. Foreman and coworkers showed that external Ca2+ was essential for
secretion (Foreman and Mongar, 1972), that calcium ionophores could elevate
intracellular Ca2+ and evoke a secretory response (Foreman et al, 1973), and that IgE-
mediated secretion was accompanied by an uptake of 45Ca2+ into the cells (Foreman
et al, 1977). Although secretion in mast cells can be triggered under certain
experimental conditions without an increase in intracellular Ca2+ (such as internal
application of GTP-y-S or artificial activation of protein kinase C) it seems that under
physiological conditions, a rise in intracellular Ca2+ is crucial for exocytosis.
The rise in intracellular Ca2+ in mast cells arises from two sources. The initial rise
that follows crosslinking of the IgE receptor results from Ca2+ release from the
endoplasmic reticulum. As discussed above, this is triggered by IP3 (Sagi-Eisenberg,
1993) and sphingosine-1-phosphate (Choi et al, 1996). The second source of Ca2+ is
an influx from the extracellular milieu, and this important pathway will be discussed
in more detail in the electrophysiology section of this review.
The effects of the rise in intracellular free Ca2+ may be manifested through the
calcium binding protein calmodulin. Calmodulin has been detected in association
with the granules of rat peritoneal mast cells (Chock and Schmauderchock, 1992),
and it may play a critical role in the regulation of intracellular enzymes and
cytoskeletal proteins, both of which may be involved in the release process.
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Exocytosis
Exocytosis is the last stage in the secretory pathway and involves fusion of the
granule membranes with those of the plasma membrane. Although the precise
mechanisms by which this occurs are not known, it is likely to involve the
cytoskeleton, fusion proteins, and granule swelling. Mast cells possess actin
filaments that are located predominantly in a cortical distribution below the plasma
membrane (Rohlich, 1975). Following activation of the IgE receptor, the actin
filaments are extensively reorganised (Nielsen et al, 1989; Nielsen, 1990; Koffer et
al, 1990), with a centripetal redistribution of F-actin from the periphery to the cell
interior (Norman et al, 1994). The disassembly of F-actin at the cortex was
dependent on a heterotrimeric G-protein, whereas the appearance of actin filaments
in the interior was dependent on two small GTPases, rho and rac. Rho was
responsible for de novo actin polymerization, whereas rac was required for
entrapment of the released cortical filaments (Norman et al, 1994). This
redistribution of the actin cytoskeleton may facilitate the translocation of granules
from the cell interior to the plasma membrane. Contact of the granule membrane
with the plasma membrane may be facilitated by Ca2+-dependent fusion proteins such
as SNAPS and SNARES (reviewed in Edwardson and Marciniak, 1995), although
these mechanisms have not yet been established in mast cells.
A second factor involved in exocytosis may be granule swelling. In one hypothesis,
the signal transduction pathways result in an influx of water into the granule whilst it
is still inside the cell (Chock and Schmauderchock, 1992). This not only causes
granule swelling, which brings the granule membrane closer to the plasma
membrane, but also activation of granule enzymes, an osmotic pressure surge, a pH
shift and activation of the arachidonic acid cascade (Chock and Schmauderchock,
1992). However, more definitive studies concluded that swelling of the mast cell
granule occurred after membrane fusion, resulting from an influx of water through
the fusion pore (Zimmerberg et al, 1987). In this model, the fusion pore then dilates,
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probably due to tension in the secretory granule membrane, and releases the granule
contents into the extracellular medium (Monck et al, 1991).
A summary of the factors that may be involved in the secretory response of mast


































Figure 1.3 - Possible signalling pathways in stimulus-secretion coupling in mast cells.
Activation of the IgE receptor subunits (a|3y2) leads to phosphorylation and activation of
Lyn and Syk tyrosine kinases and activation of G proteins. Both pathways can activate
phospholipase C-y (PLC) which leads to the formation of inositol trisjrhosphate (IP3) and
diacylglycerol (DAG). IP3, and sphingosine-1-phosphate, liberate Ca + from intracellular
stores which activates the Ca2+ influx pathway, whereas DAG activates protein kinase C
(PKC). The release of granule mediators may arise due to a rearrangement in the
actin/myosin cytoskeleton, brought about by the rise in intracellular Ca2+, PKC and the
small G proteins Rac and Rho. The heterotrimeric G protein (GE) may act in a similar way,
possibly by-passing the IgE receptor. The Syk tyrosine kinase also activates a MAP kinase
which activates phospholipase A2 (PLA2), resulting in the generation of leukotrienes B4
(LTB4), C4 (LTC4) and prostaglandin D2 (PGD2) from arachidonic acid.
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ELECTROPHYSIOLOGICAL PROPERTIES OF MAST CELLS
In recent years, the electrophysiological properties of many isolated mammalian cells
have been studied using the tight-seal whole-cell recording configuration of the
patch-clamp technique (Hamill et al, 1981). Mast cells have been a common subject
for such studies for two reasons. First, because mast cells are a valuable model for
studying the basic mechanisms involved in cellular secretion; and second because the
ion channels and ionic fluxes across the plasma membrane are critically involved in
the process of degranulation, the principle effector function of mast cells. Hence, a
knowledge of the ionic conductances in mast cells may ultimately lead to new anti¬
allergic drugs that specifically target ion channels.
Recent electrophysiological studies have identified a number of different ion
channels in mast cells. The presence or absence of these currents depended on the
phenotype of the mast cell (connective tissue or mucosal), the species from which the
cells were derived, and whether the cells were in the resting state or stimulated with
second messengers or secretagogues.
Ionic Conductances in Resting Mast Cells
In three recent studies, rat mast cells derived from bone marrow stimulated with
recombinant IL-3 (McCloskey and Qian, 1994) and RBL-2H3 cells (Lindau and
Fernandez, 1986b; Qian and McCloskey, 1993), both mucosal phenotypes, possessed
only an inwardly rectifying K+ (IRK) current in the resting state. This current was
shown to set the resting membrane potential of RBL-2H3 cells at about -90 mV. In
contrast, rat peritoneal mast cells, a connective tissue phenotype, had no significant
membrane currents in the resting state, and had a membrane potential close to zero
(Lindau and Fernandez, 1986b; McCloskey and Qian, 1994). Mouse bone marrow-
derived mast cells (BMMCs), which can potentially differentiate into both mucosal
and connective tissue phenotypes, possessed two different currents (Kuno et al,
1995). A K+ selective inwardly rectifying current was present in 36% of the cells, and
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an outwardly rectifying CI" (ORa) current was present in 46% of cells (Kuno et al,
1995). In individual cells, the two currents could be observed either concurrently or
individually, but some cells (40%) appeared electrically quiescent, displaying neither
the IRk nor the 0RCI current. In the mouse system, both the IRK and the ORcl
currents were involved in regulation of the resting membrane potential, which ranged
from -66 to +6.4 mV with a mean and s.d. of -23 ± 25 mV (Kuno et al, 1995).
Ionic Conductances in Stimulated Mast Cells
Other membrane currents have been described in rat mast cells but only when the
cells were stimulated with secretagogues or if various second messengers were
included in the pipette solution. These messenger or ligand activated channels
include: Ca2+ permeable channels; cation-selective channels; outwardly rectifying
chloride channels; and outwardly rectifying K+ channels.
Ca2+ permeable channels
Elevation of cytoplasmic free calcium ([Ca2+];) is considered to play an important
role in stimulus-secretion coupling in mast cells (Foreman et al, 1973; Ishizaka et al,
1979; Ishizaka et al, 1980; White et al, 1984; Millard et al, 1988; Gericke et al,
1995; Habara and Kanno, 1996). Although the initial rise in [Ca2+]; occurs via
release from intracellular stores (Neher and Aimers, 1986; Millard et al, 1989), entry
of Ca2+ through the plasma membrane is required to initiate secretion (MacGlashan
and Botana, 1993; Williams et al, 1990). In early studies, changes in membrane
conductance that might account for the Ca2+ influx pathway could not be identified
when rat peritoneal mast cells (Lindau and Fernandez, 1986b; Lindau and Fernandez,
1986a) or RBL-2H3 cells (Lindau and Fernandez, 1986b) were stimulated with
antigen. However, in recent patch-clamp studies, a specific Ca2+ influx-pathway was
activated in rat peritoneal mast cells when the cells were stimulated with intracellular
inositol 1,4,5-trisphosphate (IP3) or extracellular agonists such as compound 48/80 or
substance P (Kuno et al, 1989; Matthews et al, 1989b). In contrast to electrical
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excitable cells such as bovine chromaffin cells (Penner and Neher, 1988), the Ca2+
influx in mast cells was not activated by depolarization but was increased by
hyperpolarization (Matthews et al, 1989b; Kuno et al, 1989).
The Ca2+-selective entry pathway was subsequently shown to be activated by
depletion of intracellular Ca2+ stores (Hoth and Penner, 1992; Hoth and Penner,
1993) and termed ICRAC (for calcium release-activated calcium current). The link
between the filling state of the intracellular Ca2+ stores and the Ca2+ channels in the
plasma membrane has not yet been elucidated (Fasolato et al, 1994). However, the
activation mechanism of Icrac appears to involve a diffusible cytosolic factor
(Fasolato et al, 1993; Innocenti et al, 1996), a monomeric (Fasolato et al, 1993) or
heterotrimeric (Xu et al, 1995) GTP-binding protein (Fasolato et al, 1993), and it can
be inhibited by protein kinase C (Parekh and Penner, 1995) and ADP (Innocenti et al,
1996). It appears that the Ca2+ influx factor (CIF) described by Randriamampita and
Tsien (1993) does not activate Icrac (Penner, personal communication). Under
experimental conditions closely approximating physiological (perforated-patch
technique at 37°C), the Icrac could also be activated by crosslinking of the IgE
receptor, demonstrating its importance in stimulus-secretion coupling (Zhang and
McCloskey, 1995).
The single channel conductance of the Ca"+ release activated channel is extremely
small and could not be measured in mast cells using variance analysis, although it
was estimated to be well below 1 pS (Hoth and Penner, 1993). In Jurkat T-
lymphocytes, which also possess Icrac> single channel conductance was only 9 fS
in an extracellular solution containing 2 mlvl Ca2+ (Zweifac'n and Lewis, 1993).
Recent studies have suggested that proteins encoded by the trp homologue genes in
mice might represent functional subunits of the Ca2+ release activated Ca2+ channel,
not unlike those of classical voltage-gated ion channels (Zhu et al, 1996).
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Cation selective channels
In addition to the specific Ca2+ permeable channels described above, mast cells also
possess a second pathway through which Ca2+ may enter the cell. Stimulation of rat
peritoneal mast cells with compound 48/80 (Matthews et al, 1989b; Kuno et al,
1989; Fasolato et al, 1993) or intracellular guanosine 5'-0-3-thiotriphosphate (GTP-
y-S) (Matthews et al, 1989b) activated a large-conductance cation channel with a
conductance of 50 pS. Although these channels had a much larger conductance than
the Ca2+ permeable channels described above, they only partially contributed to the
plateau phase of elevated [Ca2+]j occurring after stimulation, probably due to low
specificity (Fasolato et al, 1993). However, because they are inhibited by [Ca2+]|,
they may play a greater role under conditions of low [Ca2+]j (Matthews et al, 1989b).
Outwardly rectifying chloride channels
In contrast to mouse bone marrow-derived mast cells, outwardly rectifying CI
currents have only been described in rat mast cells following stimulation with
secretagogues or intracellular messengers. In rat peritoneal mast cells, external
stimulation with compound 48/80 (Matthews et al, 1989a) or substance P (Matthews
et al, 1989a; Janiszewski et al, 1994), or internally applied cyclic AMP (Matthews et
al, 1989a; Dietrich and Lindau, 1994) or GTP-y-S (Matthews et al, 1989a) resulted in
the slow development of an outwardly rectifying Ca2+-dependent CI" current. The
channel had a unitary conductance of 1-2 pS (estimated from noise analysis) and
could be blocked by the chloride channel blockers 4,4'-diisothiocyano-2,2'-
stilbenedisulfonate (DIDS) (Matthews et al, 1989a; Dietrich and Lindau, 1994) and
5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) (Janiszewski et al, 1994).
A single channel study of cell-attached patches of RBL-2H3 cells also revealed a
slowly activating CI" channel with a conductance of 32 pS and an increasing open-
state probability with increasing depolarization (Romanin et al, 1991). This channel
could be activated by stimulating the cell-attached patches with antigen or a
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monoclonal antibody specific for the FceRl receptor. In addition, inhibition of the
CI" channel with NPPB or the anti-allergic drug disodium cromoglycate also
inhibited serotonin secretion, suggesting that the current was involved in stimulus-
secretion coupling. The difference in the two single channel conductances described
above has yet to be explained, although the possibility exists that more than one type
of CI" channel is present in mast cells.
The outwardly rectifying CI" current may play a role in regulation of the membrane
potential during degranulation (Matthews et al, 1989a). In the absence of any other
conductance, activation of the Ca2+ influx pathways described above would tend to
depolarise the cell (Penner et al, 1988). The membrane potential would then
approach the reversal potentials of the respective agonist-activated conductances i.e.
positive values for the calcium specific pathway or close to 0 mV for the non¬
selective cation conductance (Penner et al, 1988). However, activation of the CI"
current resulted in hyperpolarization of rat peritoneal mast cells to about -40 mV, a
value probably in the region of the CI" reversal potential (Penner et al, 1988). This
would tend to clamp the membrane potential at a sufficiently negative value to
support the hyperpolarization-driven Ca2+ influx (Matthews et al, 1989a; Penner et
al, 1988). Further evidence for this hypothesis was provided by studies
demonstrating 36C1" influx during antigen stimulated degranulation (Glenert et al,
1993; Friis et al, 1994).
Outwardly rectifying K+ channels
An outwardly rectifying K+ current was recently described in RBL-2H3 cells (Qian
and McCloskey, 1993) and rat BMMCs grown in the presence of rat recombinant IL-
3 (McCloskey and Qian, 1994). This current was not observed in rat peritoneal mast
cells, providing a further indication of heterogeneity. Unlike the K+ selective
inwardly rectifying current, which was constitutively active, the outwardly rectifying
K+ current was activated by intracellularly applied GTP-y-S or extracellularly applied
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adenosine 5'-[(3-thio]diphosphate (ADP) or adenosine 5'[f3,y-methylene]triphosphate
(ATP). Activation of this current was inhibited by pertussis toxin, implicating
mediation by a G protein. Once activated, the current passed outward current at
depolarised potentials and could therefore counteract the depolarising Ca2+ currents
described above in a similar way to that proposed for the outwardly rectifying CP
channel. It was concluded that adenosine nucleotides released at sites of
inflammation by platelets, endothelial cells or injured tissue might modulate the mast
cell response by inducing the outwardly rectifying K+ current, thus contributing to
the negative membrane potential required for exocytosis.
Volume-activated CI channels
A volume-activated CI" current was recently described in RBL-2H3 cells (Nilius et
al, 1994). The current was outwardly rectifying and could be induced by placing the
cells in a hyposmotic extracellular solution. At positive potentials, a large outward
current was passed, but there was virtually no current activation at negative voltages.
The current showed rapid run-down suggesting a dependency on an intracellular
factor. The single channel conductance of the volume-activated CI" channels was
approximately 6 pS, and they were blocked by 5-nitro-2-(3-phenylpropylamino)-
benzoic acid (NPPB). It was hypothesised that, as in other cell types, the current was
activated by stretching of the membrane, and probably played a role in the regulation
of cell volume (Nilius et al, 1994).
BACKGROUND TO THESE STUDIES
The role of mucosal mast cells in intestinal immune responses
Previous work in this laboratory and others has focused on the immune responses to
gastrointestinal helminths, with particular emphasis on the role of the intestinal
mucosal mast cell (MMC). As described earlier in this chapter, intestinal MMCs
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represent a distinct subpopulation of cells with specific functional and biochemical
characteristics. For example, MMCs differ from connective tissue mast cells in their
T cell dependency (Nawa and Miller, 1979), response to secretagogues (Befus et al,
1982), and in their content of proteoglycans (Enerback, 1987) and granule proteases
(Gibson and Miller, 1986). Unlike rat connective tissue mast cells (such as
peritoneal and cutaneous mast cells) which contain RMCP-I, rat MMCs contain the
highly soluble granule chymase RMCP-II (Gibson and Miller, 1986).
The importance of MMCs in intestinal immune responses was suggested by in vivo
studies in which infection of normal mice and rats with intestinal nematodes such as
Nippostrongylus brasiliensis or Trichinella spiralis induced a marked mastocytosis
in the intestinal lamina propria (Miller and Jarrett, 1971; Befus and Bienenstock,
1979; Nawa and Miller, 1979). Furthermore, histological and ultrastructural changes
indicative of mast cell discharge were observed during expulsion of N brasiliensis in
rats (Miller, 1971). Subsequent studies demonstrated that rat intestinal MMCs were
functionally active during nematode expulsion, releasing RMCP-II into both the gut
lumen and the systemic circulation (Miller et al, 1983; Woodbury et al, 1984).
Systemic release of mouse mast cell protease-I (Tuohy et al, 1990; Huntley et al,
1990b) and sheep mast cell protease (Huntley et al, 1987) was also observed
following activation of the intestinal mucosal mast cell population by nematode
infections in the respective species. Using an ex vivo perfusion model, Scudamore et
al. (1995a) demonstrated basal secretion and anaphylactic release of RMCP-II into
the rat jejunal lumen before and after challenge with N. brasiliensis worm antigen.
Furthermore, RMCP-II release during anaphylaxis was associated with the rapid
development of paracellular permeability to macromolecules, suggesting a specific
functional role for the protease in vivo (Scudamore et al, 1995b). Hence, the release
of RMCP-II is a physiologically relevant marker for mucosal mast cell activation in
vivo, and can therefore be used to monitor mast cell secretory function in vitro.
58
Characterisation of MMC and BMMC function in vitro
The initial characterisation of the properties of intestinal MMCs was based on in
vitro studies, using mast cells isolated from the rat intestinal mucosa (Befus et al,
1982; Pearce et al, 1982; Lee et al, 1985a). However, the techniques used for
isolation and purification of mast cells from the gut are laborious, and can give
variable results (Befus et al, 1982; Lee et al, 1985a). In contrast, the in vitro study of
MMC function was greatly facilitated when techniques were developed to culture
mast cells to homogeneity from rat bone marrow using cytokines derived from T
lymphocytes of Nippostrongylus brasiliensis infected rats (Haig et al, 1982; Haig et
al, 1988). These bone marrow-derived mast cells (BMMCs) have been extensively
characterised, and in all respects so far studied, they are identical to rat intestinal
MMCs. For example, like MMCs, they possess the MMC protease rat mast cell
protease-II (RMCP-II). They also contain a predominantly non-heparin proteoglycan
and low levels of histamine (McMenamin et al, 1987; Ortega et al, 1988; Broide et
al, 1988). In addition, they share similar functional characteristics including the
release of RMCP-II and ^-hexosaminidase following challenge with anti-IgE or
specific antigen (Broide et al, 1988; MacDonald et al, 1989), but are resistant to the
effects of compound 48/80 (Broide et al, 1988; Befus et al, 1982). Hence, functional
and biochemical characterisation of rat BMMCs has demonstrated that they are
useful models for studying MMCs in vitro. Such studies are important for
elucidating the mechanisms that might be involved in gastrointestinal immune
responses; they contribute to the growing body of knowledge on mast cell
heterogeneity; and they can provide an insight into the role of MMCs in various
disease states in the gut or other tissues.
Aims of this study
Despite the advances made in the above studies, a number of important aspects of
BMMC function have yet to be explored. For example, the cytokine regulation of
IgE-dependent secretion of RMCP-II by BMMCs is currently poorly understood. As
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described earlier, many aspects of mast cell function are influenced by SCF, the
ligand for the c-kit tyrosine receptor. Rat intestinal MMCs proliferate in response to
systemic injections of SCF (Tsai et al, 1991a), and SCF contributes to the MMC
hyperplasia seen in rats infected with Nippostrongylus brasiliensis and Trichinella
spiralis (Newlands et al, 1995). In addition, SCF vigorously promotes the in vitro
growth of rat BMMCs over a period of 7 - 14 days (Haig et al, 1994; Tei et al, 1994).
Furthermore, in addition to its effects on growth and development, SCF can influence
the serine protease expression by rat peritoneal mast cells and BMMCs in vitro (Haig
et al, 1994), prevent apoptosis in IL-3- (Mekori et al, 1993; Iemura et al, 1994) or
SCF- (Iemura et al, 1994) dependent mast cells, and induce or enhance mediator
release from a variety of mast cell types including mouse and human skin, mouse and
rat peritoneal, and human lung and intestinal mast cells (Wershil et al, 1992;
Columbo et al, 1992; Coleman et al, 1993; Nakajima et al, 1992; Bischoff and
Dahinden, 1992; Bischoff et al, 1996). One of the aims of this study, therefore, was
to further characterise the IgE-dependent release of RMCP-II from rat BMMCs, and
to determine the effect of SCF on their secretory response. This was achieved using
a combination of conventional mediator release assays, and a novel enzyme-linked
immunospot (ELISPOT) assay, developed to detect the release of RMCP-II from
individual BMMCs (these experiments are described in chapters 3 and 4).
A second aspect of BMMC function that has not been investigated is their
electrophysiological properties. As described earlier, the ionic conductances of mast
cells are important both in the resting state, and following activation of the IgE
receptor. Also, the presence of ionic conductances in mast cells depends on their
phenotype, providing further evidence of heterogeneity. However, the studies of
mucosal type mast cells to date have used either the neoplastic RBL-2H3 cell line
(Lindau and Fernandez, 1986b; Qian and McCloskey, 1993) or rat BMMCs grown in
rat recombinant IL-3 (McCloskey and Qian, 1994). RBL-2H3 cells are not true
functional analogues of intestinal MMCs, and the recombinant IL-3 culture system
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has not been extensively characterised in the rat. Hence, neither of these cell types
are ideal for investigating the function of intestinal MMCs. Furthermore, most of the
electrophysiological studies of mast cells have been performed using the
conventional whole-cell recording technique (Hamill et al, 1981). This method
causes "washout" of the cytoplasm which could prevent the detection of messenger-
dependent currents (Horn and Marty, 1988). Hence, a second aim of these studies
was to characterise the electrophysiological properties of rat BMMCs using the
amphotericin B perforated-patch technique (Rae et al, 1991). This technique
preserves the cell's cytoplasm, thus allowing a full complement of second
messengers and enzymes to be retained (Horn and Marty, 1988). Therefore, the
results obtained with this method, and in rat BMMCs, should be more analogous to
the electrophysiological properties of rat intestinal MMCs than those obtained in




CULTURE AND ISOLATION OF MAST CELLS
2.1 - Reagents and Solutions
The following solutions were obtained from Gibco-BRL Life Technologies, Paisley,
UK: Iscove's modified Dulbecco's medium, without supplements, with L-glutamine
(IMDM); RPMI 1640 medium with 20 mM HEPES buffer (RPMI); Hanks balanced
salt solution, without calcium, magnesium, phenol red (HBSS); 10 x Hanks balanced
salt solution without calcium, magnesium, with phenol red (xlO HBSS). A batch of
heat-inactivated horse serum (HS) previously shown to support mast cell growth was
obtained from Advanced Protein Products, Brierly Hill, UK. Foetal calf serum
(FCS) was batch tested and subsequently purchased from either Serotec, Oxford, UK
or Gibco-BRL. Penicillin 10,000 units/ml and Streptomycin 10,000 pg/ml (P/S) was
obtained from Gibco-BRL and used at dilution of 1:100 unless stated otherwise.
Percoll was obtained from Pharmacia, St. Albans, UK. Phosphate buffered saline
(PBS) was prepared as described in Appendix 1.
2.2 - Cell Culture
Unless stated otherwise, all cells were cultured in plastic tissue-culture treated flasks
with vented caps. 175 cm2 flasks were obtained from Nunclon, Gibco-BRL, and 162
2 2 2
cm , 75 cm , and 25 cm flasks were obtained from Costar, Cambridge, MA, USA.
Cells were cultured in a C02 incubator at 37°C in a humidified atmosphere of 5%
C02 in air.
2.3 - Cell handling and washing
For washing and other manipulations, cells were decanted into 50 ml or 15 ml plastic
centrifuge tubes (Costar). Cells were washed by centrifugation at 200 x g for 7
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minutes at room temperature (18 - 20°C) followed by resuspension in the appropriate
medium (see specific sections). Unless stated otherwise, this procedure was repeated
three times.
2.4 - Cell counting and viability
Cells were counted in an improved Neubauer haemocytometer after mixing 10 pil of
cell suspension with an equivalent volume of 0.2% nigrosine. Viability was assessed
based on nigrosine exclusion. For initial counts of nucleated bone marrow cells, 10
pi of cell suspension was also diluted 50:50 in white blood cell counting fluid
(0.01% Gentian violet in 3% acetic acid in distilled water).
2.5 - Cytospin and Staining
To determine the percentage of mast cells in either bone marrow cultures or
peritoneal cell preparations, lOOpl of a cell suspension containing approximately 2 -
5 x 105 cells/ml was centrifuged for 5 minutes at 600 rpm onto a glass slide in a
cytocentrifuge (Shandon Cytospin 2, Southern Instruments LTD., Runcorn, UK).
After air drying, the slides were stained with 100% Leishman's solution for two
minutes followed by 50% Leishman's solution for a further six minutes (obtained by
adding an equal volume of distilled water to the slide). The slides were then well
rinsed in tap water, air dried and mounted with DPX mountant (BDH, Poole, UK).
This procedure stained mast cell granules purple allowing easy discrimination from
contaminating cells. The percentage of mast cells on each slide was determined by
counting 400 cells in randomly chosen high power fields.
2.6 - Experimental Animals
Male Wistar rats were obtained from either Bantam and Kingman Universal, Hull,
UK or the Moredun Research Institute, Edinburgh, UK and were fed a standard
pelleted diet and given water ad libitum. For collection of bone marrow, peritoneal
washes or for preparation of lymph node conditioned medium, rats weighing between
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150g and 250g were deeply anaesthetised in an induction chamber containing 4%
halothane (Rhone Merieux, Dublin, Ireland) and killed by exsanguination followed
by cervical dislocation.
2.7 - Nippostrongylus Brasiliensis Larval Culture
A larval culture of the intestinal nematode Nippostrongylus brasiliensis was
maintained throughout these studies. To perpetuate the culture, lightly anaesthetised
rats were infected with 3000 - 4000 third stage larvae by subcutaneous injection in
the neck. On day six of infection, the rats were transferred to cages containing grids
overlying moist paper towels. After 24 hours, the faecal pellets were collected and
an egg count was performed. 3g of faeces was mixed with 45 ml of saturated NaCl
and the resulting suspension was added to a McMaster counting chamber. A good
infection normally yielded 50,000 eggs per gram. The remaining faeces were mixed
with distilled water to form a slurry, and charcoal granules (Fisons, Loughborough,
UK) were gradually added until a black, semi-moist consistency was formed. Small,
compact mounds of the charcoal/faeces mixture were placed onto the centre of
moistened, round, 5.5 cm diameter filter papers (No. 1, Whatman International,
Maidstone, UK) in the base of petri dishes and incubated in a sealed, humid chamber
at 26°C. The larvae hatched within a few days and were viable for 4-8 weeks.
2.8 - Infection of Rats with Nippostrongylus brasiliensis
Infective third stage larvae (> 7 days old) were obtained by adding drops of a 0.9%
NaCl solution at 37°C to the charcoal/faecal mounds until a small quantity of
solution collected at the bottom of the petri dishes. The solution containing the
larvae was aspirated and filtered through a single layer of paper towel (Kimwipes,
Kimberley Clark Corp., Clwyd, UK) supported by a sieve into a funnel filled with
additional NaCl solution. The larvae gravitated to the bottom of the funnel and
accumulated in a clamped silicone tube. The clamp was then released and the larvae
were transferred to a 15ml centrifuge tube. The larvae were washed twice by
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removing the supernatant and resuspending in fresh NaCl solution. The number of
live larvae in 20pl of solution was counted under a dissecting microscope and the
volume of the remaining solution was adjusted to give a final density of 6000 larvae
per ml. Rats were infected with 3000 - 4000 larvae as described above.
2.9 • Preparation of lymph node conditioned medium
Lymph node conditioned medium (LNCM) was prepared using 8 to 15 rats on day 15
of a primary infection with Nippostrongylus brasiliensis. The mesenteric lymph
nodes were excised and placed in sterile RPMI containing 5% FCS and P/S. After
removing excess fat under sterile conditions, the nodes were finely chopped with
scissors and transferred to a sterile stomacher bag (Seward Medical, London, UK) in
about 15 ml of the above medium. The lymphocytes were mechanically dispersed
using a stomacher (Seward Medical) at high speed for approximately two minutes.
The resulting cell suspension was filtered through two layers of sterile lens tissue
into 50ml centrifuge tubes, and washed four times in the above medium. The
lymphocytes were counted and resuspended in serumless IMDM (Appendix 1) at a
concentration of 4 x 106 viable cells/ml and stimulated with 3pg/ml concanavalin A.
After incubating at 37°C for 48 - 72 hours, the supernatant was separated from the
cells by centrifugation and stored at -20°C until used.
Batches of LNCM were initially tested for their ability to stimulate the growth of
mast cells from rat bone marrow in 12 well tissue culture plates (Costar). The cells
were stimulated with 10, 20 or 30% v/v LNCM, and batches supporting the growth
of 10 - 30% mast cells by day 7 were considered acceptable. These batches were
then used in bone marrow mast cell cultures (see below - 2.10) at an optimum
concentration of 15 - 25%. Twenty two batches of LNCM were prepared during the
course of these studies, of which 19 were used. Nine batches supported excellent
mast cell growth, whereas the others were either poor (n=5) or totally ineffective
(n=5), usually resulting in cultures containing only macrophages. The source of this
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variation was never determined but it probably reflected variation in the content of
cytokines in the LNCM such as IL-3, IFN-y or GM-CSF.
2.10 - Culture of bone marrow-derived mast cells (BMMCs)
The hindlimbs of a non-infected rat were dissected to expose the femurs. The
cartilaginous growth plates above the stifle joints were disarticulated and the bones
were removed close to the hip joint using bone forceps. A 5ml syringe containing
IMDM, 20% HS, and P/S was attached to a 19 gauge needle and used to flush the
bone marrow out of the bone lumen into a universal container. The cell suspension
was mixed by repeated aspiration and filtered through two layers of sterile lens tissue
into a 50ml centrifuge tube. The cells were washed three times in the above medium,
and counted and assessed for viability as described earlier (section 2.4). The cells
were initially cultured at 2.5 x 105 viable cells/ml with 15 - 25% batch-tested LNCM
for the first 5 days. They were then resuspended at 5 x 105 cells/ml in fresh medium
containing 10 -25% LNCM every 2-5 days depending on cell density and pH of the
medium (as assessed by the colour of the phenol red).
Thirty seven BMMC cultures were set up during the course of these studies. Twenty
cultures progressed to maturity, containing virtually homogeneous populations of
mast cells. The other cultures failed to develop, probably due to deficiencies in the
LNCM (see section 2.9). Figure 2.1 shows Leishman-stained cytospin preparations
from a successful bone marrow culture at 0, 4, 11 and 15 days after addition of
LNCM. At day 0, the expected mixture of bone marrow cells is present including
neutrophils, monocytes, lymphocytes and megakaryocytes (Figure 2.1A). At day 4, a
small number of granulated mast cells have developed (Figure 2.IB arrows), and
these proliferate to form clumps by day 11 (Figure 2.1C). At day 15, the culture
contains predominantly mast cells that possess large numbers of purple-staining
granules (Figure 2.ID). The growth characteristics of six representative successful
cultures, and the accumulation of the mucosal mast cell specific granule chymase, rat
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mast cell protease II (RMCP-II), are shown in Figure 2.2. The mast cells developed
rapidly initially, representing approximately 85% of the total cells by days 10 - 15 of
culture. After this, the percentage of BMMCs increased slowly to almost 100%. The
cultures survived for up to 30 - 40 days, depending on cell usage, but were not viable
after this time. The concentration of granule RMCP-II in developing BMMCs,
measured by ELISA of freeze-thawed cell pellets (see sections 2.17 and 2.18 below),
increased from 3.4 ± 0.3 pg/cell at day 4 to 30.4 ± 3 pg/cell at day 28 (Figure 2.2 -




Figure 2.1 - Leishman's-stained cytospin preparations of a representative rat bone
marrow culture.
A: Day 0, before addition of the lymph node conditioned medium (LNCM).
B: Day 4 of culture. Two developing mast cells are marked by arrows.
C: Day 11 of culture. Individual mast cells are present in addition to two mast cell
colonies (arrows).
D: Day 15 of culture. The culture contains predominantly mast cells, with a few
residual monocytes. Scale bars = 10 pm.
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Day of Culture
Figure 2.2 - Development of six successful rat bone marrow cultures showing the
typical kinetics of BMMC growth (left axis and open symbols). The percentage of
BMMCs increases rapidly until the cultures contain approximately 85% BMMCs.
After this, the number of BMMCs increases more slowly until the cultures contain
virtually 100% mast cells. The cultures lasted for up to 30 - 40 days. Mean RMCP-
II concentration in individual mast cells (right axis and solid squares) was determined
by ELISA of freeze-thawed cell pellets. The data from two cultures has been
combined so that each data point represents the mean ± s.e.m. of 12 - 24 cell pellet
assays from one, or both, of the cultures.
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2.11- Isolation and purification of rat peritoneal mast cells
Peritoneal mast cells were collected by injecting 20ml of HBSS containing 2% FCS,
penicillin/streptomycin and 10 units/ml heparin into the abdominal cavity. After
gentle massage, the abdomen was carefully opened and the fluid containing 5 - 10 %
mast cells was collected using a sterile pastette (Figure 2.3A). The cells were
washed twice in the above solution and resuspended in 1ml of 30% Percoll. The
mast cells were then purified using a two stage Percoll density step gradient
consisting of 4ml of 1.09 g/ml layered on top of 2ml of 1.1 g/ml. After
centrifugation at 500 x g for 20 minutes, the Percoll was removed and a pellet
containing > 95% mast cells was obtained (Figure 2.3B). The cells were washed
three times in HBSS to remove residual Percoll and finally resuspended at a
concentration of 2 - 4 x 105 cells/ml in RPMI containing 10% FCS and P/S. This
medium was chosen because IMDM, as used for the BMMC cultures, appeared to be
cytotoxic to rat peritoneal mast cells (experimental evidence for this is presented in
appendix 2). A direct comparison of the morphology of rat peritoneal mast cells and
rat BMMCs is shown in Figure 2.3 (C and D respectively). Rat BMMCs were
slightly smaller than rat peritoneal mast cells, and were more sparsely granulated.
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Figure 2.3 - A: Leishman's-stained cytospin preparation of rat peritoneal lavage
fluid. 20 ml of HBSS/2%FCS/PS/Heparin was injected into the abdominal cavity.
After gentle massage, the fluid was collected using a sterile pastette. The preparation
contains 5-10% mast cells (arrows).
B: Leishman's-stained cytospin preparation of Percoll purified rat peritoneal mast
cells (see text for details). The preparation contains >95% mast cells.
C and D: A comparison of the morphology of rat peritoneal mast cells (C) and rat
BMMCs (D). The BMMCs are more sparsely granulated and slightly smaller.
Scale bars = 10 pm.
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IMMUNOLOGICAT, STUDIES
2.12 - Reagents and Solutions
The following solutions were used for immunological studies. Chemicals were
obtained from BDH, and bovine serum albumin (BSA) was obtained from Sigma,
Poole, UK. Foetal calf serum (FCS) for use in flow cytometry buffer (section 2.13)







137 mM NaCl 137 mM NaCl 137 mM NaCl
2.7 mM KCI 2.7 mM KCI 2.7 mM KCI
0.4 mM NaH2P04 0.4 mM NaH2P04 0.4 mM NaH2P04
5.6 mM glucose 5.6 mM glucose 5.6 mM glucose
0.25% w/v BSA 0.25% w/v BSA 0.25% w/v BSA
10 mM HEPES 10 mM HEPES 10 mM HEPES
pH 7.25 - 7.35 1 mM CaCl2 4 mM EDTA
1 mM MgCl2 pH 7.25 - 7.35
pH 7.25 - 7.35
2.13 - Analysis of surface bound IgE by flow cytometry
BMMCs were labelled with fluorescein isothiocyanate (FITC) -conjugated anti-rat
IgE (Mare-l-FITC, Serotec, Oxford, UK) or, following sensitisation with mouse IgE
anti-DNP (SPE-7, Sigma), rat anti-mouse IgE-FITC (LO-ME-3, Serotec) as
described in detail in chapter 3 (section 3.1). The labelled cells were examined by
flow cytometry which was performed by Mr. Andrew Sanderson, Institute of Cell,
Animal and Population Biology, Department of Biological sciences, University of
Edinburgh using a FACscan (Becton Dickinson, Oxford, UK). The machine was set
for the population of cells to be analysed by ensuring that forward scatter, side scatter
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and fluorescence fell within the analytical range of the instrument. The same settings
were used for each analysis, allowing comparisons between different cell
populations. The machine was gated so that cellular debris and red blood cells were
not registered. In addition, a further gate was applied after the experimental run to
exclude extreme outliers and possible dying cells from the analysis (Figure 2.4).
Each population of cells from each culture tested comprised 105-106 cells and each
flow cytometric analysis was based on 104 cells. Results were displayed as
histograms with log fluorescence intensity along the x-axis (arbitrary units) and
number of cells on the>--axis.
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Figure 2.4 - Flow cytometric analysis of rat BMMCs showing the gating procedure.
The machine (FACScan. Becton Dickinson) was gated so that cellular debris and red
blood cells were not registered. In addition, a further gate was applied (black line)
after the experimental run to exclude extreme outliers and possible dying cells from
the analysis. Each population of cells from each culture tested comprised 103-10b
cells and each flow cytometric analysis was based on 104 cells.
2.14 - Preparation of cell suspensions for mediator release assays
Before use in mediator release experiments, BMMCs were centrifuged at 200 x g for
7 min at room temperature and resuspended in Tyrode's buffer (TB). After two
further washes, the cells were resuspended in TB+ which included 1 mM Ca2+ and 1
mM Mg2+ to support mediator release. Cells were then counted and assessed for
viability, and the percentage of mast cells was determined in Leishman's stained
cytospin preparations.
2.15 - Sensitisation of BMMCs with mouse IgE anti-DNP for mediator release
assays
In some mediator release experiments, BMMCs were sensitised with exogenous
mouse monoclonal IgE anti-DNP (SPE-7, Sigma) to increase the amount of IgE
bound to each cell. The validity of this method is demonstrated in chapter 3 (section
3.1). After washing three times in TB, a suspension of BMMCs was resuspended in
TB/EDTA and incubated with 10 pg IgE/106 cells for 1 hour at 37°C, with gentle
periodic inversion to ensure mixing. The cells were then washed again three times in
TB to remove unbound IgE, counted, and assessed for viability and the percentage of
mast cells.
2.16 - Immunological Stimulation of mediator release from BMMCs
In some experiments, unsensitised BMMCs were challenged directly with goat anti-
rat IgE (anti-IgE provided by Dr. E. Hall, Glasgow Veterinary School, UK) with
normal goat serum (NGS) as a control stimulus. Both reagents were stored at -70°C
and used at an optimal dilution of 1:250 (MacDonald. 1994). In other experiments,
cells were sensitised with exogenous IgE anti-DNP, and DNP-BSA (Calbiochem,
Nottingham, UK) was used as the secretagogue with TB+ as a control stimulus.
DNP-BSA was stored at -70°C as a 10 mg/ml stock solution. The dilution of DNP-
BSA that induced maximal mediator release was determined by assaying the release
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of (3 hexosaminidase from populations of BMMCs stimulated with concentrations
ranging from 1 mg/ml to 0.1 pg/ml (see chapter 3, section 3.2 for details).
2.17 - Assays ofmediator release from BMMC populations
Triplicate or quadruplicate aliquots (0.5ml in Eppendorf tubes) of 0.8 - 1 x 106
BMMCs suspended in TB+ were incubated with 0.5ml of appropriately diluted
stimulant (anti-IgE or DNP-BSA) or control (NGS or buffer) at 37°C for 30 min in a
shaking water bath, with occasional gentle mixing. Previous studies had shown that
the IgE-mediated release of RMCP-II and (3 hexosaminidase was maximal by 30 min
(MacDonald. 1994). The activation reaction was stopped by centrifugation of the
tubes at 12,000 x g for 4 min at 4°C to pellet the cells, after which the tubes were
transferred to an iced water bath. After collection of the supernatants, the cell pellets
were resuspended in 1ml TB+ and both pellets and supernatants were stored at -70°C
until assayed for RMCP-II or (3 hexosaminidase.
To extract the granule contents, the tubes containing the cell pellets (and the
supernatants for controls) were subjected to three freeze/thaw cycles to fracture
plasma membranes and release remaining mediators (MacDonald, 1994). This was
achieved by alternating the tubes between a methanol/dry ice bath and a water bath at
37°C. After the contents had thawed for the third time, the tubes were returned to an
iced water bath. The tubes were then centrifuged again at 12,000 x g for 4 min at 4°
C to pellet the membranous debris. The supernatants and pellet supernatants were
assayed for RMCP II or (3 hexosaminidase as described below.
2.18 - RMCP-II ELISA
Purified RMCP-II, murine monoclonal anti-RMCP-II and sheep anti-RMCP-II for
use in ELISA assays were prepared as described (Huntley et al, 1990a) and provided
by Mr. G.F.J. Newlands, Moredun Research Institute, Edinburgh, UK. 96 well plates
(M129B, Dynatech, Billinghurst, UK) were coated with 50 pi of a 1 pg/ml solution
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of affinity purified mouse monoclonal anti-RMCP-II in sodium carbonate buffer (pH
9.6) and incubated overnight at 4°C. After washing 6 times in PBS/ 0.05% Tween
20 (PBS/T20), remaining binding sites were blocked by adding 50pl/well 4% BSA in
PBS/T20 and incubating for 1 - 2 hours at room temperature (RT, 18 - 22°C). The
plate was washed once in PBS/T20 and 50 pi of appropriately diluted samples in 4%
BSA in PBS/T20 were added to the wells in duplicate and incubated for 1.5 hours at
RT. A standard curve was generated by assaying purified RMCP-II at concentrations
of 5, 4, 2, 1.5, 1.0, 0.75, 0.5 and 0.25 ng/ml. After washing 6 times in PBS/T20, 50
pi of a 1/200 dilution of affinity purified polyclonal sheep anti-RMCP-II conjugated
to horseradish peroxidase was added to the wells and incubated at RT for 1 hour.
The plate was then washed 6 times in PBS/T20 and 50 pi of 3,3',5,5'-
tetramethylbenzidine peroxidase substrate was added to each well. The colour
development was monitored in each well, and the reaction was stopped with 0.18M
H2S04 when colour first appeared in the standard with the lowest concentration.
Plates were read at 450 nm in a Dynatech MR7000 ELISA reader and RMCP-II
concentrations were calculated automatically from the standard curve by the built-in
software. The concentration of RMCP-II in supernatants was then expressed as a
percentage of the total RMCP-II in both supernatants and pellets to give the
percentage release.
2.19 - (3 Hexosaminidase assay
The preparation of the sodium citrate (pH 4.5) and 0.2 M glycine-NaOH (pH 10.7)
buffers is described in appendix 1. 1.7 mg of (3 Hexosaminidase substrate (p
Nitrophenyl N-acetyl (3-D-Glucosaminide, Sigma) was added per 1 ml of sodium
citrate buffer and sonicated in an ultrasonic water bath until dissolved. 30 pi of each
sample was added to the wells of a 96 well ELISA plate followed by 60 pi of the
substrate/citrate buffer solution. After incubating for 45 minutes at 37°C, the
reaction was stopped by adding 150 pi /well of glycine buffer and the plates were
read at 405 nm in a Dynatech ELISA plate reader. The percentage release of (3
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hexosaminidase was calculated by expressing the O.D. values of the supernatants as
a percentage of the sum of the O.D. values for the pellets and supernatants.
2.20 - Statistical Analysis
Statistical analysis of immunological studies was performed using Minitab statistical
software. Treatment groups were compared by one way analysis of variance
(ANOVA) and unpaired Student's t tests. Results are reported as mean ± s.d. or
s.e.m. as described in the appropriate sections.
2.21 - Development of an RMCP-II ELISPOT assay
Part of these studies involved developing an enzyme-linked immunospot assay
(ELISPOT) that detects release of RMCP-II from individual BMMCs. The





The following solutions were prepared using chemicals obtained from either BDH or
Sigma. Prior to use, mast cell Ringers and pipette solutions were filtered through 0.2
pm filters (Whatman Cellulose Nitrate Filters, Maidstone, UK).
Extracellular solutions
Standard Mast Cell Ringer Modified Mast Cell Ringer
137 mM NaCl 137 mM NaCl
2.7 mM KCI 2.7 mM KCI
1 mM CaCl2 2 mM CaCl2
1 mM MgCl2 5 mM MgCl2
5.6 mM glucose 5.6 mM glucose
10 mM HEPES 10 mM HEPES
pH to 7.3 with M NaOH pH to 7.3 with M NaOH
High K+ extracellular solutions for ion substitution experiments (pH 7.3)
10 mM [K+] 50 mM [K+] 90 mM [K+] 137 mM [K+] 165 mM [K+]
10 mM KCI 50 mM KCI 90 mM KCI 137 mM KCI 165 mM KCI
129.7 mM NaCl 89.7 mM NaCl 49.7 mM NaCl 2.7 mM NaCl 2.7 mM NaCl
1 mM CaCl2 1 mM CaCl2 1 mM CaCl2 1 mM CaCl2 1 mM CaCl2
1 mM MgCl2 1 mM MgCl2 1 mM MgCl2 1 mM MgCl2 1 mM MgCl2
10 mM HEPES 10 mM HEPES 10 mM HEPES 10 mM HEPES 10 mM HEPES
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Low CI" extracellular solutions for ion substitution experiments (pH 7.3)
14 mM [CI ] 51 mM [CI"] 114 mM [CP] 16.7 mM [CP]
140 mM Na-acetate 100 mM Na-acetate 47 mM Na-acetate 137 mM Na-isethionate
37 mM NaCl 90 mM NaCl
2.7 mM K-acetate 2.7 mM K-acetate 2.7 mM K-acetate 2.7 mM KC1
2 mM CaCl2 2 mM CaCl2 2 mM CaCl2 2 mM CaCl2
5 mM MgCl2 5 mM MgCl2 5 mM MgCl2 5 mM MgCl2
10 mM HEPES 10 mM HEPES 10 mM HEPES 10 mM HEPES
5.6 mM glucose 5.6 mM glucose 5.6 mM glucose 5.6 mM glucose
Pipette Solutions for conventional whole cell recordings (pH 7.3)
Standard Modified
137 mM KC1 137 mM K-methane sulfonate
2.7 mM NaCl 2.7 mM NaCl
0.1 mM CaCl2 0.1 mM CaCl2
1 mM MgCl2 1 mM MgCl2
10 mM HEPES 10 mM HEPES
1 mM EGTA 1 mM EGTA













2.23 - Ion Channel Blockers
The channel blockers 4,4' -diisothiocyano-2,2' -stilbenedisulfonate (DIDS),
4-aminopyridine and tetraethylammonium chloride (TEA) were obtained from
Sigma. Anthracene-9-carboxylic acid was obtained from Aldrich Chemical Co.,
Gillingham, UK.
2.24 - Whole-cell recording
The components of the recording setup are shown diagrammatically below and
described in detail in the subsequent text. The solid thin lines indicate voltage pulses
produced by the stimulator or the CED software. The solid bold lines indicate the
path taken by the evoked whole cell currents. The dashed lines represent a TTL
pulse produced by the stimulator to trigger the CED software.
2.25 - Recording Station
The microscope, micromanipulator, bath and perfusion system were mounted inside
an aluminium Faraday cage on an anti-vibration table (Micro-g, Technical
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Manufacturing Corporation, MA, USA). Cells were observed with an inverted
microscope (Microstar, Reichert Jung, Germany) powered by a DC power supply
(Weir 761, RS Components LTD, UK) located outside the Faraday cage to avoid
mains interference. The headstage of the patch clamp amplifier (EPC-7, List,
Germany) was mounted on a 3-dimensional oil filled hydraulic micromanipulator
(Narishige, Japan).
2.26 - Recording Bath
The recording bath was made from 8 mm perspex sheet and had a chamber volume
of 4 ml (Figure 2.5). To improve optical resolution, cells were viewed through a
rectangular hole in the base of the bath covered with a 48 x 64 mm glass coverslip.
Solution exchanges were made by a gravity-feed perfusion system comprising a 20
ml reservoir connected to the bath by fine bore tubing. The perfusion rate was
controlled by a screw valve allowing solution exchange in 30s to 2 min, depending
on flow rate. Excess solution was removed by a continuous aspiration tube
connected to a vacuum pump (Hy-Flo Model B, Potters Bar, UK). The temperature
of the bath was measured and controlled using a temperature probe and Peltier device
(Firbank Electronics, Norwich, UK) with each 5°C temperature rise taking
approximately 2 min. However, rapid cooling of the bath was not possible because
of the size of the heat sink on the Peltier element. During solution exchanges, the
perfusate passed over the activated Peltier element before reaching the cells, thus
minimising temperature changes The bath temperature typically decreased by 2-3°C













Figure 2.5 - The electrophysiological recording chamber. The bath was fabricated
from 8 mm perspex sheet. The base of the bath comprised a 48 x 64 mm glass
coverslip which was sealed to the perspex with Sylgard (Dow Corning, MI, USA).
Solution exchanges were made by a gravity-feed perfusion system from a solution
reservoir, and excess solution was removed by a continuous aspiration tube
connected to a vacuum pump. The perfusion rate was controlled using a screw valve.
The temperature of the bath was controlled using a Peltier device, and the round
coverslip supporting the cells was placed in the square hole in the centre of the
Peltier element (shaded).
83
2.27 - Reference electrodes and agar bridges
The pipette and ground electrodes were formed from silver wires which were coated
with molten AgCl (Sigma). In most experiments (including all ion substitution
experiments), the ground electrode was connected to the bath through an agar bridge
consisting of a short length of silicone tubing containing 150 mM KC1 in 5% agar.
In control experiments, exchange of mast cell ringer for either high K+ or low CI
solutions produced junctional potentials which were less than 1 mV; hence, no
corrections were made. When the KC1 in the pipette solution was replaced with
KCH3SO4, large junctional potentials developed at the pipette solution/pipette
electrode interface. These could not be cancelled using the pipette offset potential
circuitry on the amplifier. This problem was overcome by placing a fine tube
containing 150 mM KC1 in 5% agar over the pipette electrode which acted as an agar
bridge between the electrode and the pipette solution (modified from Bormann et al,
1990).
2.28 - Preparation of cells for whole-cell recordings
For electrophysiological recordings, bone marrow-derived mast cells (BMMCs) or
peritoneal mast cells were resuspended in mast cell Ringer and plated onto 10 mm
diameter circular glass cover slips (No. 1, Chance propper Ltd., Warley, UK) in petri
dishes. Both BMMCs and peritoneal mast cells adhered to untreated glass without
the need for further immobilisation. After incubating at 37°C without C02 for up to
seven hours, the coverslips were transferred from the petri dish to the recording bath
containing mast cell Ringer. The cells were washed by rapid perfusion of fresh mast
cell Ringer, which also removed non-immobilised cells. Any contaminating
macrophages in the preparation could be discerned by their large size and lack of
cytoplasmic granularity.
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2.29 - Preparation of Patch Pipettes
Pipettes were pulled from borosilicate capillary glass with an internal diameter of
1.15 mm and an external diameter of 1.55 mm (7052, Garner Glass Company, CA,
USA) using a two-stage vertical micropipette puller (PB-7, Narishige, Japan). For
perforated-patch recordings, the pipette geometry was crucial for success of the
technique. Pipettes were pulled to have short, blunt tips with a rapidly widening
shaft (see Figure 2.6 in section 2.31 - amphotericin B perforated-patch recording).
For conventional whole-cell recordings, the tip geometry was less important and
pipettes were usually longer and thinner. Pipettes were coated to near their tips with
Sylgard (Sylgard 184, Dow Corning, MI, USA) to reduce capacitance transients
evoked by voltage pulses. Immediately prior to use, pipettes were heat polished by
micromanipulating the tip close to a heated platinum wire. They were then filled
with pipette solution (see below), connected to the pipette holder on the headstage of
the amplifier and lowered into the bath.
2.30 - Obtaining seals
The development of pipette/membrane seals in the G£2 range (gigaseals) was
observed by monitoring the currents evoked by repetitive voltage pulses transmitted
to the pipette (Hamill ei al, 1981). Voltage pulses for sealing were generated in two
ways. In some experiments, a precision delay digital timer was used to trigger an
isolated stimulator (equipment produced in the departmental electronics workshop).
However, in the majority of experiments, voltage pulses were generated by CED
patch-clamp software (Cambridge Electronic Design Ltd., Cambridge, UK) on a
personal computer (DCS 286) connected to an intelligent interface (CED, 1401).
With both systems, IV pulses of 10 ms duration were applied every 300 ms to the
input of the patch clamp amplifier (EPC-7, List). The signal was scaled to 1 mV and
the evoked currents were displayed on an oscilloscope (5103N, Tektronix, Guernsey,
UK). The pipette resistance was determined from the quotient of the voltage and
current amplitudes (pipettes were heat polished to yield resistances of 0.5 - 2.5
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for perforated patch recordings and 2 - 5 M£2 for conventional whole-cell
recordings). Before formation of the gigaseal, the current output signal of the
amplifier was set to zero. The pipette tip was then placed against the cell surface
until a noticeable increase in resistance was observed. Gentle oral suction was
applied to the pipette until the resistance increased to a minimum of 1 G£2. Any fast
capacitance transients were cancelled using the capacitive cancellation circuitry on
the amplifier. In most experiments, BMMCs were then lifted off the coverslip and
suspended in the bath solution to minimize the risk of breakdown due to drift or
solution exchange. However, peritoneal mast cells adhered more tightly to the glass
and this was not always possible.
2.31 - Recording configurations
Conventional whole-cell voltage-clamp recordings (Hamill et al, 1981).
For whole-cell voltage-clamp recordings, pipettes were filled by dipping the tip in
pipette solution followed by back-filling. Any excess solution was vapourised by
placing the base of the pipette in an alcohol flame. After formation of the gigaseal,
the amplifier was placed in voltage-clamp mode at a holding potential of -40 mV and
further suction was applied to the pipette to break down the membrane patch within
the tip. Successful break-in was revealed by the sudden appearance of large
capacitance transients. These were cancelled using the slow capacitance and series
conductance cancellation dials on the amplifier. The readings on the dials
correspond to the cell capacitance (a measure of the membrane surface area) and the
series conductance. The reciprocal of the latter value yields the access resistance
which comprises both the pipette resistance and the resistance through the broken
membrane patch.
Perforated-patch recordings (Rae et al, 1991)
Perforated-patch recordings were performed using amphotericin B (Calbiochem,
Nottingham, UK) to permeabilise the membrane patch in the pipette tip. A 50 mg/ml
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stock solution of amphotericin B was prepared by dissolving 5 mg amphotericin B
powder in 100p.l tissue culture grade DMSO (Sigma). This was stored at -20°C for
up to a week. A working solution containing 200 pg/ml amphotericin B was
prepared by adding 2pl of the stock solution to 0.5 ml of pipette solution and
sonicating for 20 min in an ultrasonic water bath. This ensured that the poorly
soluble amphotericin particles were micronised. The working solution was kept in
the dark at room temperature and was stable for 2 - 3 hours. Because the presence of
amphotericin B at the tip inhibits sealing, pipettes were first filled to a length of =
150 gm with pipette solution free of amphotericin B. This was achieved by briefly
dipping (< Is) the tip in clean pipette solution. The pipettes were then back-filled
with the amphotericin B/pipette solution before being used immediately to obtain a
gigaseal as described above.
The initial application of the amphotericin B perforated-patch technique to rat
BMMCs posed a number of technical problems and the following summary indicates
the measures that had to be taken to enable success. Without adhering strictly to all
the points listed below, the technique (as described above) did not work.
1) The amphotericin B had to be fresh. After the bottle of amphotericin was opened,
it was stored at 4°C in a sealed container containing a dessicant for up to 3 months.
However, the stability was variable, so if successful perforations did not occur a new
batch of amphotericin was purchased. The amphotericin B stock solution, made up
in DMSO, was stored at -20°C for up to 7 days after which it was discarded. The
working solution, comprising 200 pg/ml amphotericin B in pipette solution, was only
stable for 2-3 hours and had to be protected from light. As some experiments could
last for 1 hour, the amphotericin solution was not used if it was more than 2 hours
old.
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2) The amphotericin B was dissolved in tissue-culture grade DMSO which was
obtained in 5ml sterile vials. The DMSO was dispensed into 1ml aliquots and stored
in Eppendorf tubes. Occasionally, the amphotericin B did not dissolve in the DMSO
and appeared to form an emulsion. This resulted in a bright yellow opaque
suspension instead of the usual translucent caramel coloured solution. This
occurrence could be minimised by ensuring that the amphotericin B powder was
warmed to room temperature before the bottle was opened, thus reducing the
possibility of condensation.
3) Amphotericin B is not soluble in electrolyte solutions. When it is added to the
pipette solution, a suspension of particles results which can be easily visualised under
a microscope. The working solution was therefore micronised in an ultrasonic water
bath for 20 min before use. If re-examined microscopically, the reduction in particle
size could be clearly demonstrated. This procedure was performed by placing 0.5ml
of pipette solution/amphotericin B in an Eppendorf tube which was allowed to float
free in the bath.
4) The shape of the pipettes was crucial to the success of the perforated patch
technique. If the tips were slightly too long, perforation was either very slow and
incomplete, or did not occur at all. The electrode puller was therefore set up to
produce pipettes with a short, rapidly tapering tip (Figure 2.6). However, analysis of
the tip geometry was somewhat subjective, despite attempts to quantify it with a
graticule, and day to day variation could result in failure of the technique. It was
therefore important to avoid altering the settings on the pipette puller, as correct




Figure 2.6 - Patch pipettes for conventional whole-cell recordings (A) and
amphotericin B perforated-patch recordings (B). For conventional whole-cell
recordings, long, thin pipettes were acceptable. For perforated-patch recordings, the
tip geometry was crucial and short, blunt tips with a rapidly widening shaft were
required.
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5) The presence of amphotericin B at the pipette tip inhibits sealing. This was
overcome by briefly dipping the pipettes in pipette solution free of amphotericin B
before back-filling. The length to which the pipettes were filled was also critical to
the success of the technique. It was found that filling to a length of = 150 pm
produced reasonably consistent results. If pipettes were filled beyond this,
perforation was very slow or did not occur. If pipettes were not filled to this level,
the chances of obtaining a seal were reduced.
If the above measures were adopted, perforation of the membrane patch was revealed
by the gradual appearance of capacitance transients in response to the command
pulse. These were cancelled using the capacitance cancellation circuitry on the
amplifier to yield the cell capacitance and the access resistance. With optimal tip
geometry and filling, the access resistance decreased rapidly within 5-25 min and
continued to fall for up to 2 hours.
2.32 - Measurement ofMembrane Potential
The membrane potential of rat BMMCs was measured with the conventional whole-
cell configuration using the current clamp mode of the patch clamp amplifier.
Immediately following break-in, the amplifier was switched to current clamp and the
displayed voltage was recorded. If the voltage fluctuated, the range was noted and
the median value was taken as the resting membrane potential.
2.33 - Voltage Pulse Protocols
Voltage pulses for detection of whole-cell currents were generated by the CED
voltage-clamp software as described earlier. In all experiments, 5 or 10 mV voltage
steps of 200 ms duration were applied every second from a holding potential of -40
mV. Four different voltage step ranges were used throughout the course of these
studies: -80 mV to +50 mV; -100 mV to + 40 mV; -140 mV to + 40 mV; and -140
mV to + 100 mV. The range used for each particular cell is given in the results and
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in appendix 4. The voltage pulse protocols were either triggered internally by the
program, or externally by repetitive 5 V TTL pulses at 1 Hz generated by the isolated
stimulator.
2.34 - Data Storage
The voltage pulses and the evoked whole-cell membrane currents were stored in
three different ways allowing flexibility in data acquisition and analysis.
1. Video tape
The whole-cell currents first passed from the current output of the amplifier to a
digital audio processor (Pulse code modulation-701ES, Sony Corporation, Japan) and
were recorded digitally on a video cassette recorder (Betamax SL-HF100E, Sony)
along with the voltage steps. To allow the recorded data to be subsequently handled
directly by the CED software, the 5 V TTL triggering pulses were also recorded on
the videotape using an additional input channel (modification by Electronics
Department, Cambridge University, UK). The recorded pulse was then used to
trigger the CED software during playback.
2. Computer Disk
After passing through the digital audio processor, the membrane currents were
filtered at 2 kHz by an 8 pole Bessel type filter (Department of Preclinical Veterinary
Sciences Electronic Workshop, University of Edinburgh), passed to the input of the
analogue-digital interface (CED 1401), and displayed with the voltage steps in real
time on the computer monitor. The current and voltage traces could be saved to the
hard drive (DCS 286) during experiments and subsequently downloaded onto
diskettes for later analysis. However, due to limitations in memory, entire
experiments could not be recorded in this way. Hence, only important sections of the
experiment were saved to disk and if additional analysis was required, the relevant
periods of the experiment were replayed into the computer from video tape.
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3. Pen Recorder
The currents and voltage steps were also displayed in real time on a 2 channel
continuous pen recorder (Electromed MX 216, Devices LTD, Welwyn Garden City,
UK).
2.35 ■ Calibration
Electronic instruments were calibrated by the manufacturers. The magnitude of
voltage pulses generated by the stimulator or the CED software was verified on an
oscilloscope before and after scaling. Current responses during sealing and voltage
pulse protocols were verified by applying voltage steps to a model cell (Model circuit
MC-7, List) and recording the evoked currents on an oscilloscope and pen recorder.
2.36 - Data analysis
1. Generation of current/voltage (I/V) relationships
Current/voltage relationships were generated and analysed with the CED voltage-
clamp software. The currents elicited by each voltage pulse were sampled at 1 kHz
and averaged over a 20 ms period. In most cases, the currents were sampled in the
middle of the 200 ms pulse. However, if there was evidence of time-dependent
inactivation, the currents were sampled in the region of the peak. To generate the I/V
plot, the sampled currents were plotted against the corresponding voltage steps.
Although the software-generated I/V plots can be printed, the figures presented in
chapter 5 were produced by transferring the current and voltage cursor values to a
separate graphics program (Cricket Graph).
2. Leak Subtraction
Leak currents were identified as the data points in the linear (ohmic) region of the I/V
plot (Martin et al, 1992). Before calculating slope conductances, the slope of this
region was subtracted using the leak subtraction program of the of the CED voltage-
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clamp software. The following arbitrary example illustrates how the program
calculates a leak current that is subtracted from all the events in the I/V curve
In the above I/V plot, the five data points represent an ohmic leak conductance.
After leak subtraction, the slope of this line should be reduced to zero. The program
performs the calculation by summing both the current steps (i.e. 20 pA) and voltage
steps (i.e. 10 mV) from the five data points chosen as leak. The current subtracted
from each event in the curve is the ratio of the summed currents and summed
voltages (i.e. 20 pA/10 mV) multiplied by the voltage step for each particular event.
In this case, the current subtracted from each event is the voltage at each event
multiplied by 2. Therefore, at the 1 mV step, a current of 2 pA is subtracted; at the 2
mV step, a current of 4 pA is subtracted, and so on. As can be seen from this
example, the calculation has the desired effect of reducing the slope of the line to
zero.
3. Slope Conductance
Slope conductances were calculated by the CED software using a least squares fit to
data points on the I/V curve between set voltage ranges. In most cases these were
-140 mV to -100 mV for inward currents and +80 mV to +100 mV for outward
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currents. In some cases (e.g. when recordings were made in high [K+] buffers), the
conductance was calculated in the range -100 mV to -80 mV.
2.37 - Statistical Analysis
Statistical analysis of electrophysiological studies was performed using Minitab
statistical software and Microsoft Excel 5.0. Comparisons between normally
distributed conductances in different treatment groups were made by ANOVA.
Individual groups were compared by unpaired Student's t tests. When recordings
were made on the same cell under different conditions, paired Students t tests were
used for comparison. Comparisons between groups with non parametric
distributions were made by Kruskal Wallis and Mann-Whitney tests. Whole-cell
conductances are expressed as mean ± s.d.
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Chapter 3
CHARACTERISATION OF IGE-DEPENDENT SECRETION IN
RAT BONE MARROW-DERIVED MAST CELLS USING A
NOVEL ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY
TO DETECT THE RELEASE OF RMCP-II
INTRODUCTION
The secretory function of many mast cell types has been studied extensively in vitro
in an attempt to further understand the pathogenesis of allergic diseases (Paterson et
al, 1976; Flint et al, 1985; Lawrence et al, 1987; Benyon et al, 1989) or
gastointestinal immune responses (Befus et al, 1982; Rees et al, 1988). Many of
these studies are designed to investigate the release of particular mediators in
response to challenge with various secretagogues. Hence, the responses of numerous
mast cell types to compound 48/80 (Befus et al, 1982; Broide et al, 1988; Barrett et
al, 1985), substance P (Shanahan et al, 1985; Broide et al, 1988), GTP-y-S
(Gomperts, 1983), and Ca2+ (Foreman et al, 1973) have all been investigated (see
chapter 1 for details). However, activation of mast cells via the IgE receptor provides
a more physiological stimulus that is analogous to the response seen in vivo during
allergic reactions.
In experimental protocols, the IgE receptor can be aggregated in three ways. Firstly,
by using divalent antibodies directed against the receptor itself (Ishizaka and
Ishizaka, 1978; Isersky et al, 1978). Secondly, by using anti-IgE antibodies to cross¬
link receptor bound IgE (Lawrence et al, 1987; Levi-Schaffer et al, 1987a;
MacDonald et al, 1989). And thirdly, by sensitising the receptors with IgE specific
for a particular antigen, and challenging the cell with the antigen (Broide et al, 1988).
The last method most commonly involves IgE antibodies raised against the
multivalent hapten dinitrophenyl-bovine serum albumin (DNP-BSA).
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Cultured rat BMMCs stimulated with lymph node conditioned medium (LNCM) are
ordinarily exposed to 1 - 2 pg of rat IgE per ml, most likely derived from B cells in
the Con A-stimulated mesenteric lymph node cell cultures (Haig et al, 1983). This
endogenous IgE binds to the BMMCs via the FceRI receptors, allowing anti-rat IgE
to be used as a secretagogue in studies of these cells (MacDonald, 1994).
MacDonald (1994) demonstrated the presence of this surface bound IgE by flow
cytometry, but also showed that the level of IgE binding could be increased by
sensitising the cells with IR162 rat myeloma IgE (Experimental Immunology Unit,
Faculty of Medicine, University of Louvain, Belgium). However, this sensitisation
regime resulted in high background mediator release (15-20%), probably due to
activation of the IgE receptors by aggregated IgE molecules (MacDonald, 1994).
Attempts to remove these aggregates by ultracentrifugation and gel filtration were
only partially successful. Therefore, in this study, it was decided to adapt the IgE
anti-DNP system to rat BMMCs. This would allow the secretory responses of
"unsensitised" and "IgE-sensitised" cells to be compared.
In studies of mast cell function, the effects of immunological or non-immunological
stimuli are usually measured in terms of percentage release of various mediators.
Typically, secretagogue-activated mast cell populations specifically release 10-50%
of the stored mediators present in the cells (White and Pearce, 1982; Pearce et al,
1982; Razin et al, 1983; Levi-Schaffer et al, 1987a; Kaplan et al, 1991; Lavens et al,
1992; Swieter et al, 1993; Shalit et al, 1993; Jaffar and Pearce, 1993). Similar
studies with rat BMMCs showed that, under optimum conditions, 16% of the RMCP-
II (MacDonald et al, 1989) and 16-26% of ^-hexosaminidase (Broide et al, 1988;
MacDonald et al, 1989) was released following IgE-mediated stimulation. An
important question relevant to the control of mediator secretion is how these values
for specific mediator release might reflect the extent to which individual BMMCs
within the population respond to stimulation. For example, 20% RMCP-II release
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from a population of cells could entail:- 1) all the cells releasing 20% of their
contents; 2) 20% of the cells releasing all their contents; or 3) variable proportions of
cells releasing variable quantities of RMCP-II. This question could have important
implications for the mechanisms involved in regulating mast cell function. For
example, factors that upregulate mast cell secretion could do so either by increasing
the proportion of cells that respond to stimulation, or by increasing the quantity of
mediator released from each cell. It would therefore be useful to develop a technique
that allowed mediator release to be detected from individual BMMCs within the
population.
Two techniques have been used previously to detect secretion from single mast cells:
whole-cell capacitance measurements (Fernandez et al, 1984; Lindau and Neher,
1988) and fast voltammetry using carbon fibre electrodes (Tatham et al, 1991).
However, these techniques do not allow the responses of single cells to be compared
to the response of the whole population. Hide et al. (1993) used flow cytometry to
monitor degranulation of individual rat peritoneal mast cells by relating the reduction
in 90° side scatter to the loss of cytoplasmic granules. In a similar technique,
MacGlashan (1995) used both the reduction in forward scatter and the loss of
granules stained with acridine orange as measures of degranulation in human
basophils following challenge with secretagogues. However, flow cytometry does
not provide a direct measure of mediator release from mast cells, making
comparisons with conventional secretion assays more difficult.
Sedgwick and Holt (1983) introduced an alternative technique for monitoring
secretion from individual cells. They developed a solid phase immunoenzymatic
method to detect secretion of specific antibodies from individual lymphocytes. This
technique, subsequently named the enzyme-linked immunospot (ELISPOT) assay
(Czerkinsky et al, 1983), relies on the binding of secreted cellular products to a
capture antibody bound to the base of plastic wells. The secreted product binds in a
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small zone surrounding each cell so that, following the addition of an enzyme-
labelled antibody and subsequent enzymatic development, a grossly visible spot
appears at the site of secretion. To date, ELISPOT assays have been restricted to the
detection of immunoglobulins and cytokines, including immunoglobulins A
(Feltelius et al, 1991), G (Tarkowski et al, 1984), M (Nick et al, 1987), and E
(Thomas and Przybilla, 1992), and various cytokines including IL-2, IL-4 and IL-6
(Fujihashi et al, 1993), and IL-5 and IFN-y (Taguchi et al, 1990; Sedgwick and
Czerkinsky, 1992).
Previous studies in this laboratory had suggested that a similar assay could possibly
be developed to monitor secretion in rat BMMCs. For example, when activated
immunologically, rat BMMCs secrete RMCP-II in a dose- and time-dependent
manner, and this correlates significantly with the release of the granule mediators (3
hexosaminidase and histamine (MacDonald et al, 1989; MacDonald, 1994).
Furthermore, a highly specific enzyme-linked immunosorbent assay (ELISA) has
been developed to measure RMCP-II in tissues and cell supernatants (Huntley et al,
1990a). Hence, the monoclonal anti-RMCP-II antibody used in the ELISA could
potentially be used as a capture antibody in an ELISPOT assay.
The initial aims in this part of the study were to further characterise IgE-dependent
secretion in rat BMMCs, with particular emphasis on how individual cells within the
population respond to stimulation. The specific aims were:-
1) To determine if an IgE anti-DNP sensitisation protocol could be used in rat
BMMCs.
2) To develop and validate an ELISPOT assay that could detect the release of
RMCP-II from individual rat bone marrow-derived mast cells (BMMCs).
3) To use the ELISPOT assay to determine how individual BMMCs within the
population respond to IgE-mediated stimulation. This might provide important clues
as to how rat BMMC secretory function is modulated.
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EXPERIMENTAL METHODS AND RESULTS
3.1 • Flow cytometric analysis of surface bound IgE on rat BMMCs
Aims
The initial aim of these experiments was to determine if an IgE anti-DNP
sensitisation protocol could be used in rat BMMCs. Unfortunately, a rat IgE anti-
DNP reagent was not available for these studies, but previous investigators have
demonstrated that mouse IgE binds equally well to the rat FceRI receptor (Sterk and
Ishizaka, 1982). Therefore, to determine the feasibility of using mouse IgE anti-DNP
to sensitise rat BMMCs, flow cytometry was used to compare cells possessing
endogenous IgE to cells passively sensitised with mouse monoclonal IgE anti-DNP
(SPE-7, Sigma).
Methods
The BMMCs in these and subsequent experiments were cultured, washed, identified,
counted and assessed for viability as described in detail in chapter 2 (sections 2.1 -
2.9). A suspension of cells was removed from each of three different bone marrow
cultures containing 19%, 80% and 93% BMMCs respectively (all > 98% viability).
The cells were washed three times and resuspended in flow cytometry buffer (FCB,
comprising PBS with 0.1% NaN3 and 3% v/v FCS). Half the cells from each culture
were incubated with lOpg mouse IgE anti-DNP / 106 cells for 1 hour at 37°C; the
other half were incubated with buffer alone. After washing a further three times in
FCB to remove unbound IgE, cells from each group were incubated for 1 hour at 4°C
with one of the following labels:-
1) A 1/200 dilution of fluorescein isothiocyanate (FITC) conjugated mouse
monoclonal IgG! anti-rat IgE (Mare-1- FITC, Serotec, Oxford, UK) to detect
endogenous IgE. Previous studies using an irrelevant monoclonal mouse IgGj
specific for a viral protein (VPM-FITC provided by G. Entrican, Moredun Research
Institute, Edinburgh) showed that this class of antibody did not bind non-specifically
to BMMCs (MacDonald, 1994).
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2) A 1/100 dilution of rat monoclonal IgG, anti-mouse IgE-FITC conjugate (LO-
ME-3, Serotec) to detect bound mouse IgE.
3) Buffer alone.
After labelling, the cells were washed three times in FCB, fixed in 2%
paraformaldehyde and stored in 15 ml centrifuge tubes at 4°C in the dark until
analysed by flow cytometry (described in chapter 2, section 2.13). Each population
of cells from each culture comprised 10 -106 cells and each flow cytometric analysis
was based on 104 cells.
Results
The binding of the endogenous IgE derived from the LNCM, and of the added IgE in
the cultures containing 19%, 80% or 93% BMMCs is shown in figures 3.1 to 3.3 and
summarised in table 3.1. Within the three cultures, 11%, 70% and 71% of the
unsensitised cells respectively were labelled with anti-rat IgE. Similar figures were
obtained for the cells sensitised with mouse IgE, indicating that the anti-rat IgE did
not cross-react with the mouse IgE. However, in the mature culture containing 93%
BMMCs, 14% of the cells appeared to fluoresce after labelling with buffer only (see
Figure 3.3). This apparently high background fluorescence may represent
autofluorescent cells, and does not necessarily indicate that the percentage of cells
labelled with anti-rat IgE or anti-mouse IgE in this culture is artificially high.
However, the proportion of cells labelled with anti-rat IgE did not increase between
the 80% and 93% cultures, and if this high background fluorescence is subtracted, the
percentage of cells labelled with anti-rat IgE is less in the culture containing 93%
BMMCs than that containing 80%. In addition, the mean fluorescence intensity
(proportional to the number of IgE molecules per cell) is higher in the fluorescing
cells from the culture containing 19% BMMCs than in either of the more mature
cultures (Table 3.2). These results suggest that the proportion of BMMCs bearing
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endogenous IgE, and the occupancy of the IgE receptors on each BMMC, might
actually decrease as the cultures reach maturity.
After sensitisation with monoclonal mouse IgE anti-DNP, 33%, 76% and 95% of the
cells from the same cultures were positively labelled with rat anti-mouse IgE (Table
3.1), demonstrating that the mouse IgE had bound to the rat IgE receptor. However,
24, 21 and 25% of the cells respectively from the unsensitised groups were also
labelled by the rat anti-mouse IgE, suggesting that this reagent might be cross-
reacting with rat IgE and/or binding non-specifically to other cell types. The latter
conclusion was also suggested by the finding that 33% of the cells fluoresced in the
culture that only contained 19% BMMCs. However, when cells from cultures
containing 80% and 93% BMMCs were sensitised with IgE and labelled with anti-
mouse IgE, the fluorescence histograms shifted to the right (Figures 3.2 and 3.3),
demonstrating both an increase in the proportion of fluorescing cells and an increase
in mean fluorescence (Table 3.2). Taken together, these results suggest that the
binding of endogenous IgE to BMMCs may decrease throughout culture, but the
proportion of cells with surface-bound IgE, and the occupancy of the IgE receptors
on each cell, can be increased by passive sensitisation with mouse IgE anti-DNP.
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Figure 3.1 - Flow cytometric analysis of rat BMMC culture containing 19% mast
cells. Cells were either unsensitised (A,B,C) or sensitised with mouse IgE anti-DNP
(D.E.F). Cells from both groups were then labelled with either buffer alone (A and
D), mouse anti-rat IgE-FITC conjugate (B and E), or rat anti-mouse IgE-FITC
conjugate (C and F). A bi-modai distribution with a small peak to the right appears
in the cells labelled with anti-rat IgE or anti-mouse IgE. indicating the subpopulation
of cells with bound IgE (see text for details).
x-axis = log units of fluorescence: y-axis = number of cells: Ml marker placed at the
right border of the negative control histogram (A. cells labelled with buffer only).
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Figure 3.2 - Flow cytometric analysis of rat BMMC culture containing 80% mast
cells. Cells were either unsensitised (A.B.C) or sensitised with mouse IgE anti-DNP
(D,E,F). Cells from both groups were then labelled with either buffer alone (A and
D), mouse anti-rat IgE-FITC conjugate (B and E), or rat anti-mouse IgE-FITC
conjugate (C and F). A bi-modal distribution with a large peak to the right appears in
cells labelled with anti-rat IgE or anti-mouse IgE. but cells labelled with anti-mouse
IgE have a higher mean fluorescence (see text for details).
Axes and Ml marker as in Figure 3.1.
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Figure 3.3 - Flow cytometric analysis of rat BMMC culture containing 93% mast
cells. Cells were either unsensitised (A.B.C) or sensitised with mouse IgE anti-DNP
(D.E.F). Cells from both groups were then labelled with either buffer alone (A and
D), mouse anti-rat IgE-FITC conjugate (B and E), or rat anti-mouse IgE-FITC
conjugate (C and F). Cells labelled with either anti-rat IgE or anti-mouse IgE are
labelled as a normal distribution, with no second peak. The proportion of cells
labelled with anti-mouse IgE is higher than those labelled with anti-rat IgE, and they
have a higher mean fluorescence.
Axes as in Figure 3.1. The Ml marker was placed at the start of the tail on the right
border of the negative control histogram (A. cells labelled with buffer only). This
region was excluded because it may contain autofluorescent cells.
104
Table 3.1 - Percentage of BMMCs labelled with anti-IgE
IMaturity of Culture
Treatment Label 19% BMMCs 80% BMMCs 93% BMMCs
Buffer 0.8% 2% 14%
Unsensitised a rat IgE 11% 70% 71%
a mouse IgE 24% 21% 25%
Buffer 0.9% 1.7% 14%
Sensitised a rat IgE 11% 70% 69%
a mouse IgE 33% 76% 95%
Table 3.2 - Mean log fluorescence of labelled cells
Maturity of Culture
Treatment Label 19% BMMCs 80% BMMCs 93% BMMCs
Buffer 39 51 101
Unsensitised a rat IgE 205 146 134
a mouse IgE 160 201 158
Buffer 43 52 102
Sensitised a rat IgE 166 166 136
a mouse IgE 124 234 282
Tables 3.1 and 3.2 - Detection of surface bound endogenous or exogenous IgE by
flow cytometry in three different bone marrow cultures containing 19%, 80% and
93% BMMCs. Cells from each culture were either unsensitised or sensitised with
mouse IgE anti-DNP. Cells from both groups were then labelled with either buffer
alone, mouse anti-rat IgE-FITC conjugate or rat anti-mouse IgE-FITC conjugate.
Table 3.1 - The figures indicate the percentage of total cells labelled.
Table 3.2 - The figures indicate the mean log fluorescence of the labelled cells
(arbitrary units).
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3.2 - Activation of BMMC secretion by challenging IgE-sensitised cells with
DNP-BSA
Aims
The flow cytometry analysis showed that i) mouse IgE anti-DNP could bind to rat
BMMCs, and ii) that passive sensitisation with mouse IgE could increase both the
proportion of cells binding IgE, and the amount bound. However, it was important to
demonstrate that DNP-BSA could trigger mediator release from IgE-sensitised
BMMCs. The following preliminary experiment was designed to compare the
responses of sensitised BMMCs to a range of DNP-BSA concentrations with those of
unsensitised BMMCs to an optimal dilution of anti-IgE.
Methods
A suspension of BMMCs from a culture containing 98% mast cells (100% viability)
was washed three times in Tyrodes buffer/EDTA (TB/EDTA, chapter 2, section
2.12) and divided into two aliquots. One aliquot was sensitised with mouse
monoclonal IgE anti-DNP as described in chapter 2 (section 2.15) and the other
aliquot was incubated with buffer alone. After three further washes in TB to remove
unbound IgE, the cells were resuspended in TB/Ca2+/Mg2+ (TB+) and divided into 14
treatment groups as shown overleaf. Each group comprised a suspension of 0.9 x 106
cells in a volume of 0.5 ml TB+. The BMMCs were challenged with various
concentrations of DNP-BSA or anti-IgE as described in chapter 2 (sections 2.16 -
2.17), and the pellets and supernatants were assayed for (3 hexosaminidase as
described in section 2.19.
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Experimental Design
IgE-Sensitised Cells Unsensitised Cells
Tube Secretagogue Dilution Tube Secretagogue Dilution
1. DNP-BSA 1/10 9. Goat anti-rat IgE 1/250
(lmg/ml)
2. DNP-BSA 1/100 10. Goat anti-rat IgE 1/250
3. DNP-BSA 1/1000
4. DNP-BSA 1/10,000 11. DNP-BSA 1/100
5. DNP-BSA 1/100,000 12. DNP-BSA 1/100,000
6. Tyrode's Buffer 13. Normal goat serum 1/250
7. Tyrode's Buffer 14. Normal goat serum 1/250
8. Tyrode's Buffer
Results
The percentage release of (3 hexosaminidase from BMMCs in each treatment group is
shown in Figure 3.4. As described in previous studies (MacDonald, 1994), goat anti-
rat IgE triggered the release of [3 hexosaminidase from BMMCs without the need for
prior sensitisation with IgE (11% release for anti-IgE vs. 0.5% in response to NGS,
or 1.2% in response to DNP-BSA, mean of 2 tubes). DNP-BSA stimulated (3
hexosaminidase release from IgE-sensitised cells at all dilutions tested, but dilutions
of 1/1000 or less were required for optimum secretion (14.3% at 1/1000 vs. 0.4% in
response to buffer alone, Figure 3.4). In subsequent secretion assays, DNP-BSA was
therefore used at a final dilution of 1/1000 (10pg/ml). These assays, and the
statistical analysis of the effects of anti-IgE and DNP-BSA on BMMC secretion, are
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Figure 3.4 - Preliminary experiment showing the percentage release of (3
hexosaminidase from BMMCs in response to IgE-dependent stimulation. BMMCs
from a culture containing 98% mast cells were either sensitised with mouse IgE anti-
DNP or incubated with buffer alone. The sensitised cells were challenged with
concentrations of DNP-BSA ranging from 1 mg/ml (1/10) to 10 ng/ml (1/100,000),
and the unsensitised cells were challenged with goat anti-rat IgE at an optimal
dilution of 1/250. The number above each bar represents the number of tubes, each
containing 0.9 x 106 cells, that received each stimulus. For replicate tubes, the range
is shown. DNP = DNP-BSA, Buffer = Tyrode's buffer/Ca2+/Mg2+, algE = goat anti-
rat IgE, NGS = normal goat serum.
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3.3 ■ Development of an enzyme-linked immunospot (ELISPOT) assay for the
detection of IgE-dependent RMCP-II release from individual BMMCs
Aims
The aim of this section was to determine the feasibility of detecting RMCP-II release
from individual cells using an ELISPOT method.
Methods
The mouse monoclonal anti-RMCP-II and the affinity-purified polyclonal sheep anti-
RMCP-II for use in the ELISPOT assay was kindly provided by Mr. G.F.J.
Newlands, Moredun Research Institute, Edinburgh, UK. The purified RMCP-II was
provided by Mr. G.F.J. Newlands and Dr. C.L. Scudamore, Royal (Dick) School of
Veterinary Studies, University of Edinburgh, UK. The preparation of these reagents
has been described (Huntley et al, 1990a).
The ELISPOT assay methodology was a modification of the solid-phase immuno-
enzymatic technique introduced by Sedgwick and Holt (1983). The principle of the
assay is shown in Figure 3.5 and described below. 48 well cell culture plates (Costar,
Cambridge, MA, USA) were incubated overnight at 4°C with 150 pl/well mouse
monoclonal anti-RMCP II (lpg/ml) in PBS, pH 7.5. After washing twice with
PBS/0.05% tween 20 (PBS/T20), remaining binding sites were blocked by adding
200pl of 1% non fat milk (Marvel, Premier Brands, Stafford, UK) in PBS to each
well and incubating for 1 hour at 37°C. The plate was then washed 4 times in PBS
and a known number of BMMCs suspended in 125 pi of TB+ was added to each well.
Cells were usually diluted to provide between 100 and 400 cells/well using the
following dilution factor:
Dilution factor = Number of BMMCs/pl x 125
Number of BMMCs/well
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Hence, with a typical initial cell density of 5 x 103 BMMCs/ml (500/pl), a dilution of
1:625 would provide 100 cells per well. The presence of a single cell suspension was
confirmed by examination of the wells under a phase contrast microscope. RMCP II
(125pl at 50ng/ml) was added to one or two wells as a positive control, and wells
containing buffer but no cells were included as negative controls. The cells were
challenged with 125 pi of appropriately diluted secretagogue (anti-IgE or DNP-BSA)
or control stimulus (NGS or TB+) and incubated for 30 min at 37°C. The wells were
washed four times in PBS/T20 to remove the cells, and bound RMCP-II was detected
by sequentially incubating the plate with 150pl/well 1:1000 sheep anti-RMCP-II and
150pl/well 1:10,000 donkey anti-sheep IgG-alkaline phosphatase conjugate (Sigma),
both diluted in PBS/T20/4% BSA. Incubations were for one hour at 37°C and plates
were washed four times after each incubation in PBS/T20. The substrate solution
was prepared as described (see appendix 1 and Sedgwick & Holt, 1983) and
comprised 1 mg/ml 5-bromo-4-chloro-3-indoyl phosphate (BCIP, Sigma) dissolved
in AMP buffer (1.0 M 2-amino-2-methyl-l-propanol (Sigma), 0.7mM MgCl2 and
0.01% v/v Triton-X-405, pH 10.25). This solution was heated to 40°C and mixed
with an agarose solution (Type 1, Sigma) at 60°C to yield a final concentration of
0.6% w/v agarose. 200pl of the substrate/agarose mixture was added immediately to
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Figure 3.5 - Principle of the ELISPOT assay. A - Wells are coated with mouse
monoclonal anti-RMCP-II. B - A known number of BMMCs are added to each well.
C - The cells are challenged with a secretagogue causing mediator release by a
proportion of the cells. The granule chymase RMCP-II binds to the capture antibody
in a focal spot surrounding each cell. D - The cells are washed away and the bound
RMCP-II is detected with a polyclonal sheep anti-RMCP-II antibody. E - The sheep
anti RMCP-II is recognised by a donkey anti-sheep IgG-alkaline phosphatase
conjugate. F - A substrate for alkaline phosphatase is added resulting in colour
development at the site of the focal spot of bound RMCP-II (see text for details).
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Results
The results of a typical ELISPOT assay are shown in Figure 3.6 (The plate map for
this and subsequent ELISPOT assays, along with the spot counts, are shown in
appendix 3). For this assay, a suspension of BMMCs from a culture containing 92%
mast cells (viability 100%) was washed three times in TB/EDTA and sensitised with
IgE as described in chapter 2 (section 2.15). The cells were then diluted to yield 134
BMMCs (150 cells) per well, which were added to columns 1 - 7 of the plate.
Column 8 contained buffer but no cells, and well F8 contained 50 ng/ml RMCP-II as
a positive control (Figure 3.6). The cells in rows A to E were challenged with DNP-
BSA, and those in row F were challenged with TB+ to detect spontaneous release.
During development of the plate, discrete blue spots started to appear within 10 min
of addition of the substrate, but complete development took a number of hours. The
plates were therefore left overnight before the number of spots was assessed (Figure
3.6). The spots reveal sites at which individual BMMCs had degranulated, releasing
RMCP-II which bound to the capture antibody. The spots could be counted under a
bright light without magnification, although they were more clearly visualised with a
6.4 x dissecting microscope (Figure 3.6). Examination of wells at higher
magnification was unhelpful because pin-point foci of substrate became visible, even
in the negative control wells. The size of the spots was not measured objectively,
although variation was observed in all assays, as can be seen in Figure 3.6. An
attractive feature of the assay was that the coloured spots of substrate were fixed in
the solidified agarose matrix, allowing plates to be kept for a number of weeks
without deterioration.
The wells in which BMMCs were challenged with DNP-BSA contained 18 ± 5 spots
(mean ± s.d., n=35), which was significantly greater those challenged with Tyrode's
buffer (2 ± 1 spots, n=7, p < 0.0001). As would be expected with any biological
system, the number of spots varied from well to well, and this variability is addressed
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in detail in section 3.6 of this chapter. The positive control well (F8, 50 ng/ml
RMCP-II) and the negative (no cells) control wells (A8 to E8) were diffusely blue
and clear respectively (Figure 3.6). However, in some assays, spots were
occasionally observed in the negative control wells (see appendix 3). In this case, the
spot counts were averaged and subtracted from the spot counts in treatment wells
before statistical analysis.
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Figure 3.6 - A: 48 well plate showing the typical appearance of an ELISPOT assay.
134 IgE-sensitised BMMCs were added to columns 1-7. Column 8 contained
buffer but no cells as a negative control, and well F8 contained 50 ng/ml RMCP-II as
a positive control. Rows A to E were challenged with DNP-BSA, and row F was
challenged with Tyrode's buffer/Ca2+/Mg2+. The spots represent sites at which
individual BMMCs had degranulated, releasing RMCP-II which bound to the capture
antibody. The bound RMCP-II was detected by an immuno-enzymatic method (see
text for details). Scale marker = 1 cm.
B: Magnified wells showing the discrete blue spots that can be easily visualised and
counted. Scale marker = 1 cm.
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3.4 - Sensitivity and specificity of the ELISPOT assay
Aims
The previous experiment demonstrated that the ELISPOT assay could detect RMCP-
II release from IgE-sensitised BMMCs challenged with DNP-BSA. However, at this
stage it was not known whether the assay was sufficiently sensitive to detect RMCP-
II release from all the cells. For example, a mean of 18 spots appeared in the
antigen-stimulated wells, although these wells contained 134 BMMCs. This might
occur if the assay could only detect RMCP-II release from a proportion of larger cells
with the most RMCP-II. Hence, if conclusions were to be drawn about the
proportion of BMMCs within the population that responded to IgE-mediated
stimulation, it was important to determine the sensitivity of the assay. In addition, it
was important to determine that the released RMCP-II was binding specifically to the
capture antibody rather than non-specifically to the plate.
Methods
To determine if the ELISPOT assay was sufficiently sensitive to detect the release of
RMCP-II from individual cells, the lowest concentration of purified RMCP-II that
could be detected in 1 pi droplets was measured. The droplets were added to the anti-
RMCP-II antibody-coated plates using a lpl pipette in an attempt to reproduce the
small quantities of RMCP-II released from BMMCs during degranulation. Four
separate experiments were performed in which twofold serial dilutions of RMCP-II
from 500 pg/pl to 0.03 pg/pl were added to wells, lpl droplets containing only
buffer were added to three wells as controls. The plates were wrapped in clingfilm to
prevent evaporative losses and incubated for 30 min at 37°C in a humidified
incubator. The droplets had not dried out when the plates were removed from the
incubator and were still clearly visible. After the plates were washed to remove the
droplets, they were developed as described above (section 3.3).
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To ensure that RMCP-II was binding specifically to antibody coated wells, a similar
experiment was performed in which serial dilutions of RMCP-II in lpl droplets were
added to wells coated with PBS, rabbit polyclonal anti-RMCP-I, or mouse
monoclonal anti-RMCP-II.
Results
Figure 3.7 shows one of four similar experiments in which serial dilutions of RMCP-
II were added to anti-RMCP-II-coated plates in the form of lpl droplets (4 droplets
per well). The plate is divided into three regions comprising the upper two, middle
two and lower two rows. The serial dilutions ranging from 500 pg/pl to 0.03 pg/pl
run from left to right, with droplets in wells B8 and D8 containing only buffer and
well F8 containing 50 ng/ml RMCP-II. The limit of detection was taken as the last
well in which four distinct spots could be clearly visualised (arrows). In this assay,
spots were visible at a concentration of 0.24 pg/pl, but in three similar experiments
the end points were 0.98 pg/pl, 1.95 pg/pl, and 3.9 pg/pl yielding a mean theoretical
sensitivity of 1.8 ± 1.6 pg RMCP-II/pl (mean ± s.d., n=4).
The mean RMCP-II concentration in individual mast cells, determined by ELISA of
freeze/thawed cell pellets, increased from 3.4 ± 0.3 pg/cell at day 4 to 30.4 ± 3
pg/cell at day 28 (see chapter 2, Figure 2.2). Thus, the ELISPOT assay could
theoretically detect a mature mast cell that released = 6% of its RMCP-II, and a
developing BMMC at day 4 that released = 50% of its RMCP-II. However, the size
of the applied droplets was inevitably much larger than the diffusional area of
RMCP-II released from a cell, resulting in a wider spread of the applied protease
over the base of the well than would occur following degranulation (compare the spot
sizes in Figures 3.7 and 3.6). It is likely, therefore, that the observed limit of
detection of 1.8 pg RMCP-II/pl is an under-estimate of the true sensitivity of the
assay. Despite this, these results demonstrate that the ELISPOT assay is sufficiently
sensitive to detect RMCP-II release from the vast majority of BMMCs, with the
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possible exception of extremely immature cells that release less than 50% of their
RMCP-II.
In a similar experiment to that described above, RMCP-II only bound to wells coated
with anti RMCP-II, and no spots developed in wells coated with PBS or anti-RMCP-
I (not shown), thus confirming that the binding of RMCP-II represented a specific
antibody-antigen interaction.
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Figure 3.7 - Sensitivity of the ELISPOT assay. The 48 well plate was coated with
anti-RMCP-II and is divided into three regions: upper two (A and B), middle two (C
and D) and lower two rows (E and F). Serial dilutions of RMCP-II running from left
to right and ranging from 500 pg/p.1 (wells Al, CI, El)to 0.03 pg/p.1 (wells B7, D7,
F7) were added to the wells as 1 ptl droplets (4 per well). Wells B8 and D8 contained
droplets of buffer only, and well F8 contained 50 ng/'ml RivlCP-II as a positive
control. The limit of detection was taken as the last well in which four distinct spots
could be clearly visualised (arrows, 0.24 pg/pil).
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3.5 ■ Correlation between cell density and the number of spots per well in
ELISPOT assays
Aims
The previous experiments demonstrated that the ELISPOT assay could detect
RMCP-II release from individual BMMCs. However, for accurate interpretation of
ELISPOT assays, it was important to demonstrate that the number of spots appearing
in each well correlated with the number of cells placed in each well, even if only a
proportion of the BMMCs responded to stimulation.
Methods
Four similar ELISPOT assays were performed in which cell suspensions from
cultures containing different proportions of BMMCs were serially diluted to yield
400, 200, 100, 50, 25, 12 and 6 cells per well. The estimated number of BMMCs per
well in each experiment is shown below, with the number of replicate wells in
brackets.
Percentage of BMMCs in each culture
38% 53% 95% 97%
Total cells per well Approximate number of BMMCs per well
400 150 (5) 210 (2) 380 (8) 390 (8)
200 75 (5) 105 (2) 190 (8) 195 (8)
100 38 (5) 52 (2) 95 (8) 98 (8)
50 19 (5) 26 (2) 48 (8) 49 (8)
25 9 (5) 13 (2) 24 (8) 25 (8)
12 5 (3) 7 (2) 12(8) 12 (8)
6 2 (3) 3 (2) 6 (8) 6(8)
The cells from cultures containing 38% and 53% BMMCs were challenged with goat
anti-rat IgE and those from cultures containing 95% and 97% BMMCs were
sensitised with mouse IgE and challenged with DNP-BSA (described in chapter 2,
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sections 2.14-2.16). Normal goat serum (NGS) and TB+ were used as negative
controls as described previously. The number of spots that developed in each well
was then counted and compared to the estimated number of BMMCs in each well.
Results
The relationship between cell density and number of spots per well in the four
experiments is shown in Figure 3.8. In all assays, the number of spots in wells
challenged with either anti-IgE or DNP-BSA increased linearly with increasing cell
density (solid circle, r=0.99 in each case, p<0.001). The slope of the lines therefore
indicates the proportion of BMMCs that responded to stimulation. Hence, 21% and
16% of the BMMCs from the cultures containing 38% and 53% mast cells
respectively detectably released RMCP-II in response to anti-IgE. The spontaneous
degranulation of BMMCs from these cultures was extremely low, with spot counts
amounting to 1.1% of the BMMC counts in both cases (Figure 3.8 A and B, solid
triangles). In the cultures containing 95% and 97% mast cells, 16% and 15% of the
BMMCs respectively released RMCP-II in response to DNP-BSA. However, the
spontaneous release from BMMCs challenged with buffer alone was higher than in
the immature cultures (3.9% in both cases), and again, cell density correlated closely
with the number of spots counted (Figure 3.8 C and D, solid triangles, r=0.99,
pcO.OOl).
These results demonstrate that the spots developing in ELISPOT assays are closely
correlated with the number of BMMCs placed in each well. They also indicate that
only 12 - 15% of BMMCs within the population specifically responded to challenge
with either anti-rat IgE or DNP-BSA. This phenomenon is discussed further in
section 3.7 of this chapter.
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Figure 3.8 - The relationship between density of BMMCs and the number of spots
per well in ELISPOT assays. BMMCs were serially diluted as described in the text.
BMMCs from cultures containing 38% (A) and 53% (B) mast cells were challenged
with goat anti-rat IgE (A and B solid circles) or normal goat serum (solid triangles).
BMMCs from cultures containing 95% (C) and 97% (D) mast cells were sensitised
with mouse IgE anti-DNP and challenged with DNP-BSA (C and D solid circles) or
Tyrode's buffer (solid triangles). Each point represents the mean ± s.e.m. of
individual spot counts from the number of wells indicated in the text. Correlation
coefficients for all lines = 0.99, p<0.001, except for the groups challenged with
normal goat serum in A and B (A, r = 0.97, p<0.01; B, r = 0.64, p = 0.12).
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3.6 - Repeatability and statistical analysis of the ELISPOT assay
Aims
The variability of other immunological assays such as ELISAs and
radioimmunoassays (RIAs) depends chiefly on physico-chemical factors such as
pipetting, dilutions, antibody coating, antibody/antigen interactions and enzyme
kinetics. However, in the case of the ELISPOT assay, an additional source of
variation is the biological responses seen in a population of cells (see the variation in
the number of spots per well in Figure 3.5). Hence, it was important to characterise
this variation to allow correct statistical analysis of ELISPOT data.
Methods
A suspension of IgE-sensitised BMMCs from a culture containing 98% mast cells
(100% viability) was diluted to provide 100 BMMCs/well. The cells were added to
42 wells of 5 separate 48 well plates. Cells in 28 wells in each plate were challenged
with DNP-BSA and the cells in 14 wells were challenged with TB+. The remaining 6
wells contained buffer but no cells, and comprised the positive and negative controls
(Figure 3.9).
100 100 100 100 100 100 100 _
DNP-BSA 100 100 100 100 100 100 100 _
100 100 100 100 100 100 100 _
100 100 100 100 100 100 100 -
Buffer 100 100 100 100 100 100 100 _
100 100 100 100 100 100 100 ©
Figure 3.9 - Plate map for the above experiment. Five identical plates were prepared
in which 100 BMMCs were placed in each well marked 100. - = negative control (no
cells), © = 50 ng/ml RMCP-II. The top four rows were challenged with DNP-BSA,
the lower two with Tyrode's buffer/Ca2+/Mg2+.
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Results
The spot counts from the five replicate plates are shown below.
1 2
7 12 16 11 10 16 5 0 17 6 13 13 6 9 11 0
5 13 20 11 15 5 26 0 11 5 21 12 18 12 16 0
8 15 11 16 17 23 12 0 11 11 14 7 19 20 15 0
9 13 9 21 18 18 17 0 17 12 13 8 11 16 13 0
2 2 3 2 1 3 2 0 0 1 1 5 1 4 2 0
3 1 1 1 2 6 0 + 1 1 1 4 2 1 5 +
3 4
9 15 14 7 13 8 11 0 18 11 13 10 12 13 12 0
8 12 13 9 23 8 14 0 10 18 26 14 25 13 10 0
11 14 11 17 17 8 14 0 7 17 16 16 24 33 17 0
8 22 14 12 22 22 12 0 9 16 12 20 20 16 25 1
1 3 4 2 1 2 3 0 3 3 2 5 1 1 1 0
2 1 0 3 1 1 1 + 3 1 1 2 1 0 0 +
5
14 16 12 11 9 9 10 0
15 12 17 19 25 11 16 0
14 14 17 17 27 20 14 0
12 16 18 20 11 27 11 0
4 3 2 4 2 0 0 0
0 2 1 3 2 2 3 +
The spot counts in each of the five replicate ELISPOT assays from both the DNP-
BSA treated cells and the buffer-treated cells were normally distributed as assessed
by the Ryan-Joiner test (Minitab Statistical Software). The data was therefore
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suitable for analysis by parametric tests. The proportions of BMMCs releasing
RMCP-II following challenge with DNP-BSA or buffer are shown below (means ±
s.d. to nearest whole number):
Plate Number DNP-BSA Buffer
1 14 ±5% 2 ± 1%
2 13 ±4% 2 ±2%
3 13 ±5% 2 ± 1%
4 16 + 6% 2+1%
5 16 + 5% 2+1%
The well to well coefficients of variation for the five plates (based on the 28 DNP-
BSA challenged wells) were 40%, 33%, 36%, 38% and 32%, yielding a mean well to
well coefficient of variation of 36 ± 3%. This relatively high figure represents the
biological variation within the cell population, and has an important bearing on the
performance of the ELISPOT assay. Clearly, experiments involving the comparison
of individual wells would be unacceptable. Hence, it was important to determine
how many wells would be required for meaningful comparisons to be made between
different treatment groups. Put differently, how many wells in the above experiment
would need to be compared to yield an acceptable (= 10-15%) coefficient of
variation? This problem was addressed by assigning the 28 DNP-BSA-stimulated
wells in the above experiment to arbitrary treatment groups, allowing the inter-plate





Figure 3.9 - Comparison of different numbers of wells for determination of the inter-
plate coefficient of variation (c.v. = s.d.-5-mean xl00%). The shaded regions
represent corresponding wells in which the cells are regarded as one group. In A, the
spot counts from the 28 wells in each plate are regarded as one treatment group and
averaged. The inter-plate c.v. is then based on the mean and s.d. of the 5 averages. In
B, C, and D the mean and s.d. of the 5 average spot counts from 14, 7, or 4
corresponding wells are compared. The coefficients of variation for each calculation
are 10.6% (A), 10.9% (B, mean of 2), 11.5% (C, mean of 4) and 17.5% (D, mean of
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The inter-plate coefficient of variation was calculated by comparing spot counts from
either 4, 7, 14 or 28 corresponding wells from the 5 plates (Figure 3.9). If the spot
counts in the 28 wells were averaged and regarded as one treatment group, the
coefficient of variation between the 5 plates was 10.6%. If 14 corresponding wells
per plate were regarded as separate treatment groups, the mean coefficient of
variation was 10.9 ± 1% (n=2). When 7 wells per plate were compared, the mean
coefficient of variation was 11.5 ± 4% (n=4), and this increased to 17.5 ± 6% (n=7)
when 4 corresponding wells were compared. As expected, these results indicate that
the larger the treatment group (in terms of the number of wells counted), the lower
the variability. However, they suggest that treatment groups studied in the ELISPOT
assay should preferably comprise at least seven wells to avoid excessive inter-assay
variation.
A further question regarding the analysis of data from ELISPOT assays concerns the
use of statistical tests. As the data is normally distributed, parametric tests such as
one way analysis of variance (ANOVA) and Student's t test should be appropriate for
comparing treatment groups. However, when the spot counts in the 28 identically
treated DNP-BSA-challenged wells from the 5 plates were compared by ANOVA,
the mean spot counts were marginally different at a significance level of 0.05
(p=0.047). Hence, when using parametric tests such as ANOVA, a significance level
of 0.01 would be more appropriate for analysis of ELISPOT data. When the 28 wells
from the 5 plates were compared by the non-parametric Kruskal Wallis test (which is
more robust against outliers), the spot counts were not significantly different
(p=0.113). In summary, these results suggest that if spot counts from different
treatment groups are compared using ANOVA, a significance level of 0.05 might
reflect assay variation. Therefore, treatment groups should be compared at a
significance level of 0.01, or alternatively, non parametric statistical tests should be
used.
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3.7 - Characterisation of IgE-mediated RMCP-II release by BMMCs at various
stages of culture
Aims
This section provides a summary of all the ELISPOT assays performed to date in
which BMMCs were challenged with either anti-IgE or DNP-BSA. Some of the
assays were described earlier in this chapter, and the remainder represent controls for
experiments described in chapter 4. The purpose of this section is to allow a
comparison between the effects of anti-rat IgE on unsensitised BMMCs at various
stages of culture, and DNP-BSA on BMMCs sensitised with mouse IgE anti-DNP.
Methods
To characterise the response of BMMCs to anti-IgE during various stages of
maturation, a series of 16 ELISPOT assays was performed on cells taken at intervals
throughout the growth of 3 different cultures (summarised in Table 3.3). In addition,
a further 7 ELISPOT assays were performed using IgE-sensitised BMMCs from
mature cultures (Table 3.3). The cells were prepared, diluted and stimulated as
described in chapter 2 (sections 2.10, 2.14-2.16) and the ELISPOT assays were
performed as described in section 3.3.
Results
The results of the 22 ELISPOT assays are summarised in Table 3.3 (and shown in
appendix 3). Overall, 7 ± 7% of unsensitised BMMCs specifically released RMCP-II
in response to challenge with anti rat IgE (calculated by subtracting the percentage of
BMMCs that released RMCP-II in response to NGS). However, this response was
dependent on the stage of culture from which the BMMCs were derived. In eight
experiments performed using cultures containing 8, 36, 38, 41, 53, 64, 66% or 85%
BMMCs, a highly significant (p<0.001) proportion of BMMCs responded to anti-IgE
when compared to NGS controls, with a mean specific response of 13 ± 7%. By
contrast, in eight experiments performed using cultures containing 87, 89, 92, 95, 95,
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96, 98 or 99% mast cells, only 1.8 + 1% of the BMMCs specifically responded to
anti-IgE.
To determine if the poor specific response in mature cultures was related to the level
of IgE binding, BMMCs from four different mature cultures were sensitised with
mouse IgE anti-DNP IgE and challenged with DNP-BSA. In seven experiments
performed using cultures containing 92, 95, 97, 98, 98, 99, or >99% mast cells, a
mean of 12 ± 2% of BMMCs specifically released RMCP-II in response to DNP-
BSA (Table 3.3)
The explanation for the poor specific response to anti-IgE in the mature cultures did
not appear to be related to higher spontaneous release from these cells. Although the
spontaneous release of RMCP-II was higher in the BMMCs showing a poor specific
response (11 ± 10%) than those showing a significant specific response (2.4 ± 0.8%),
the difference was not significant. Likewise, the poor response of the mature
BMMCs to anti-IgE did not seem to be related to poor cell viability, although in one
experiment, a viability of only 77% resulted in spontaneous release of RMCP-II from
34% of the cells (see Table 3.3).
These results, together with the flow cytometry analysis, strongly suggest that the
level of endogenous IgE binding may be deficient in mature BMMC cultures,
resulting in a sub-optimal response to challenge with anti-IgE. However, more
interestingly, even when BMMCs were passively sensitised with exogenous IgE,
only 12% of the cells apparently degranulated. This suggests that, under our
experimental conditions, a large proportion of the BMMC population was refractory
to IgE-dependent stimulation.
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A - Response of BMMCs to anti-IgE
Culture Day of % % Response to Spontaneous Specific No. Wells Details of
Culture BMMCs Viability a-IgE (%) release (%) response (%) Counted Experiment
1 8 38 92 21a 1.1" 20* 31 Section 3.5
10 53 97 16a l.la 15* 14 Section 3.5
11 66 97 15.8 ±4.5 3.2 ±2.7 16* 8 Section 3.7
15 89 98 2.8 + 0.5 1.5 ±0.4 1 9 Section 3.7
17 96 99 3.1 ±0.4 2± 1.2 2 9 Section 4.2
2 4 8 >99 26.8 ± 6.8 2.4 ± 2.7 24* 18 Section 4.4
8 41 >99 8.1 ± 1.9 2.5 ± 1.3 6* 18 Section 4.4
11 64 97 10.6 ±3 2.2 ± 1.2 8* 18 Section 4.4
15 85 96 9.9 ± 1.9 3.1 ± 1.6 7* 18 Section 4.4
18 92 96 12.5 ±4.2 10.2 ±2.6 2 18 Section 4.4
21 98 93 20.5 ±5.3 20.5 ± 5.9 0 18 Section 4.4
3 9 36 98 8.9 ±3.2 2.9 ± 1.2 6* 18 Section 4.4
17 87 98 9.5 ±5.7 6.4 ±3.7 3 18 Section 4.4
21 95 96 9.4 ±3.3 7.6 ± 2.4 2 18 Section 4.4
24 95 92 9.1 ±3.7 6.5 ± 2.8 3 18 Section 4.4
28 99 77 35.3 ±9.3 34 ±8.9 1 18 Section 4.4

















4 16 98 100 12.7 ± 1.7 3.4 ±3 9* 9 Section 4.5
17 99 100 14.7 ±4.9 1.9 ± 1.5 13* 9 Section 4.5
22 >99 100 9.7 ±3.6 3.1 ± 1.3 6.6* 8 Section 4.3
5 19 92 100 13.7 ±5 1.6 ± 1.2 12* 35 Section 3.3
26 95 100 16a 3.9a 12* 56 Section 3.5
6 19 97 100 15a 3.9a 11* 56 Section 3.5
7 23 98 100 14.5 ± 5 1.9 ± 1.4 13* 140 Section 3.6
Table 3.3 - Proportion of BMMCs that responded to anti-IgE or DNP-BSA,
caicuiated by expressing spot counts in ELISPOT assays as a percentage of the
number of BMMCs per well. BMMCs from immature cultures (<85% BMMCs)
show a significant response to anti-IgE, but a poor response is seen in cells from
mature cultures. The response can be restored by sensitising the BMMCs with IgE
anti-DNP and challenging with DNP-BSA. a = values determined from the slope of




In this chapter, the development of a novel enzyme-linked immunospot (ELISPOT)
assay to detect RMCP-II release from individual BMMCs is described. This
technique has proved remarkably successful, allowing basic questions concerning the
regulation of IgE-dependent mediator release in rat BMMCs to be addressed. The
technique is also the first to quantify the release of a specific mediator from
individual mast cells of any type.
The assay was based on the detection of rat mast cell protease-II (RMCP-II), a
granule chymase specific to rat intestinal mucosal mast cells and rat bone marrow-
derived mast cells (BMMCs) (Gibson and Miller, 1986; McMenamin et al, 1987).
Release of RMCP-II from BMMCs correlates closely with the release of other
preformed granule mediators such as (3 hexosaminidase and generation of membrane-
derived lipid mediators such as leukotriene C4 (MacDonald et al, 1989). Detection
of RMCP-II release is therefore a useful marker of secretion in these cells. In
addition, RMCP-II is released by rat intestinal mucosal mast cells both constitutively
and following IgE-mediated activation, and is thought to play an important role in the
expulsion of gastro-intestinal nematodes (Miller et al, 1983; Woodbury et al, 1984;
Scudamore et al, 1995b). Thus, detection of RMCP-II release by BMMCs in the
ELISPOT assay in vitro has great relevance in vivo, and provides an insight into the
regulation of mast cell responses in the gut.
As with any new biological assay, specificity, sensitivity and reproducibility are
important considerations. The assay was developed using reagents that are highly
specific for RMCP-II (Huntley et al, 1990a), and the protease was shown to bind
specifically to wells coated with anti-RMCP-II antibodies. More importantly, the
assay was shown to be sufficiently sensitive to detect RMCP-II release from
individual cells, allowing the proportion of responding BMMCs within a population
to be determined. In terms of repeatability, the mean intra-assay (well to well)
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coefficient of variation in the ELISPOT assay (36%) was much higher than that
accepted for ELISAs or RIAs (Kemeny, 1991). However, this would be expected
because the ELISPOT assay relies on biological responses which inevitably
introduce more variation than physico-chemical factors such as antibody binding and
enzyme kinetics. This problem could be overcome by increasing the number of wells
per treatment group. For example, if 7 replicate wells were compared between two
plates, the inter-assay coefficient of variation was an acceptable 11.5%. The well to
well variation in the ELISPOT assay also influences the use of statistical tests. As
the spot counts in replicate wells were normally distributed, the use of parametric
tests is appropriate. However, the inter-plate variability between 5 replicate plates
introduced sufficient variation to yield a significant difference when spot counts from
28 wells were compared by ANOVA (p = 0.047). Hence, statistical comparisons
between treatment groups in different plates should be interpreted with caution,
preferably at a significance level of 0.01 or less.
Possible explanations for the variation in spot size noted in the ELISPOT wells
(Figure 3.6) include variation in RMCP-II content per cell, wider diffusion of
RMCP-II from cells degranulating more rapidly after addition of the secretagogue,
and mediator release from a cluster of cells. Clustering of cells was considered
unlikely because, in order to reduce the cell density from 5 x 105 /ml to a few
hundred cells/well, three dilution steps were performed which completely separated
clumps of cells. In addition, examination of wells under phase contrast microscopy
revealed single cell suspensions. The actual area of the spots could therefore be used
to estimate the quantity of RMCP-II released from each cell. Although spot size was
not quantified in this study, it could possibly be measured in future studies using
computerised digital imaging.
The initial reason for developing an ELISPOT assay was to determine how
individual BMMCs within the population responded to stimulation. The assay was
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therefore used to investigate the responses of rat BMMCs to two IgE-mediated
stimulation protocols. Surprisingly, only 6-24% of the BMMCs within a population
appeared to respond to stimulation by either anti-IgE or specific antigen (Table 3.3).
When compared to previous studies, which showed 10-25% mediator release from
populations of BMMCs (Broide et al, 1988; MacDonald et al, 1989; and Figure 3.4),
these results suggest that the behaviour of the cells under these experimental
conditions approached that described in the introduction under hypothesis 2, i.e. the
total mediators released by a population of BMMCs arise from a group of cells that
release most, if not all, their stored mediators ("all-or-none" mode of secretion).
However, although the total number of BMMCs per well correlated closely with the
number of spots per well (Figure 3.8), the detection of responding cells could be
artifactually decreased if all the BMMCs were not in contact with the base of the
well. For example, if a number of BMMCs degranulated whilst in suspension, the
released RMCP-II would not result in a spot. Although examination of the wells
under phase contrast microscopy revealed that the majority of cells were in contact
with the base of the well, this could not be quantified due to the low cell densities. A
potential solution to the problem in future studies would be to develop a stimulation
protocol that results in 100% mediator release from rat BMMCs, but this has not yet
been achieved. Hence, at this stage, the above figures can not be interpreted as direct
evidence for an "all-or-none" mode of secretion in rat BMMCs.
Despite this, the above problem was not of a sufficient magnitude to explain the large
refractory population of BMMCs that failed to respond to IgE-mediated stimulation
(75-90% of the cells). This phenomenon could result from a deficiency in individual
cells at any stage of the signal transduction pathway including: inadequate FceRl
expression; insufficient IgE; lack of intracellular transduction proteins; reduced
intracellular calcium stores; and/or reduced ion channel expression. In mouse bone
marrow-derived mast cells, expression of FceRl coincides with granule formation,
suggesting that cultured mast cells possess IgE receptors at the onset of maturation
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(Lantz and Huff, 1995b). In addition, flow cytometry demonstrated that rat BMMCs
have surface bound endogenous IgE throughout culture, and therefore FceRl
receptors, although this appeared to be sub-optimal for stimulation in cells from
mature cultures. However, when cells were passively sensitised with exogenous
mouse IgE, which increased occupancy of the IgE receptors, a refractory population
of BMMCs still remained indicating that failure to respond was not purely related to
the degree of IgE binding. In rat basophil leukaemia (RBL-2H3) cells (Millard et al,
1988; Millard et al, 1989), and human basophils and mast cells (MacGlashan and
Guo, 1991; MacGlashan and Botana, 1993), stimulation of populations of cells via
the FceRl resulted in variable intracellular calcium fluxes and oscillations.
Correlation of intracellular calcium fluxes with mediator release from individual cells
indicated that a sustained rise in intracellular calcium, seen only in a proportion of
the cells, was required to initiate secretion (Kim, T.D., personal communication).
Although calcium responses have not been imaged in rat BMMCs, a similar
heterogeneity of intracellular calcium responses could explain the large proportion of
BMMCs that failed to respond to immunological stimulation in this study.
The ELISPOT assay therefore proved to be a useful method for analysing the
secretory responses of individual rat BMMCs. However, the assay also possessed a
number of features that offer potential for other areas of mast cell research. First, it
was simpler and more economical to perform than conventional mediator release
assays. The latter assays require populations of cells to be stimulated and then
separated from their supernatants. Remaining mediators have to be extracted from
the cell pellets, and then both supernatants and cell pellets have to be assayed for
mediator levels, typically using ELISA or radioimmunoassays. With the ELISPOT
assay, the release of RMCP-II is detected directly so the results are obtained with a
single assay.
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A second advantage of the ELISPOT assay is that mast cell secretion can be studied
using far fewer cells than previously possible. Conventional mediator release assays
require 104 - 106 cells per treatment group so that sufficient mediator is released to be
detectable by conventional assays such as ELISA or RIA. In general, mast cells in
sufficient numbers for these experiments can only be obtained in four ways. Firstly,
by using tumour cell lines such as the rat basophilic leukaemia cell (RBL-2H3)
which is an analogue of mucosal mast cells (Barsumian et al, 1981; Crews et al,
1981); secondly, by growing mast cells in culture by stimulating bone marrow or
umbilical cord blood with various cytokines (Razin et al, 1983; Haig et al, 1988;
Mitsui et al, 1993); thirdly, by isolation and purification of mast cells from
laboratory rodents, such as rat peritoneal mast cells or intestinal mucosal mast cells
(White and Pearce, 1982; Befus et al, 1982); and finally by isolation and purification
of mast cells from pathological specimens such as human lungs, skin, nasal polyps,
or intestines (Paterson et al, 1976; Schulman et al, 1982; Lawrence et al, 1987;
Finotto et al, 1994; Bischoff et al, 1996). Unfortunately, the study of mast cell
activation in other species, or in clinical cases of allergic disease, has been limited
because it is not feasible to obtain mast cells in such high numbers. For example,
samples of broncho-alveolar lavage fluid (Flint et al, 1985) or skin biopsies from
atopic patients would not be amenable to such large-scale studies, even though the
mast cells in these disease states may have distinctive and interesting properties.
However, if the ELISPOT methodology was modified to detect mediator release
from human mast cells, statistically quantifiable results could be obtained with as
few as 5000 cells per assay. Such an assay could be a valuable tool in the
investigation of allergic diseases, and could potentially be used for diagnostic
purposes to determine if mast cells were sensitised to specific antigens.
In summary, the results in this chapter show that mediator release from individual
mast cells can be detected with a sensitive and repeatable RMCP-II ELISPOT assay.
The assay was used to characterise IgE-mediated secretion from rat BMMCs at
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various stages of culture and showed that only 6-24% of BMMCs within a
population responded to stimulation, leaving a large residual refractory population.
If a similar assay was developed for other species, it could be very valuable for




EFFECTS OF STEM CELL FACTOR ON IGE-DEPENDENT
MEDIATOR RELEASE FROM RAT BONE MARROW-DERIVED
MAST CELLS
INTRODUCTION
In the previous chapter, the IgE-dependent release of rat mast cell protease-II from
rat BMMCs was investigated using a novel ELISPOT assay. In this chapter, the
effect of the multi-functional cytokine stem cell factor (SCF) on IgE-dependent
mediator release from BMMCs is investigated using both the ELISPOT assay and
conventional mediator release assays.
As described in detail in chapter 1, SCF has a wide range of effects on mast cell
function both in vivo and in vitro. Hence, an absolute or partial deficiency in SCF or
its receptor, c-kit, results in greatly reduced mast cell numbers in Sl/Sld (Kitamura
and Go, 1979) or W/Wv (Kitamura et al, 1978) mice respectively. Injection of
soluble SCF into Sld/Sld mice reversed the mast cell deficiency (Zsebo et al, 1990a),
and in normal rats caused a marked increase in the numbers of both connective tissue
and mucosal mast cells (Tsai et al, 1991a). In addition, SCF contributed to the
mucosal mast cell hyperplasia seen in response to infection with the parasites
Nippostrongylus brasiliensis and Trichinella spiralis (Newlands et al, 1995;
Donaldson et al, 1996), and stimulated the expansion of lymph node conditioned
medium-dependent rat BMMCs in vitro (Haig et al, 1994). Furthermore, SCF
enhanced the survival of mast cells by preventing apoptosis (Mekori et al, 1993;
Iemura et al, 1994). SCF was also shown to be a chemotactic agent for mast cells
(Blumejensen et al, 1991; Meininger et al, 1992), and regulated the adhesion of mast
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cells to fibroblasts (Adachi et al, 1992) or extracellular matrix components such as
fibronectin (Dastych and Metcalfe, 1994; Kinashi and Springer, 1994).
In addition to these roles in chemotaxis, adhesion, proliferation, differentiation,
maturation and survival, recent studies have shown that SCF can also influence
mediator release from a number of mast cell types. Treatment with SCF in isolation
directly induced mediator release from mouse peritoneal mast cells (Coleman et al,
1993), rat peritoneal mast cells (Nakajima etal, 1992; Koike et al, 1993; Taylor et al,
1996), mouse skin mast cells (Wershil et al, 1992) and human skin mast cells (Costa
et al, 1996) without the need for IgE receptor activation. In these connective tissue
phenotype mast cells, SCF acted as a secretagogue at concentrations ranging from 20
- 500 ng/ml. However, SCF can also act as apotentiator of IgE-dependent mediator
release in both connective tissue and mucosal mast cells. For example, brief
preincubations (10 - 15 minutes) with the cytokine (100 ng/ml) enhanced IgE-
dependent mediator release from human skin, lung and intestinal mast cells
(Columbo et al, 1992; Bischoff and Dahinden, 1992; Bischoff et al, 1996). In the
latter two studies, involving mucosal mast cells from the lung and intestine, SCF had
no significant secretagogue effect per se, but it augmented the release of histamine
by 226% (lung) and 46% (intestine) following activation of the cells with an
antibody to the IgE receptor (Bischoff and Dahinden, 1992; Bischoff et al, 1996).
Taken together, these studies provide evidence that SCF may be directly involved in
the regulation of immune responses by modulating the secretory function of mast
cells.
Similar studies have not been performed on mast cells isolated from the intestinal
tract of the rat. However, earlier work by MacDonald (1994) showed that SCF was
not a secretagogue for rat BMMCs, but it enhanced IgE-dependent mediator release
from these cells in a concentration and time-dependent manner. Preincubation of
BMMCs with 10, 100 and 1000 ng/ml SCF for 15 minutes significantly increased (3
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hexosaminidase release from populations of BMMCs stimulated with anti-IgE, but
concentrations of 0.001 to 1 ng/ml had no effect (see Figure 1 in Hill et al, 1996 at
the back of this thesis). When mature BMMCs were incubated with SCF (50 ng/ml)
for 5, 15, or 60 minutes, or 3 or 24 hours before challenge with anti-IgE, maximal
enhancement of RMCP-II and (3 hexosaminidase occurred after a 5 minute
preincubation, but the effect declined thereafter and was not statistically significant
in cells treated with the cytokine for 3 or 24 hours (see Figure 2 in Hill et al, 1996).
Hence, as in the studies of other mast cell types, these preliminary results suggested
that SCF may play a critical role in the regulation of secretory responses in rat
BMMCs.
The main aim in this chapter was to further characterise the role of SCF in
modulating the secretory function of rat BMMCs. The specific aims were:-
1) To confirm and extend the results of MacDonald (1994) by investigating the
effects of SCF on IgE-mediated secretion from unsensitised BMMCs, and BMMCs
sensitised with mouse IgE anti-DNP.
2) To determine whether SCF-dependent enhancement in IgE-mediated secretion
from BMMCs reflected individual cells releasing more mediator, or increased
numbers of cells responding to stimulation. This question could have important
implications for the regulation of mast cell secretory function in vivo. Therefore, the
effects of SCF on IgE-dependent mediator release were re-examined using
conventional mediator release assays and the RMCP-II ELISPOT assay described in
the previous chapter.
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EXPERIMENTAL METHODS AND RESULTS
4.1 - The effect of SCF on IgE-dependent mediator release from BMMC
populations
Aims
The aim of this initial experiment was to confirm the results of MacDonald (1994)
using the present BMMC cultures and the mouse IgE anti-DNP sensitisation regime.
Methods
Stem cell factor (recombinant rat SCF164, 2.2 mg/ml) was kindly provided by Dr.
Keith Langley of Amgen Inc., Thousands Oaks, CA. It was stored in aliquots at
-70°C and was thawed once before use. For secretion experiments, SCF was diluted
in Tyrodes buffer/Ca2+ /Mg2+ (TB+) and TB+ was used as a control (see chapter 2,
section 2.12).
The BMMCs for this and subsequent experiments were cultured, washed, identified
and assessed for viability as described in chapter 2 (sections 2.1-2.9). A suspension
of cells from a culture containing 96% BMMCs (100% viability) was washed three
times in TB/EDTA and divided into two aliquots. One aliquot was sensitised with
mouse IgE anti-DNP (section 2.15) and the other was incubated with buffer alone.
After three further washes in TB to remove unbound IgE, the cells were resuspended
in TB+ and divided into 8 treatment groups as shown overleaf. Each group
comprised triplicate tubes containing 106 viable BMMCs in a volume of 0.5 ml TB+.
To determine the effect of SCF on BMMC secretion, SCF (or TB+ as a control) was
added to the Eppendorf tubes in a volume of 55pl at a concentration of 500 ng/ml to
give the required concentration (50 ng/ml) when the cells were added. The cells
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The cells were challenged with DNP-BSA, TB+, anti-IgE or NGS as described in
chapter 2 (sections 2.16-2.17) and the pellets and supernatants were assayed for (3
hexosaminidase as described in section 2.19. The percentage release of (3-
hexosaminidase in the various treatment groups was compared by ANOVA and
Student's t test, and the results are reported as mean ± s.e.m.
Challenge of both the sensitised or unsensitised groups of BMMCs with DNP-BSA
or anti-IgE respectively induced significant release of (3 hexosaminidase in this
experiment (16.1 ± 0.4% for DNP-BSA vs. 1.3 ± 0.2% for buffer, p<0.001; 10.4 ±
0% for anti-IgE vs. 1.2 ± 0.02% for NGS, p<0.001, Figure 4.1). However, as
described in previous reports (MacDonald, 1994), preincubation of unsensitised rat
BMMCs with 50 ng/ml SCF for 5 minutes before challenge with anti-IgE
significantly increased the release of (3 hexosaminidase to 22 ± 0.2% (p<0.001,
Figure 4.1). A similar effect was seen following challenge of IgE-sensitised cells
with DNP-BSA, with the release of (3 hexosaminidase increasing significantly to 30.6
± 0.3% (p<0.001) after a 5 min preincubation with SCF. In addition, the responses
of the BMMCs to DNP-BSA alone, or SCF/DNP-BSA, were both significantly
higher than those seen in the corresponding groups challenged with anti-IgE, or
SCF/anti-IgE (p<0.001 for either comparison, Figure 4.1). This would be expected
because the levels of endogenous IgE are likely to be sub-optimal in mature cultures
(see chapter 3). However, SCF increased the percentage release of (3 hexosaminidase
Results
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approximately two-fold in both groups, suggesting that the specific effect of the
cytokine was not dependent on the degree of IgE binding. In agreement with
previous reports (MacDonald, 1994), incubation of BMMCs with SCF did not cause
significant release of (3 hexosaminidase in the absence of DNP-BSA or anti-IgE (1.5
± 0.2% for SCF/TB+ vs. 1.3 ± 0.2% for TB+, p=0.35; 1.2 ± 0.02 % for SCF/NGS vs.
1 ± 0.05% for NGS, p=0.074). These results confirm that, in isolation, SCF was not
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Figure 4.1 - Effect of SCF on the percentage release of (3 hexosaminidase from IgE-
sensitised or unsensitised BMMCs in response to challenge with DNP-BSA or anti-
IgE. The BMMCs (106 per tube) were preincubated with 50 ng/ml SCF or buffer
alone for 5 min, followed by DNP-BSA (DNP, 1/1000), Tyrode's buffer/Ca2+/Mg2+
(TB+), goat anti-rat IgE (a IgE, 1/250), or normal goat serum (NGS, 1/250) for a
further 30 min. Each bar represents the mean ± s.e.m. of triplicate release assay
tubes. * = significant difference from negative control (p<0.001), A = significant
difference from challenge with DNP-BSA or anti-IgE (p<0.001).
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4.2 - The effect of SCF on the proportion of BMMCs that release RMCP-II in
response to anti-IgE
Aims
The previous experiment confirmed that SCF augments the secretory response of rat
BMMCs resulting in an increase in total mediator release from the population of
cells. The RMCP-II ELISPOT assay was then used to determine whether pre¬
incubation with SCF altered the proportion of BMMCs within the population that
responded to stimulation with anti-IgE.
Methods
BMMCs from a culture containing 96% mast cells (99% viability) were washed and
diluted to yield 400, 200 and 100 cells per triplicate well (384, 192 and 96 BMMCs
per well) as shown in the plate map in appendix 3. The cells were preincubated with
50 ng/ml SCF or buffer alone for 5 min before addition of anti-IgE or NGS. The
plates were developed and the spots counted as described previously (chapter 3,
section 3.3). To facilitate statistical analysis of the data, the spot counts in each well
were expressed as a percentage of the number of BMMCs per well, and the results
from the 9 wells in each treatment group were compared by ANOVA and Student's t
test. The results are reported as mean ± s.e.m. In a second (dose response)
experiment, BMMCs from a culture containing >99% mast cells (100% viability)
were diluted to yield 100 BMMCs per quadruplicate well, and were preincubated
with concentrations of SCF ranging from 400 ng/ml to 1.56 ng/ml (or buffer alone)
before addition of anti-IgE.
Results
The spot counts from BMMCs releasing RMCP-II in response to anti-IgE in the
presence or absence of 50 ng/ml SCF are shown in Figure 4.2. The proportion of
BMMCs responding to SCF/anti-IgE was significantly higher than in BMMCs
challenged with anti-IgE alone (7.2 ± 0.8% vs. 3 ± 0.7%, p<0.005, n=9).
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Interestingly, the proportion of responding cells was increased approximately two¬
fold by preincubation with SCF, as occurred in the previous conventional mediator
release assay (section 4.1). The proportion of BMMCs responding to anti-IgE alone
(3 ± 0.7%) was not significantly different from that of cells challenged with NGS (2
± 0.6%), probably due to sub-optimal IgE binding. As in the previous experiment,
SCF had no significant direct secretagogue effect on rat BMMCs (1.6 ± 0.6%, p>0.5
vs. NGS alone).
The effect of SCF was dependent on concentration as shown in Figure 4.3.
Preincubation with concentrations of 50 or 25 ng/ml SCF resulted in the highest
proportion of BMMCs responding to anti-IgE (35 ± 5% or 36 ± 3% respectively,
n=4), compared to 4 ± 0.7% of cells treated with anti-IgE alone or 4.5 ± 1% of cells
treated with buffer alone. These results are in agreement with those of MacDonald
(1994) who showed that concentrations of >10 ng/ml SCF were optimal for
enhancing IgE-dependent mediator release from BMMCs. Therefore, in subsequent
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Figure 4.2 - Effect of SCF on the proportion of BMMCs responding to challenge
with anti-IgE as determined by ELISPOT assay. BMMCs from a culture containing
96% mast cells were diluted to yield 384, 192 and 96 BMMCs per triplicate well.
The cells were preincubated with 50 ng/ml SCF or buffer alone for 5 min, followed
by challenge with goat anti-rat IgE or NGS (both at 1/250) for a further 30 min.
Each point represents the mean ± s.e.m. of spot counts from triplicate wells, and the
points are joined by regression lines (r=0.99 for SCF/anti-IgE; r= 0.97 for anti-IgE).
For statistical analysis, the spot counts in each well were expressed as a percentage of
the number of BMMCs per well, and the results from the 9 wells in each treatment
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Figure 4.3 - Effect of SCF concentration on the proportion of BMMCs responding to
challenge with anti-IgE as determined by ELISPOT assay. BMMCs from a culture
containing >99% mast cells were diluted to yield 100 BMMCs per quadruplicate
well. The cells were preincubated with various concentrations of SCF or buffer alone
for 5 min before challenge with goat anti-rat IgE or NGS (both at 1/250) for a further
30 min. Each point represents the mean ± s.e.m. of spot counts from quadruplicate
wells. Neg = cells not challenged with SCF or anti-IgE.
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4.3 - Time course of the SCF effect
Aims
The previous experiments demonstrated that SCF enhanced both the total release of
(3-hexosaminidase from populations of BMMCs (section 4.1) and the proportion of
BMMCs that responded to challenge with anti-IgE (section 4.2). In previous studies,
the effect of SCF on IgE-dependent mediator release from BMMCs was maximal
after short (5 min) preincubations (MacDonald, 1994). In this section, the time
course of the SCF effect was investigated in both ELISPOT and conventional
mediator release assays.
Methods
In an initial ELISPOT assay, BMMCs from a culture containing 99% mast cells
(100% viability) were diluted to yield 200 BMMCs per well, with each treatment
group comprising 6 wells. The cells were then preincubated with 50 ng/ml SCF for
5, 15, 30, 60, or 120 min, or with buffer alone for 120 min, before challenge with
anti-IgE or NGS. In a second experiment, BMMCs from a culture containing >99%
mast cells (100% viability) were sensitised with mouse IgE anti-DNP as described
previously (section 2.15). After washing, the cells were divided into 5 treatment
groups, each containing 3 x 106 BMMCs. The cells in three of the groups were
incubated with 50 ng/ml SCF for 5, 15, or 30 min respectively, and in the remaining
two groups with buffer only. The cells were then washed twice in TB/EDTA to
remove the SCF. Cells from each group were either added to triplicate release assay
tubes (0.6 xlO6 cells per tube) as described in section 2.17, or diluted to yield 200
BMMCs per well in an ELISPOT plate (8 wells per treatment group). The cells were
challenged with DNP-BSA or TB+ as shown overleaf.
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Experimental Design
Group SCF Secretagogue No. of Replicate No. of Replicate
incubation Tubes Wells
1. 5 min DNP-BSA 3 8
2. 15 min DNP-BSA 3 8
3. 30 min DNP-BSA 3 8
4. No SCF DNP-BSA 3 8
5. No SCF Tyrode's Buffer 3 8
Results
In the initial ELISPOT assay, preincubation of BMMCs with SCF for 30 min before
challenge with anti-IgE resulted in the highest proportion of cells releasing RMCP II
(34 ± 2%, n=6), but this was not significantly different from the results obtained after
a 5 min incubation (26 ± 3%, Figure 4.4). Both values were significant when
compared to results for cells treated with anti-IgE alone (8 ± 1%, n=6, p<0.01 for
either comparison).
The results of the combined ELISPOT/conventional release assay are shown in
Figure 4.5. In the conventional release assay, the percentage release of (3-
hexosaminidase from the cells incubated with SCF for 5 min (12.3 ± 0.3%), 15 min
(11.1 ± 0.5%) or 30 min (9.2 ± 0.2%) was significantly higher than the cells
challenged with DNP-BSA alone (8.2 ± 0.2%, p<0.05 for each comparison). In
addition, the response of cells incubated with SCF for 5 min was significantly higher
than those incubated with the cytokine for 30 min (P<0.05). An almost identical
trend was observed in the ELISPOT assay, with the shortest SCF incubation time
causing the greatest proportion of BMMCs to release RMCP-II in response to
challenge with DNP-BSA (Figure 4.5). However, in the ELISPOT assay, the
difference between the responses of cells incubated in the presence or absence of
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SCF did not reach statistical significance, probably due to the larger variation seen in
this experiment.
Taken together, these results indicate that short preincubations with SCF (5-30 min)
increase both total mediator release from a population of BMMCs and the proportion
of cells responding to IgE-dependent challenge. Hence, for all subsequent secretion
assays, BMMCs were incubated with SCF for 5 min before addition of the
secretagogue (anti-IgE or DNP-BSA) or control.
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Figure 4.4 - Release of RMCP-II from anti-IgE challenged BMMCs (200 BMMCs
per well, from a culture containing >99% mast cells) after incubation with SCF (50
ng/ml) for varying periods of time. The graphic illustrates the increased number of
spots in wells after 5, 15, or 30 min preincubations with SCF compared to 60 or 120
min, or control wells (no SCF). The spot counts in each well were halved to yield
the percentage of cells releasing RMCP-II. Bars represent the mean ± s.e.m. of the













































Figure 4.5 - The effect of SCF incubation time on the total percentage release of (3-
hexosaminidase from BMMC populations (A), and the proportion of BMMCs
responding to IgE-dependent challenge (B). BMMCs from a culture containing
>99% mast cells were sensitised with mouse IgE anti-DNP and preincubated with
SCF (50 ng/ml) for 5, 15, or 30 min, or with buffer alone. After washing the cells to
remove the SCF, BMMCs were challenged with DNP-BSA or TB+ in a conventional
mediator release assay (A), or in an ELISPOT assay (B).
A: Each bar represents the mean ± s.e.m. of triplicate release assay tubes, each
containing 0.6 xlO6 BMMCs. *= significant difference from DNP alone, p<0.05; A=
significant difference from a 30 min incubation with SCF, p<0.05.
B: The spot counts from each well (each containing 200 BMMCs) were halved to
yield the percentage of BMMCs responding to challenge with DNP-BSA. Each bar
represents the mean ± s.e.m. of the halved spot counts from 8 wells.
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4.4 - The effect of SCF on anti-IgE-induced RMCP-II release from BMMC
populations at various stages of culture
Aims
In chapter 3, the response of BMMCs to anti-IgE was shown to be influenced by the
stage of culture from which the cells were derived (section 3.7 and Table 3.3). In
some of the experiments summarised in Table 3.3, the effect of SCF on the
proportion of BMMCs responding to anti-IgE was also investigated (those performed
using cultures 2 and 3). These experiments were designed to determine if the effect
of SCF was dependent on the maturity of BMMC cultures.
Methods
For each experiment in this series, a suspension of cells was removed from one of
two different cultures at various stages of maturity. After three washes, the cells
were counted, assessed for viability, and the percentage mast cells determined (as
described in chapter 2, sections 2.1-2.10).. The details of the cultures are provided in
Table 4.1.
Table 4.1 - Percentage BMMCs and viabilities for experiments performed
throughout the growth of two cultures
Culture Day % BMMCs % Viability












For each experiment, the cell suspension was diluted to yield 400, 200 or 100 viable
BMMCs per triplicate well in each of two separate 48 well plates. The cells were
preincubated with 50 ng/ml SCF or buffer alone for 5 min, followed by challenge
with anti-IgE or NGS as shown in the plate map below (Figure 4.6).
1 2 3 4 5 6 7 8
A 400 200 100 400 200 100 a e
Anti-IgE B 400 200 100 400 200 100 b f
C 400 200 100 400 200 100 c g ;
D 400 200 100 400 200 100 d h
NGS E 400 200 100 400 200 100 - i
F 400 200 100 400 200 100 © ©
Buffer 50 ng/ml SCF No cells
Figure 4.6 - ELISPOT plate map. Each number indicates the approximate number of
viable BMMCs per well. Columns 7 and 8 contained no cells but a,b = SCF/anti-
IgE; c,d = SCF/NGS; e,f = buffer/anti-IgE; g,h = buffer/NGS. - = Tyrode's buffer; ©
= 100 ng/ml RMCP-II. Each experiment comprised two replicate plates.
The plates were developed and the spots counted as described previously (section
3.3). Apart from confirming the relationship between cell density and number of
spots per well (see chapter 3, section 3.5), the serial dilution of cells from 400 to 100
BMMCs per well was not particularly useful, especially for statistical analysis. The
spot counts in each well were therefore expressed as a percentage of the number of
BMMCs in each well, and the overall percentage of BMMCs responding to each
treatment was calculated by averaging the data from 18 corresponding wells (9 wells
from each plate containing 400 (n=3), 200 (n=3), and 100 (n=3) cells per well - see
figure 4.6). The data from each treatment group were compared by ANOVA and
Student's t test, and the results are expressed as mean ± s.e.m.
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Results
The proportions of BMMCs responding to each treatment throughout the course of
two cultures are shown in Figure 4.7. The response of BMMCs to SCF fell into two
categories. In four experiments performed using cultures containing 8, 36, 41, or
64% BMMCs, a highly significant (p<0.001) proportion of BMMCs responded to
anti-IgE alone when compared to NGS controls, but addition of SCF had no
significant effect (Figure 4.7). In contrast, SCF significantly increased (p<0.001) the
proportion of BMMCs responding to anti-IgE in 4 out of 5 experiments performed
using cultures containing 85, 87, 92, 95, or 95% mast cells. In addition, the spots in
SCF treated wells appeared to be larger than those treated with anti-IgE alone,
although this was not quantified. At no stage did SCF alter the response of cells
treated with NGS, providing additional evidence that, in isolation, it had no
detectable secretagogue activity in these BMMC populations (Figure 4.7).
In three experiments performed during this series, there was no significant effect of
either anti-IgE or SCF (Day 21, culture 2; Days 21 and 28, culture 3). The lack of
response of BMMCs in the experiments performed on days 21 of culture 2, and 28 of
culture 3, is probably related to cell viability. In both cultures, the viability had
started to decline at this stage (93% and 77% respectively). This was associated with
a high background release of RMCP-II, suggesting that the cells had become "leaky"
and unable to respond to specific stimuli. The reason for the failure of the BMMCs
from day 21/culture 3 to respond to SCF is not known, but the most likely
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Figure 4.7 - The effect of SCF on IgE-dependent RMCP-II release from individual
BMMCs derived from cultures at different stages of maturity. A: Culture 2. B:
Culture 3. Cells were incubated in the presence (50 ng/ml for 5 min) or absence of
SCF before challenge with goat anti-rat IgE or normal goat serum (NGS). Each bar
represents the mean ± s.e.m. of the percentage of BMMCs responding to each
treatment in 18 wells (9 from two separate ELISPOT plates). A = significant effect
of anti-IgE vs. NGS, p<0.001. * = significant effect of SCF vs. anti-IgE, p<0.001.
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4.5 - The effect of SCF on the release of RMCP-II from individual IgE-sensitised
BMMCs compared directly with the percent mediator release by an entire
population of BMMCs
Aims
The aim of these experiments was to determine the relationship between the
increased proportion of BMMCs that responded to IgE-dependent stimulation after
treatment with SCF and the increase in total mediator release by a BMMC
population. In addition, the previous experiments had shown that the effect of SCF
was limited to mature cultures, in which IgE binding is sub-optimal. To determine if
SCF was merely compensating for insufficient IgE, these experiments were
performed using BMMCs sensitised with IgE anti-DNP.
Methods
The responses of BMMCs to SCF and IgE-dependent stimulation in conventional
mediator release assays were compared to those obtained in parallel ELISPOT assays
using aliquots of the same cell populations. BMMCs from a culture containing 99%
mast cells (100% viability) were removed on two consecutive days (for two separate
experiments). The cells were washed and sensitised with mouse IgE anti-DNP as
described previously, and divided into four treatment groups. Each group was
diluted to yield 0.8 x 106 BMMCs per quadruplicate release assay tube, and 200 cells
per ELISPOT well (9 wells per treatment group). After preincubation with 50 ng/ml
SCF or buffer alone for 5 min, the cells were challenged with DNP-BSA or TB+ as
described previously. The pellets and supernatants from the release assay tubes were
assayed for RMCP-II and (3 hexosaminidase as described previously, and the
percentage of BMMCs responding was calculated from the spot counts in each
ELISPOT well. Results from different treatment groups were compared by ANOVA
and Student's t test, and are reported as mean ± s.e.m.
156
Results
The percentage release of RMCP-II and ^-hexosaminidase from populations of
BMMCs is compared to the proportion of responding BMMCs in Figure 4.8. The
mean specific IgE-dependent release of RMCP-II or [3-hexosaminidase (calculated by
subtracting the % release in control tubes from the % release in DNP tubes) in the
absence of SCF was 9 ± 0.5% and 12 ± 0.3% respectively (p<0.01 vs. results with
buffer alone). After pretreatment with 50 ng/ml SCF, the response to antigen
mediated stimulation increased significantly (p<0.001) to 26 ± 1% or 36 ± 3% for
RMCP-II and (3-hexosaminidase respectively. In the ELISPOT assays, a mean of 14
± 1% individual IgE.sensitized BMMCs released RMCP-II in response to DNP-BSA
alone, and this increased significantly (p<0.01) to 21 ± 1% after pretreatment with








































Buffer Buffer/SCF DNP DNP/SCF
Figure 4.8 - A: Conventional mediator release assay showing percentage release of (3
hexosaminidase and RMCP II from entire populations of BMMCs (from a culture
containing >99% mast cells) tested in two separate experiments. BMMCs were
sensitised with mouse monoclonal IgE anti-DNP and then stimulated with DNP-BSA
in the presence (50 ng/ml for 5 min before challenge) or absence of SCF. Each bar
represents the mean ± s.e.m. from quadruplicate aliquots of 0.8 xlO6 BMMCs.
B: ELISPOT assays measuring the proportion of BMMCs that released RMCP-II,
performed in parallel to the experiments in A using aliquots of the same cell
populations. The spot counts in each well (200 BMMCs/well) were used to calculate
the percentage of cells releasing RMCP-II. Each bar represents the mean ± s.e.m. of
data from 9 wells in each ELISPOT assay. The increased mediator release in the
conventional assay (A) is clearly associated with an increase in the number of cells
responding to immunological stimulation as demonstrated in the ELISPOT assay (B).
A - significant difference from buffer or buffer/SCF (p<0.01).
* - significant difference from cells stimulated with DNP alone (p<0.05).
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DISCUSSION
In contrast to mouse (Coleman et al, 1993) or rat (Nakajima et al, 1992; Koike et al,
1993; Taylor et al, 1996) peritoneal mast cells, or mouse (Wershil et al, 1992) or
human (Columbo et al, 1992) skin mast cells, SCF did not directly induce significant
mediator release from rat BMMCs, either in conventional release assays (Figures 4.1
and 4.8A) or in ELISPOT assays (Figures 4.2, 4.7 and 4.8B). However, pretreatment
of mature BMMCs with SCF (50 ng/ml) for 5 min before challenge with anti-IgE
resulted in a 1.5 - 2.5 fold increase in total mediator release (Figures 4.1, 4.5A and
4.8A). These results suggest that SCF can "prime" rat BMMCs for subsequent
activation via the IgE receptor, but can not directly induce degranulation. Similar
results have been described for other mucosal type mast cells including human lung
mast cells (Bischoff and Dahinden, 1992) and human intestinal mast cells isolated
from patients with inflammatory bowel disease and controls (Bischoff et al, 1996).
In the latter study, IgE receptor stimulation or treatment with SCF alone induced only
marginal mediator release. However, preincubation of the mast cells with 100 ng/ml
SCF for 15 min before challenge with an antibody to the IgE receptor resulted in
significant release of histamine and leukotrienes. Perhaps more interestingly, the
SCF-enhanced mediator release was significantly greater in mast cells isolated from
actively inflamed tissue compared to normal tissue. These results, and the
experiments described in this chapter, suggest that SCF may play a role in the
regulation of mast cells responses in the gut, acting as a modulator of gastro¬
intestinal immune responses.
The enhancement in IgE-dependent mediator release from rat BMMCs following
preincubation with SCF was similar to that described when mouse BMMCs were
cocultured with fibroblasts (Levi-Schaffer et al, 1987b). In the latter study, the
release of histamine increased 2- to 3-fold after challenge with specific antigen, but
only in cells that were adherent to the fibroblast monolayer. These results suggest
that mast cells in close contact with fibroblasts, as occurs in vivo, are likely to be
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"primed" for subsequent mediator release as suggested by the in vitro studies in this
chapter.
One of the aims of this study was to determine whether SCF-dependent enhancement
of mediator release reflected individual cells releasing more mediator, or increased
numbers of cells responding to stimulation. The results of the ELISPOT assays
clearly demonstrate, for the first time, that the proportion of mature BMMCs
responding to IgE-dependent stimulation was significantly increased by pretreatment
with SCF (Figures 4.2, 4.3, 4.4, 4.7 and 4.8B). In addition, preincubation with SCF
typically resulted in a 1.5 - 2.5 fold increase in the proportion of responding cells,
which is similar to that reported for increases in total mediator release from
populations of BMMCs (MacDonald, 1994, and Figure 4.1). When the results of
ELISPOT assays and conventional mediator release assays were directly compared
(using the same populations of cells as in Figures 4.5 and 4.8), the increase in percent
total mediator release was similar to the increase in the proportion of responding
cells. Taken together, these results suggest that SCF upregulates secretion from
mature BMMCs primarily by activating previously unresponsive cells. However,
close analysis of Figure 4.8 shows that the percentage release of total mediators
increases = 3-fold whereas the proportion of responding cells increases = 1.5-fold.
Although this may reflect biological variation within the two assay systems, it does
suggest that there was a concomitant increase in mediator release from individual
cells. The latter conclusion was also suggested by an increase in spot size from
BMMCs treated with SCF, but this effect was not quantified objectively. It is
possible, therefore, that SCF upregulates secretion from mature BMMCs in two
ways: firstly by "priming" previously unresponsive cells, allowing a subsequent
response to IgE-mediated challenge, and secondly, by enhancing mediator release
from individual cells.
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The enhancement of IgE-dependent mediator release by SCF was previously found to
be maximal after short pre-incubations (5 min) and was not evident after incubations
over 3 hours (MacDonald, 1994, and see Figure 2 in Hill et al, 1996 at the back of
this thesis). In the ELISPOT assays, the same effect was observed, although
incubations of 5 - 30 min yielded similar results. This phenomenon has also been
reported for human skin (Columbo et al, 1992) and lung (Bischoff and Dahinden,
1992) mast cells, and is most likely due to internalisation of c-kit receptor/SCF
complexes following ligand binding (Yee et al, 1993). The significance of this
finding is not known, and it is complicated by the potential role of membrane bound
SCF in providing a constant stimulus for mast cells in vivo. However, it could be a
control mechanism to prevent mast cells from being in a state of heightened
sensitivity for prolonged periods following stimulation with soluble SCF.
The ELISPOT assay was used to investigate the effect of SCF on the secretory
pattern of individual BMMCs at various stages during culture. Pretreatment of
BMMCs with SCF enhanced IgE dependent mediator release from mature BMMCs
(i.e. from cultures containing at least 85% mast cells), but did not upregulate
secretion from cells derived from immature cultures containing less than 85% mast
cells. The lack of an effect of SCF on IgE-dependent mediator release from
immature populations of BMMCs might have reflected effects of "contaminating
cells" in these preparations. Immature cultures contain other bone marrow derived
cells (especially macrophages), which could potentially influence the effects of
cytokines on mast cells. Alternatively, lower expression of the SCF receptor (c-kit)
in developing cells, or differences between mature and immature BMMCs in the
intracellular signal transduction mechanisms may have contributed to the apparent
lack of SCF responsiveness in these populations. Whether the different effects of
SCF on BMMC at various stages of growth/maturation in vitro reflect a similar
phenomenon in vivo remains to be determined.
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As discussed in chapter 3, the response of unsensitised BMMCs to anti-IgE
decreased in mature cultures, probably due to sub-optimal IgE binding. This raised
the possibility that SCF was merely compensating for a reduced signal through the
FceRl receptor rather than specifically enhancing the secretory response. This could
occur because activation of both the FceRl receptor (Kawakami et al, 1992; Sagi-
Eisenberg, 1993; Benhamou et al, 1993; Fukamachi et al, 1994; Kinet, 1992) and the
c-kit receptor (Welham and Schrader, 1992) leads to extensive tyrosine
phosphorylation of multiple cytosolic proteins, and overlap between the two
signaling pathways has already been demonstrated in mouse bone marrow-derived
cultured mast cells (Tsai et al, 1993; Tsai et al, 1993)and rat peritoneal mast cells
(Koike et al, 1993). To address the possibility that SCF was in some way
compensating for sub-optimal binding of endogenous IgE, the BMMCs were
sensitised with IgE anti-DNP and challenged with DNP-BSA. In these experiments,
pre-treatment with SCF resulted in a similar augmentation of the secretory response
as was observed when unsensitised cells were stimulated with SCF and anti-IgE
(compare the enhancement of mediator release between sensitised and unsensitised
cells in Figure 4.1, and the increased proportion of responding cells in Figure 4.8B
with Figure 4.7). These results suggest that the effect of the cytokine was not
dependent on the degree of IgE binding.
Is the effect of SCF on IgE-dependent mediator release from rat BMMCs and other
mast cell types unique? For example, a number of cytokines and growth factors are
known to modulate mediator release from basophils, including IL-3, IL-5,
granulocyte/macrophage colony stimulating factor (GM-CSF) and nerve growth
factor (Bischoff and Dahinden, 1992). In mouse peritoneal mast cells, SCF (20 - 100
ng/ml) enhanced the antigen-mediated release of serotonin after a 15 min
preincubation, whereas IL-3 and IL-4 were without effect (Coleman et al, 1993).
Likewise, in human lung mast cells, the cytokines IL-1, -2, -3, -4, -5, -6, -7, -8, and -
9, along with G-CSF, M-CSF, GM-CSF, TNF-a, TGF-|3, IFN-y, and NGF did not
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induce, or enhance, mediator release either alone or when preceding activation of the
IgE receptor (Bischoff and Dahinden, 1992). Preincubation of human intestinal mast
cells with IL-3 for 15 min before stimulation of the IgE receptor enhanced the release
of histamine and leukotrienes, but the effect was less pronounced than with SCF
(Bischoff et al, 1996). In contrast, IFN-y inhibited IgE-dependent mediator release
from rat (Holliday et al, 1994; Bissonnette et al, 1995) and mouse (Coleman et al,
1991) peritoneal mast cells. Hence, in terms of cytokine regulation of secretory
function, SCF appears to have a unique and potent role in the modulation of mast cell
responses.
In summary, the experiments in this chapter showed that the cytokine, SCF,
enhanced mediator release from a population of mature, but not immature, BMMCs.
This upregulation was shown to be due to activation of previously unresponsive cells
and possibly augmentation of the secretory response in individual cells. The many
similarities between rat BMMCs and rat MMCs suggest that SCF may also be
involved in regulation of mast cell responses in the gut, acting as a unique modulator
of gastrointestinal immune responses.
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Chapter 5
ELECTROPHYSIOLOGICAL PROPERTIES OF RAT BONE
MARROW-DERIVED MAST CELLS
INTRODUCTION
The previous chapters were concerned with characterisation of IgE-dependent
mediator release from rat bone marrow-derived mast cells. In this chapter, the
electrophysiological properties of rat BMMCs are described.
In chapter 1, the electrophysiological properties of various mast cell types were
reviewed. These studies revealed marked differences in properties between mast cell
phenotypes which are summarised in Tables 5.1 and 5.2.
Table 5.1 - Ionic conductances in resting mast cells. IRK = inwardly rectifying K+
current; ORc, = outwardly rectifying CI" current; RBL-2H3 = rat basophilic
leukaemia cell; WCR = conventional whole-cell recording configuration; RT = room
temperature.
Conductance Mast Cell Type Technique References







Lindau and Fernandez, 1986
Qian and McCloskey, 1993
Kuno et al, 1995





Nilius et al, 1994
None Rat peritoneal
mast cell
WCR at RT Lindau and Fernandez, 1986
McCloskey and Qian, 1994
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Table 5.2 - Ionic conductances in stimulated mast cells. Icrac = calcium release
activated calcium current; ORcl = outwardly rectifying CI" current; ORK = outwardly
rectifying K+ current; WCR = conventional whole-cell recording configuration; RT =
room temperature; 48/80 = compound 48/80; Sub P = substance P.





WCR at RT, cell stimulated with
48/80, Sub P, IP3, GTP-y-S
Kuno et al, 1989




WCR at RT, cell stimulated with IP3,
ionomycin
Perforated-patch at 37°C, cell
stimulated with antigen







WCR at RT, cell stimulated with
48/80, IP3, GTP-y-S
Kuno et al, 1989
Mathews et al, 1989
Fasolato et al, 1993
ORc: channels Rat peritoneal
mast cell
RBL-2H3 cell
WCR at RT, cell stimulated with
48/80, Sub P, c-AMP, GTP-y-S
Single channel study, patches
stimulated via FceRl
Mathews et al, 1989
Janiszewski et al, 1994
Dietrich and Lindau. 1994
Romanin et al, 1991
ORk channels RBL-2H3 cells
Rat BMMCs
(grown in IL-3)
WCR at RT, cells stimulated with
GTP-y-S, ADP, ATP
Qian and McCloskey, 1993
McCloskey and Qian, 1994
Most of the above studies were performed using the conventional whole-cell
recording configuration (Hamill et al, 1981) which causes dialysis of the intracellular
milieu and loss of many cytoplasmic components including solutes, enzymes and
messengers (Penner et al, 1987; Horn and Marty, 1988). This "washout"
phenomenon can greatly influence the function of ion channels and can lead to the
absence or rundown of whole-cell currents. Two methods have been used to
overcome the problem of washout. The first is to add back various cytosolic
components such as cyclic AMP, ATP or GTP as described in some of the above
experiments. This method can also allow intracellular signalling mechanisms to be
elucidated by selectively replacing or removing critical cytoplasmic factors (Penner
et al, 1987). The second method (Lindau and Fernandez, 1986a), originally referred
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to as "slow whole-cell recording", was developed to prevent washout in rat peritoneal
mast cells so that degranulation could be observed concurrently with electrical
recording. In this method, the cell-attached patch was partially permeabilised by
including ATP in the pipette solution, thus allowing electrical access to the cell.
Peritoneal mast cells contain purinergic receptors that bind ATP resulting in an
increase in conductance. However, the access resistance in such recordings was 200
- 5000 MQ which is 100 - 5000 fold higher than conventional whole-cell recordings.
This methodology was improved by the use of the pore-forming polyene antibiotic
nystatin (Cass et al, 1970; Horn and Marty, 1988). Inclusion of nystatin in the
pipette solution perforated the cell-attached patch to a much greater degree than ATP
(access resistances as low as 4 - 10 MQ could be achieved) and the method did not
rely on the presence of ATP receptors. The perforated-patch technique, as it is now
known, was further developed by Rae et al. (1991) who used the structurally similar
amphotericin B to permeabilise 13 different cellular preparations including various
lens and corneal epithelia, guinea pig ventricle cells, human gastric smooth muscle
cells, neuroblastoma and flounder enterocytes. The importance of this method was
recently highlighted when the perforated-patch technique allowed the first
demonstration of the IgE receptor-activated Ca2+ influx in RBL-2H3 cells (Zhang
and McCloskey, 1995). In parallel experiments, the conductance was not observed in
any cells using the conventional whole-cell recording technique, indicating that
preservation of cytoplasmic components was critical for demonstration of the
currents. In addition to the use of the conventional whole-cell recording technique,
most investigators have studied mast cells at room temperature which can also
influence the results of electrical recordings. For example, Zhang and McCloskey
(1995) could only detect the IgE receptor-activated Ca2+ conductance if the cells
were warmed to 37°C.
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To date, the electrophysiological studies of mucosal type mast cells have
concentrated on the RBL-2H3 cell. Although this cell line shares certain similarities
with intestinal mucosal mast cells (Seldin et al, 1985), it possesses a number of
important differences. First, it is neoplastic, which could influence many of its
properties. Second, it is poorly granulated and contains low levels of RMCP-II
(Seldin et al, 1985). And thirdly, it is substantially larger than rat mucosal mast cells
(McCloskey and Qian, 1994). Hence, it can not be assumed that the RBL-2H3 cell is
a functional analog of intestinal mucosal mast cells. To avoid this problem,
McCloskey and Qian (1994) studied rat mast cells derived from bone marrow in the
presence of rat recombinant IL-3. However, this culture system has not been
extensively characterised in the rat, and it is not known for certain how the cells
compare to mucosal mast cells in terms of functional or biochemical properties.
The purpose of this study was to characterise the whole-cell currents of rat BMMCs
grown in the presence of a mixture of cytokines (including IL-3) derived from
concanavalin A stimulated T-lymphocytes. These cells have not been studied
electrophysiologically but they have been extensively characterized biochemically
and immunologically and in all respects so far studied they are identical to intestinal
mucosal mast cells (McMenamin et al, 1987; Broide et al, 1988; MacDonald et al,
1989; Befus et al, 1982). They may, therefore, represent a better model for
electrophysiological studies of mucosal mast cells than RBL-2H3 cells (Lindau and
Fernandez, 1986b) or mast cells grown solely in the presence of rat recombinant IL-3
(McCloskey and Qian, 1994).
167
Specific Aims of the Electrophysiological Studies
1. To characterise the basic electrophysiological properties of resting rat BMMCs
(membrane potential, capacitance and whole-cell currents) to allow comparison with
other studies of rat mast cells.
2. To determine if cytoplasmic disruption or bath temperature affected the whole-
cell currents of rat BMMCs by comparing conventional whole-cell recordings with
perforated-patch recordings at various temperatures.
3. A further aim was to determine if stem cell factor (SCF) influenced the
electrophysiological properties of rat mast cells. As shown in chapter 4, SCF has a
dramatic effect on IgE-mediated secretion from rat BMMCs after only 5 min
incubations, yet in isolation it does not directly induce degranulation. As secretion is
critically dependent on ion channel function, it was hypothesised that SCF might
modulate or activate ion channels in rat BMMCs. However, as this series of
experiments did not demonstrate electrophysiological effects, the data has been




The preparation of BMMCs for these experiments has been described in detail in
chapter 2 (sections 2.1-2.10). Thirteen mature bone marrow cultures ranging in age
from 13-37 days and each containing more than 85% mast cells (>95% viability)
were used with consistent results. The mast cell Ringer, used to suspend BMMCs for
electrophysiological recordings, was initially formulated to be as similar to Tyrode's
buffer as possible. Hence, standard mast cell Ringer (section 2.22) was Tyrode's
buffer/Ca2+/Mg2+ (section 2.12) without the BSA or NaH2P04 (these were omitted
because they can inhibit pipette-membrane seals). However, in a number of
preliminary experiments, the sealing rate with standard mast cell Ringers was still
very low. Therefore, to improve sealing, the mast cell Ringers was modified to
include 2 mM CaCl2 and 5 mM MgCl2 instead of 1 mM of each (section 2.22).
Preparation ofcells for electrophysiological recordings
The BMMCs or peritoneal mast cells were removed from the culture medium
(IMDM or RPMI) by gently mixing a 2 - 5ml aliquot of cell suspension with
approximately 10 ml of mast cell Ringer in a 15 ml centrifuge tube. After
centrifugation at 1100 r.p.m. (200 x g) for 5 min, the supernatant was removed and
the cells were resuspended in 1.5 ml of mast cell Ringer and plated onto glass
coverslips in petri dishes. The coverslips were maintained at 37°C in an incubator
without extraneous C02 for up to 7 hours, and were transferred to the recording
chamber when needed.
Electrophysiological techniques
The procedures for obtaining seals, recording membrane potentials, measuring cell
capacitance and recording whole cell currents have been described in detail in
chapter 2 (sections 2.24-2.33). Briefly, in this study, experiments were performed
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with both the conventional whole-cell recording configuration and the amphotericin
B perforated-patch technique (section 2.31), allowing the effects of cytoplasmic
disruption to be determined. Whole-cell voltage-clamp recording (in both
configurations) was performed with a patch-clamp amplifier (EPC-7, List) by
applying voltage steps over a set voltage range from the holding potential of -40 mV
(section 2.33). The evoked currents were filtered, and stored on video tape and a
personal computer for later analysis (sections 2.34 and 2.36). In this chapter, the
currents are shown as superimposed steps with accompanying current/voltage
relationships, or as continuous pen recordings (see relevant sections).
Control ofthe bath temperature
The temperature of the recording chamber was controlled with a Peltier device
(section 2.26). To determine the effect of temperature on the recordings, currents
were measured at various bath temperatures. At 37°C, it was difficult to obtain
pipette-membrane seals, and the stability of seals at this temperature was unreliable,
often resulting in breakdown of the preparation. To overcome this problem, seals
were formed at room temperature (16 - 20°C) and the temperature of the bath was
increased in 5°C increments. Currents from individual cells were therefore recorded
at room temperature, and 25°C, 30°C and 37°C if possible. For most of the statistical
analysis, data acquired at the three temperatures has been grouped and the results are
reported for the range 25 - 37°C.
Detection ofspontaneous degranulation
The studies described here were concerned with the electrophysiological properties
of resting BMMCs. In this chapter, "resting" is defined as cells not stimulated via
the IgE receptor, by extracellular agonists or by intracellular messengers. In
addition, the term refers to a cell not undergoing degranulation. Occasionally, during
these studies, a mast cell degranulated spontaneously. This usually resulted in
breakdown of the seal and a morphological transformation that was visible under the
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microscope. The appearance of this process differed between the two cell types and
was much more obvious in peritoneal cells than in BMMCs. This is illustrated in
Figure 5.1 which shows the appearance of rat BMMCs and rat peritoneal mast cells
in the recording chamber both in the resting state (A and C), and after a stimulus to
induce degranulation (B and D). The results that follow were all obtained from mast
cells in the absence of visible degranulation, and can therefore be interpreted as the
electrophysiological properties of resting BMMCs.
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Figure 5.1 - Microscopic appearance of rat BMMCs (A) and rat peritoneal mast cells
(C) in the electrophysiological recording chamber. The cells are adhered to glass
cover slips and bathed in mast cell Ringer. The BMMCs had been previously
sensitised with IgE anti-DNP. B: Appearance of the same BMMCs as in A, 15 min
after addition of DNP-BSA. Degranulation has occurred in the 3 cells in which the
cellular outline is angular and less distinct (arrows). D: Appearance of the same
peritoneal mast cells as in C, 15 min after addition of 10 pg/ml compound 48/80.
Degranulation is more obvious than in BMMCs because the cells are covered in a
tight mass of refractile granules. Scale bars =10 p.m.
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RESULTS
5.1 - Membrane Potential of Rat Bone Marrow-Derived Mast Cells (BMMCs)
The membrane potential was measured by switching the patch-clamp amplifier to the
current clamp mode immediately after breaking in to the cell to establish the whole
cell recording configuration (section 2.32). This measured the voltage required to
keep the membrane current at zero which by definition is the resting membrane
potential. The membrane potentials of 33 BMMCs measured with standard KC1
pipette solution (section 2.2) at room temperature are shown in Table 5.3. The
membrane potential in individual cells fluctuated as shown by the range of values.
The distribution of the membrane potentials (taken as the mid-point of the observed
range) is shown in Figure 5.2, with a mean and s.d. of -28.5 ± 16.5 mV.
5.2 - Whole-Cell Capacitance in Rat BMMCs
The capacitance of a cell is an important electrophysiological parameter because it is
related to the surface area of the plasma membrane and can thus give an indication of
cell size. It can also be used to monitor cellular processes such as secretion because
incorporation of granule membranes into the plasma membrane results in an increase
in cell surface area (Fernandez et al, 1984). In these experiments, cell capacitance
was determined by measuring the transient current that arises during charging of the
cell membrane in response to a voltage pulse. This capacitance transient can be
cancelled using the cancellation circuitry of the patch-clamp amplifier, yielding the
whole-cell capacitance (section 2.31). Appearance of capacitance transients was also
used to monitor perforation of the membrane patch by amphotericin B as described in
chapter 2. Capacitance measurements obtained throughout the course of these
studies are summarised in Figure 5.3. The perforated-patch technique and the
conventional whole cell recording configuration yielded similar values for cell
capacitance, being 4.8 ± 1.6 pF (n=116) and 4.2 ± 1.6 pF (n=62) respectively (Figure
5.3).
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Cell M.P. Range (mV) Median M.P. (mV)
1 -27.9 to -30 -29
2 -19 to -25 -22
3 -17 to -24 -20.5
4 -15 to-17 -16
5 -41 to -50 -45.5
6 -9 to -15 -12
7 -30 to -34 -32
8 -22 to -26 -24
9 -38 to -40 -39
10 -19 to -25 -22
11 -68 to -74 -71
12 -33 to -38 -35.5
13 -19 to -20 -19.5
14 -19 to -28 -23.5
15 -3 to -5 -4
16 -13 to-17 -15
17 -14 to -20 -17
18 -60 to -64 -62
19 -23 to -28 -25.5
20 -18 to -23 -20.5
21 -8 to-11 -9.5
22 -46 to -49 -47.5
23 -42 to -45 -43.5
24 -29 to -39 -34
25 -47 to -50 -48.5
26 -26 to -30 -28
27 -28 to -32 -30
28 -27 to -34 -30.5
29 -18 to -22 -20
30 4 to 5 4.5
31 -25 to -30 -27.5
32 -10 to-14 -12
33 -57 to -58 -57.5
Table 5.3 - Membrane potential of rat BMMCs. The membrane potential was
measured by switching the patch-clamp amplifier to the current-clamp mode
immediately after establishing the whole-cell recording configuration. Extracellular
solution = standard mast cell Ringers, pipette solution = standard KC1 solution.
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Figure 5.2 - Distribution of membrane potentials in rat BMMCs. The membrane
potential was measured by switching the patch-clamp amplifier to the current-clamp
mode immediately after establishing the whole-cell recording configuration.
Extracellular solution = standard mast cell Ringers, pipette solution = standard KC1










Figure 5.3 - Whole-cell capacitance in rat BMMCs measured in the conventional
whole-cell recording configuration (A, n=62) or with the perforated-patch technique
(B, n=116). The capacitance was measured by cancelling the transient that develops
in response to a voltage pulse (see text for details). The extracellular solution was
either standard or modified mast cell Ringer. The pipette solution was either
standard (KC1) or modified (K-methane sulfonate).
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5.3 - Characterisation of Whole-Cell Currents in Rat BMMCs
In this section, the results from experiments performed with the perforated patch
technique at temperatures between 25 - 37°C are described first, because this group
most closely approximates the normal physiological state of the cells. The results are
then compared to those obtained at room temperature and/or with the conventional
whole-cell configuration.
Two types of whole-cell current were observed in rat BMMCs using the perforated-
patch technique at temperatures between 25- 37°C. In 51 out of 79 cells (65%), there
was an inwardly rectifying (IR) current that was rapidly activated by hyperpolarizing
potential steps (Figure 5.4). The I/V curves typically contained a region showing a
small outward current just positive to the reversal potential as shown in Figure 5.4.
The second type of current, seen in 52 out of 79 cells (66%), was an outwardly
rectifying (OR) current that was activated by depolarizing potential steps (Figure
5.5). At potentials between -100 mV and +40 mV, the OR currents were
instantaneous and sustained, but at more positive potentials the current exhibited a
degree of time-dependent inactivation (Figure 5.6). In individual cells, the
expression of the two currents was variable. 37 out of 79 cells (47%) exhibited the
inwardly and outwardly rectifying currents concurrently (Figure 5.7). 15 cells (19%)
showed only the outward current, and in 14 cells (18%) only the inward current was
observed. In the remaining 13 cells (16%), no voltage-dependent currents were
observed and the current-voltage relationship was ohmic and resembled a basal leak
conductance (Figure 5.8). Both the IR and OR currents were observed in
experiments performed with pipette solutions containing either KC1 (n=69) or
KCH3SO4 (n=13) suggesting that movement of CI" from the pipette into the cell was
not responsible for induction of the currents.
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Figure 5.4 - A: Whole-cell membrane currents recorded from a rat BMMC using the
amphotericin B perforated-patch technique. B: The accompanying leak subtracted
current-voltage relationship. The cell was clamped at a holding potential of -40 mV
and voltage pulses of 200 ms duration were applied from -100 mV to + 40 mV in 10
mV steps at 1 s intervals. The current shows strong inward rectification, reverses at
about -70 mV, and exhibits slight time-dependent inactivation. A small outward
current is also passed at potentials just positive to the reversal potential. This type of
current/voltage relationship was seen in 14 out of 79 BMMCs (18%) at temperatures






Figure 5.5 - A: Whole-cell membrane currents recorded from a rat BMMC using the
amphotericin B perforated-patch technique. B: The accompanying leak subtracted
current-voltage relationship. The cell was clamped at a holding potential of -40 mV
and voltage pulses of 200 ms duration were applied from -100 mV to + 40 mV in 10
mV steps at 1 s intervals. The current show strong outward rectification, reverses at
about -30 mV, activates instantaneously and shows no inactivation over the voltage
range shown. This type of current/voltage relationship was seen in 15 out of 79
BMMCs (19%) at temperatures between 25 - 37°C. Recording solutions: modified
mast cell Ringer, standard KC1 pipette solution.
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Figure 5.6 - A: Whole-cell membrane currents recorded from a rat BMMC over an
extended voltage range. B: The accompanying leak subtracted current-voltage
relationship. The cell was clamped at a holding potential of -40 mV and voltage
pulses of 200 ms duration were applied from -140 mV to +100 mV in 10 mV steps at
1 s intervals. The current shows time-dependent inactivation at potentials over +40





Figure 5.7 - A: Whole-cell membrane currents recorded from a rat BMMC using the
amphotericin B perforated-patch technique. B: The accompanying leak subtracted
current-voltage relationship. The cell was clamped at a holding potential of -40 mV
and voltage pulses of 200 ms duration were applied from -100 mV to +40 mV in 10
mV steps at 1 s intervals. Both inwardly rectifying and outwardly rectifying currents
are present with features similar to those described in Figures 5.4 and 5.5
respectively. This type of current/voltage relationship was seen in 37 out of 79
BMMCs (47%) at temperatures between 25 - 37°C. Recording solutions: modified
mast cell Ringer, standard KC1 pipette solution.
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Figure 5.8 - A: Whole-cell membrane currents recorded from a rat BMMC using the
amphotericin B perforated-patch technique. B: The accompanying current-voltage
relationship. The cell was clamped at a holding potential of -40 mV and voltage
pulses of 200 ms duration were applied from -100 mV to +40 mV in 10 mV steps at
1 s intervals. No voltage-dependent currents are present and the current/voltage
relationship represents a basal leak conductance. In this experiment, the current
traces are less noisy than in the preceding figures, suggesting a lack of ion channel
activity. This type of current/voltage relationship was seen in 13 out of 79 BMMCs
(16%) at temperatures between 25 - 37°C. Recording solutions: modified mast cell
Ringer, standard KC1 pipette solution.
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The expression of IR and OR currents in the 79 BMMCs recorded at 25 - 37°C is
summarised in Table 5.4.
Table 5.4 - The number and proportion of BMMCs showing inwardly rectifying (IR)
or outwardly rectifying (OR) whole-cell currents with the perforated-patch technique
at temperatures between 25 - 37°C (n=79).
IR only IR and OR OR only No Currents
14 (18%) 37 (47%) 15 (19%) 13 (16%)
The voltage range over which the above currents were recorded varied as described
in chapter 2 (section 2.33), and is shown in Appendix 4. To allow comparison
between cells, slope conductances were only calculated from I/V curves obtained
over the range -140 mV to -100 mV for inward currents and +80 mV to +100 mV for
outward currents. The IR conductance in the range 25 - 37°C was 1.74 ± 1.1 nS (n =
41) and the OR conductance was 2.21 + 1.4 nS (n = 31). Linear leak currents were
subtracted from the I/V curves before calculating the above slope conductances (see
chapter 2, section 2.36). The mean leak conductance in the range 25 - 37°C was 0.75
± 0.62 nS (n=53).
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5.4 - Ionic Selectivity of the Inwardly Rectifying Current
The inwardly rectifying currents observed in rat BMMCs were very similar in
appearance to those described in RBL-2H3 cells (Lindau and Fernandez, 1986b;
Qian and McCloskey, 1993), rat BMMCs grown in the presence of IL-3 (McCloskey
and Qian, 1994), and cultured mouse BMMCs (Kuno et al, 1995), in which the
currents were characterised as a potassium-selective inward rectifier. To determine
the ionic selectivity of the IR current, current-voltage relationships were obtained
from BMMCs in extracellular solutions containing different concentrations of K+. In
an initial series of 21 perforated-patch experiments, whole-cell currents were
recorded from BMMCs suspended in both mast cell Ringer and 10 mM K+ Ringer
(section 2.22). In mast cell Ringer (2.7 mM K+), 15 out of 21 cells (71%) showed the
IR current but when the extracellular K+ was increased to 10 mM, the current was
present in all 21 cells (100%), suggesting that expression of the IR current in
BMMCs was dependent on extracellular K+ concentration. In a further series of
experiments, the effect of increasing extracellular K+ concentration on the
conductance and reversal potential of the IR current was investigated. As the
extracellular K+ was increased from 2.7 mM to 165 mM (with a corresponding
decrease in the Na+ concentration), the reversal potential of the I/V curves shifted in
a positive direction (Figure 5.9A). The linear relationship between reversal potential
and log extracellular K+ concentration with a least squares slope of 52 mV/decade
indicates that the conductance is essentially potassium selective (Figure 5.9B). The
slope conductance measured between -100 mV and -80 mV also increased with
extracellular K+ and was 1.48 ± 0.7 nS in 10 mM K+(n=9), 4.27 ± 1.4 nS in 50 mM
K+ (n=9), 5.50 ± 2.3 nS in 90 mM K+(n=5), 6.24 ± 2.8 nS in 137 mM K+(n=7), and
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5.8 ± 4.0 nS in 165 mM K+(n=3). Increase in conductance with increasing
extracellular K+ concentration also indicates that the current is predominantly carried
by K+ ions. Taken together, these results indicate that the IR current in rat BMMCs
is a K+ selective inwardly rectifying current.
Increasing the extracellular K+ concentration in the above experiments also increased
the slope conductance and reversal potential of the linear range of the I/V curves
(Figure 5.10). Although this effect was small in comparison to the effect on the
rectifying part of the curve, it indicates that at least a proportion of the conductance





Figure 5.9 - Effect of extracellular K+ concentration on inwardly rectifying currents.
A: Whole-cell I/V curves of a BMMC in six different concentrations of extracellular
K+. The cell was held at a holding potential of -40 mV and voltage pulses of 200 ms
duration were applied from -100 mV to + 40 mV in 10 mV steps at 1 s intervals.
There is a positive shift in reversal potential as the extracellular K+ increases from
2.7 mM to 165 mM. The curves were leak subtracted. Pipette solution = standard
KC1, bath temperature = 20°C.
B: Reversal potentials (E rev) plotted against log10 extracellular K+ (mM). The line
is a least-squares fit to the data. The slope of 52 mV/decade is close to that predicted
for a K+-selective membrane. The numbers above each data point represent the












Figure 5.10 - Effect of extracellular K+ concentration on the linear region of the I/V
curves. The I/V curves in Figure 5.9 were leak subtracted before calculation of the
conductance and reversal potential. The 4 data points in the linear region of the
curves just positive to the reversal potential were used for leak subtraction.
However, extrapolation from these points shows that the conductance and reversal
potential of the "leak" current is also increased by the increase in extracellular K+
concentration, suggesting a basal K+ conductance in this region.
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5.5 - Ionic Selectivity of the Outwardly Rectifying Current
The OR current was not affected by changes in extracellular K+ concentration.
However, when the extracellular CI" concentration was reduced to 51 mM by
substituting Na acetate for NaCl, the OR conductance decreased by 82 ± 8.5 %
(Figure 5.11), from a mean of 2.7 ± 2.1 nS to 0.51 ± 0.53 nS (n=5). In three cells
bathed in extracellular solution containing 14 mM CI" the peak OR conductance was
reduced to 0.24 nS in one cell and completely abolished in the other two cells.
As substitution of acetate could cause cytoplasmic acidification, which might
influence the above results, the experiments were repeated using Na-isethionate as
the impermeant anion. When Na-isethionate was substituted for NaCl to yield an
extracellular solution containing 16.7 mM CI", the OR conductance decreased from
3.39 ± 2.3 nS to 0.88 ± 1.2 nS (n=4), and this effect was reversible on washout of the
bath. A typical experiment showing the effect of Na-isethionate substitution is
shown in Figure 5.12. The figure shows continuous pen recordings made during the
solution exchange, and demonstrates the reduction in both current amplitude and
slope conductance as the extracellular CI" concentration is reduced to 16.7 mM.
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Figure 5.11 - Effect of extracellular CI" concentration on the outwardly rectifying
current. The BMMC was held at a holding potential of -40 mV and voltage pulses of
200 ms duration were applied from -140 mV to +100 mV in 10 mV steps at 1 s
intervals. When the extracellular CI" concentration was decreased from 153.7 mM to
51 mM by substituting Na-acetate for NaCl, the outwardly rectifying conductance
was markedly decreased. The curves were leak subtracted. Pipette solution =
standard KC1, bath temperature = 25°C.
189
.

























Figure 5.12 - Effect of extracellular CI" concentration on the outwardly rectifying
current. A: The voltage step protocol. The BMMC was held at a holding potential of
-40 mV and voltage pulses of 200 ms duration were applied from -140 mV to +100
mV in 10 mV steps at 1 s intervals. B: Typical continuous pen recording of the I/V
relationship. Below the tracings are the original superimposed currents evoked by
the 25 voltage steps labelled by each encircled number. At the first arrow, the mast
cell Ringer (153.7 mM CI") was exchanged for an extracellular solution containing
Na-isethionate (16.7 mM CI"). The outwardly rectifying (OR) current, showing time-
dependent inactivation at potentials above +60 mV, is markedly reduced between (1)
and (2). At the second arrow, the bath was washed out with mast cell Ringer
resulting in restoration of the current (3). Noise indicates the time taken for solution
exchange. Pipette solution contained KCH3S04. Bath temperature = 30°C.
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5.6 - Reversal Potential of the Outwardly Rectifying Current
The above results suggested that the OR conductance was CI" selective. However,
determination of the reversal potential of the CI" current from the I/V curves proved
problematical for a number of reasons. First, the linear region, and reversal potential,
of the I/V curves was influenced by the basal K+ conductance and leak as described
in the previous section. This region was not influenced by changes in extracellular
CI" concentration as shown in the non-leak subtracted curves in Figure 5.13 (A and
B), suggesting that the OR current was minimally active over this voltage range. To
overcome this problem, the linear range of the I/V curve was used for leak
subtraction, and the point at which the current became positive was used as an
estimate of the reversal potential in different extracellular CI" concentrations (Figure
5.13, C and D). However, this approach would not yield the actual reversal potential
of the OR current if the CI" conductance was a component of the linear range of the
I/V curve. A second problem arises in perforated-patch experiments because the
contents of the pipette solution are not the same as the cytosol, so the cytoplasmic CI"
concentration is not known. Pipette CI" ions either diffuse into or out of the cell
(depending on pipette CI" concentration) until a Donnan equilibrium is established
(Horn and Marty, 1988). The time taken for CI" redistribution is not known for each
cell, so the OR current could be measured under different cytoplasmic CI"
concentrations which could actually vary during the solution exchange. This latter
problem could be overcome by using the conventional whole-cell recording
configuration, in which the cytosolic CI" concentration is known. Unfortunately, as
described later in section 5.9, the OR current was dependent on the maintenance of
cytoplasmic integrity and was rarely observed with this configuration. A potential
solution to the problem is to determine the shift in reversal potential that occurs as
the extracellular CI" concentration is changed. This allows comparison with the
change in reversal potential predicted by the Nernst equation for a CI" selective
membrane, which can be calculated independently of cytosolic CI" as shown below.
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Expected Reversal Potential Change for a Chloride Selective Membrane




Expected shift in Erev as extracellular CI" changes from X mM to Y mM
= 59.16 log10 Cij - 59.16 logj0Oi
Y X




As the extracellular CI" concentration changes from 153.7 mM to either 51 mM (Na-
acetate) or 16.7 mM (Na-isethionate), the expected change in reversal potential
predicted by this equation is 28 mV or 57 mV respectively. When the extracellular
CI" concentration was reduced from 153.7 mM to 51 mM the reversal potential of the
OR current shifted by +31 ±21 mV (n=5), thus approximating the change predicted
by the Nernst equation (Figure 5.11). However, changing the extracellular CI" from
153.7 mM to 16.7 mM resulted in a reversal potential shift of only +34 ± 19 mV
(n=4). The departure from theory, and the large standard deviations, may reflect both
the inherent problems described above, or, in addition, partial selectivity for anions.
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153.7 mM CI
Figure 5.13 - Effect of extracellular CF concentration on the reversal potential of the
current/voltage relationship.
A and B: Non leak subtracted curves. Reducing the extracellular CF from 153.7 mM
to 16.7 mM decreases the current amplitude and slope conductance, but does not
change the reversal potential, probably because this region of the curve is dominated
by a basal leak conductance.
B and C: Leak subtracted curves derived from A and B. The data points at voltages
ranging from -30 mV to -70 mV were used for leak subtraction. The estimated
reversal potential shifts in a positive direction by approximately 15 mV, although the
expected shift for a CF-selective membrane is 57 mV. The discrepancy could reflect
changes in intracellular CF concentration, partial anion selectivity, or a contribution
by the K+-selective current.
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5.7 - Effect of Channel Blockers on the Outwardly Rectifying Current
In preliminary experiments, the outwardly rectifying current was not affected by the
K+ channel blockers 4-amino pyridine (100 pM) or tetraethylammonium (25 mM).
However, the OR conductance was reversibly decreased by the chloride channel
blocker 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS). Addition of 20 pM
DIDS to the extracellular solution reduced the outwardly rectifying conductance by
69 ± 23% from a mean of 2.8 ± 2.0 nS to 1.0 ± 1.3 nS (n=7). Figure 5.14 shows a
pen recording from a typical experiment in which the OR current amplitude and
slope conductance decreased after addition of 20 pM DIDS to the bath, but partially
recovered after the blocker was washed out. Taken together with the effects of
extracellular CI" concentration on the OR current, the above observations indicate





















Figure 5.14 - Effect of the CI" channel blocker DIDS on whole-cell membrane
currents in rat BMMCs. A: The voltage step protocol. The cell was held at a holding
potential of -40 mV and voltage pulses of 200 ms duration were applied from -140
mV to +100 mV in 10 mV steps at 1 s intervals. B: Typical continuous pen
recording of the current-voltage relationships. Below the trace are the original
superimposed currents evoked by the 25 voltage steps labelled by each encircled
number. At the first arrow, 20 pm DIDS was added to the bath resulting in gradual
diminution of the OR current. At the second arrow, the DIDS was washed out of the
bath resulting in recovery of the OR current. Extracellular solution = modified mast
cell Ringer, pipette solution = standard KC1, bath temperature = 25°C.
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5.8 ■ Effect of Temperature on the Expression ofWhole-Cell Currents
The outwardly rectifying chloride conductance was not described in two previous
studies of rat mucosal type mast cells (Lindau and Fernandez, 1986b; McCloskey
and Qian, 1994). However, in contrast to the methods described above, these studies
used conventional whole-cell recording techniques at room temperature. To
determine if the ORa current was influenced by bath temperature, the results of 117
perforated-patch recordings obtained at room temperature (16 - 20°C) were compared
with the results obtained at temperatures between 25 - 37°C. At room temperature,
23% of BMMCs displayed both IRK and 0RC1 currents concurrently, with a further
49% showing only IRK currents. In marked contrast to the results obtained at 25 -
37°C, only 3% of BMMCs displayed exclusively outward currents. 25% of cells
appeared quiescent, displaying neither inward nor outward currents. The difference
between these results and those described earlier is primarily attributable to the
decreased proportion of cells showing ORc, currents at room temperature compared
to 25 - 37°C (26% as shown in Table 5.5 vs. 66% as shown in Table 5.4).
Table 5.5 - The number and proportion of BMMCs showing inwardly rectifying (IR)
or outwardly rectifying (OR) whole-cell currents with the perforated-patch technique
at room temperature (16 - 20°C) (n=117).
IR only IR and OR OR only No Currents
57 (49%) 27 (23%) 3 (3%) 30 (25%)
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This effect is illustrated in Figure 5.15, which shows the effect of warming on a
population of 31 BMMCs that showed the ORa conductance at 25 - 37°C. The shift
in the distribution of conductances to the right indicates the activation of the 0RCI
current by the rise in temperature. In addition, the development of the ORa current
could be seen in individual cells by monitoring the I/V relationships as BMMCs were
warmed (Figure 5.16). The temperature at which the ORa current developed varied
from cell to cell; in most BMMCs, the current developed at 25°C, but in some cells
the current only appeared at 30 or 37°C. In cells that exhibited the ORC) current, the
time from the start of warming to development of the peak conductance ranged from
132 to 696 s with a mean and s.d. of 309 ± 132 s (n=21). After activation, the ORa
current was typically stable for long periods, and in one cell it was monitored for 60
min without deterioration. Taken together, these results indicate that detection of the
ORq current is more likely if the temperature of the cells is increased towards
physiological values.
The slope conductances of the IRK and 0RCI currents at room temperature were
significantly lower than those recorded at 25 - 37°C (p<0.005). Although the
expression of the IRK current was not affected by temperature in the same way as the
ORcl current, its conductance was 1.22 ± 0.7 nS (n=56) at room temperature
compared to 1.74 ± 1.1 nS (n=41) at 25 - 37°C (Figure 5.17). A similar difference
was found when cells showing the ORc, conductance at room temperature (1.25 ± 0.9
nS, n=20) were compared to those showing the conductance at 25 - 37°C (2.21 ±1.4
nS, n=31, Figure 5.18). The median ORa conductance increased with each
temperature increment (25, 30 and 37°C) but the difference between the three






Figure 5.15 - Effect of increasing bath temperature on a population of 31 BMMCs
that showed the ORa current at 25 - 37°C. The distribution of ORa conductances at
room temperature (16 - 20°C) is shown in A, and at 25 - 37°C in B. The shift of the
distribution to the right indicates activation of the current by the rise in temperature.
Extracellular solution = modified mast cell Ringer, pipette solution = standard KC1
solution.
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Figure 5.16 - Perforated-patch experiment showing activation of the ORcl current as
the bath temperature was increased from room temperature to 30°C. The BMMC
was clamped at a holding potential of -40 mV and voltage pulses of 200 ms duration
were applied from -100 mV to +40 mV in 10 mV steps at 1 s intervals. I/V
relationships are shown at intervals following activation of the Peltier device. Leak
currents were subtracted. Extracellular solution = modified mast cell Ringer, pipette
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Figure 5.17 - Comparison of the IRK current slope conductances at room temperature
(A), and in the range 25 - 37°C (B). Slope conductances were calculated using a
least squares fit to data points in the voltage range of the I/V curve running from -140
mV to -lOOmV. The IR conductance was significantly higher at temperatures
between 25 - 37°C (1.74 ±1.1 nS, n=41) than at room temperature (1.22 ± 0.7 nS,
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Figure 5.18 - Comparison of the ORcl current slope conductances at room
temperature (A), and in the range 25 - 37°C (B). Slope conductances were calculated
using a least squares fit to data points in the voltage range of the I/V curve running
from +80 mV to +100mV. The OR conductance was significantly higher at
temperatures between 25 - 37°C (2.21 ± 1.4 nS, n=31) than at room temperature
(1.25 ± 0.9 nS, n=20, p<0.005). Only those cells showing the current were included
in the analysis.
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5.9 - Effect of Cytoplasmic Disruption on the Whole-Cell Currents
To determine if maintenance of cytoplasmic integrity was also important for
demonstration of the ORa current, a series of experiments was performed using the
conventional whole-cell recording technique. In this method, the cytoplasm of the
cell is dialysed with the pipette solution, thus removing enzymes or second
messengers which could be critical to the function of ion channels. Current-voltage
relationships showed that 41 out of 44 BMMCs at room temperature (93%) displayed
the IRk current (Figure 5.19), with a mean slope conductance of 0.83 ± 0.5 nS
(n=22). The OR current was only present at room temperature in 3 out of 44
BMMCs (7%), with a mean slope conductance of 0.87 ± 0.6 nS. These 3 cells came
from a series of experiments in which KCH3S04 was used in the pipette solution
(n=13). The OR current was also present in 3 out of 6 BMMCs (50%) when
conventional whole-cell recordings were performed at room temperature using
standard KC1 pipette solution containing 0.3 mM GTP and 0.2 mM ATP (mean slope
conductance = 1.43 ± 1.4 nS, Figure 5.20). These experiments suggest that the OR
conductance may be dependent on one of these cytosolic factors.
Increasing the temperature of cells to 25°C in the whole-cell configuration often
resulted in breakdown of the pipette-membrane seal. Hence, it was not possible to
obtain a large series of recordings under these conditions. However, when 14 cells
dialysed with KCH3S04 pipette solution were successfully warmed to temperatures
between 25 - 37°C, 3 BMMCs showed some OR current, but the conductance was
much lower than that measured in perforated-patch recordings (0.69 ±0.1 nS).
A summary of the effects of temperature and cytoplasmic disruption on the whole-
cell currents in rat BMMCs is shown in Table 5.6. The results indicate that the
activity of the ORcl current is dependent both on temperature and the maintenance of
cytoplasmic integrity. In contrast, the IRK current was active both at room
temperature and with the conventional whole-cell recording configuration.
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Interestingly, the proportion of BMMCs showing the IRK current actually decreased
with the perforated-patch technique at higher temperatures. Although the
explanation for this phenomenon is not known, it may reflect differences between
intracellular and extracellular K+ concentrations with the two techniques (the
proportion of cells showing the IRK current with the perforated-patch technique was
increased to 100% when the extracellular K+ concentration was raised to 10 mM - see
section 5.4).
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Figure 5.19 - A: Whole-cell membrane currents recorded from a rat BMMC using
the conventional whole-cell recording configuration at room temperature. B: The
accompanying leak subtracted current-voltage relationship. The cell was clamped at
a holding potential of -40 mV and voltage pulses of 200 ms duration were applied
from -100 mV to + 35 mV in 5 mV steps at 1 s intervals. The current shows strong
inward rectification, reverses at -60 mV, and exhibits time-dependent inactivation at
potentials more negative than -85 mV. A small outward current is also passed at
potentials just positive to the reversal potential. Recording solutions: standard mast
cell Ringer, standard KC1 pipette solution.
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A
Figure 5.20 - A: Whole-cell membrane currents recorded from a rat BMMC using
the conventional whole-cell recording configuration. The pipette solution contained
KC1 and 0.3 mM GTP/0.2 mM ATP. B: The accompanying leak subtracted current-
voltage relationship. The cell was clamped at a holding potential of -40 mV and
voltage pulses of 200 ms duration were applied from -55 mV to +40 mV in 5 mV
steps at 1 s intervals. The current is very similar to the ORa current seen with the
perforated-patch technique, showing strong outward rectification, instantaneous
activation and no inactivation over the voltage range shown. The current reverses at
about 0 mV, as expected with almost symmetrical Cb concentrations. The bath







Temperature 16 - 20°C 25 - 37°C 16 - 20°C 25 - 37°C
% Cells showing IRK 93% 86% 72% 65%
Number cells showing IRK 41/44 12/14 84/117 51/79
Mean conductance ± s.d. (nS) 0.83 + 0.5 1.04 ±0.6 1.22 ±0.7 1.74 ±1.1
B
Parameter Conventional WCR: Perforated Patch Recording:
Cytoplasm Disrupted Cytoplasm Preserved
Temperature 16 - 20°C 25 -37°C 16 - 20°C 25 - 37°C
% Cells showing ORa 7% 21% 26% 66%
Number cells showing ORa 3/44 3/14 30/117 52/79
Mean conductance ± s.d. (nS) 0.87 ±0.6 0.69 ±0.1 1.25 ±0.9 2.21 ± 1.4
Table 5.6 - Effect of recording conditions on the IRK (A) or ORcl (B) currents.
Expression of the IRK current is not dependent on temperature or the maintenance of
cytoplasmic integrity, whereas the probability of observing the 0RC1 current
increases as the conditions approach physiological. The whole-cell conductance (for
both currents) increases significantly with the perforated-patch technique at the
warmer temperatures (p<0.005).
WCR = Whole-cell recording. Conventional WCR was performed with pipette
solutions containing either KC1 or KCH3S04, without added GTP or ATP (see
section 2.22 and appendix 4 for details).
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5.10 - Whole-cell currents in rat peritoneal mast cells
The outwardly rectifying chloride current in rat BMMCs was similar to that
described in rat peritoneal mast cells (RPMCs) when c-AMP was included in the
pipette solution or when the cells were stimulated with secretagogues (Matthews et
al, 1989a; Dietrich and Lindau, 1994; Janiszewski et al, 1994). The aim of this
section was to determine if an ORc, current could also be detected in resting RPMCs.
Peritoneal mast cells were obtained and purified as described in chapter 2 (section
2.11), and were used either on the day of collection, or after 24 - 48 hours incubation
in the presence or absence of 10 ng/ml SCF (see appendix 4 for details). The cells
were prepared for electrophysiological recording as described previously (section
2.28), and the perforated-patch technique was used to obtain current-voltage
relationships from cells at room temperature and in the range 25 - 37°C. Figure 5.21
shows the superimposed whole-cell currents from a RPMC warmed to 25°C with the
accompanying leak-subtracted I/V curve. An outwardly rectifying current is present
that closely resembles the ORc, current described in rat BMMCs. Figure 5.22 shows
the development of the OR current in a RPMC as the cell was warmed to 25°C, and
the abrupt decrease in current amplitude and slope conductance following addition of
20 pM DIDS to the bath. In five similar experiments, 20pM DIDS reduced the mean
OR conductance in RPMCs by 53 ± 28% from 1.7 ± 0.96 nS to 0.75 ± 0.53 nS (n=5).
A similar effect was observed when RPMCs showing the OR conductance in mast
cell Ringer were bathed in an extracellular solution containing 16.7 mM CI" (Figure
5.23), again indicating that the conductance was CI" selective. As in rat BMMCs, the
expression of the ORa current was variable and dependent on recording conditions.
10 out of 40 RPMCs (25%) showed the OR current between 25 - 37°C in contrast to
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9 out of 55 cells (16%) recorded at room temperature. The slope conductance also
increased with temperature from 1.15 ± 0.36 nS (n=9) to 1.51 ± 0.86 nS (n=10)
although the difference did not reach statistical significance, probably due to small
group sizes. The ORcl was also more commonly observed in RPMCs that had been
incubated for > 24 hours with 10 ng/ml SCF. From 55 RPMCs recorded at room
temperature, 12 cells had been incubated with SCF; the ORa was present in 5 cells
from this subgroup (42%) in contrast to 4 out of the remaining 43 cells (9%). The
mean OR conductance was higher in the SCF treated group (1.3 ± 0.4 nS vs. 0.96 ±
0.23 nS) but the difference was not statistically significant.
In accordance with previous reports (Lindau and Fernandez, 1986b; McCIoskey and
Qian, 1994), a K+ selective inwardly rectifying current was not observed in RPMCs
under these experimental conditions (see Figure 5.21), and in 3 cells bathed in high




Figure 5.21 - A: Whole-cell membrane currents recorded from a rat peritoneal mast
cell (RPMC) using the perforated-patch technique. B: The accompanying leak
subtracted current-voltage relationship. The cell was clamped at a holding potential
of -40 mV and voltage pulses of 200 ms duration were applied from -140 mV to
+100 mV in 10 mV steps at 1 s intervals. The current is very similar to the ORc,
current seen in rat BMMCs (see Figure 5.5), showing strong outward rectification,
instantaneous activation, and time-dependent inactivation at potentials over 60 mV.


























Figure 5.22 - Effect of temperature and DIDS on whole-cell membrane currents in
rat peritoneal mast cells (RPMCs). A: The voltage step protocol. Cells were held at
a holding potential of -40 mV and voltage pulses of 200 ms duration were applied
from -140 mV to +100 mV in 10 mV steps at 1 s intervals. B: As the cell was
warmed to 25°C (first arrow), an outwardly rectifying (OR) current developed
between (1) and (2). The current exhibited slight time-dependent inactivation at
potentials greater than +60 mV (2). At the second arrow, 20 pm DIDS was added to
the bath resulting in a sudden diminution of the OR current (3). The bath contained
modified mast cell Ringer and the pipette solution contained KCH3S04.
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Figure 5.23 - Effect of extracellular CI concentration on whole-cell membrane
currents in rat peritoneal mast cells (RPMCs). A: The voltage step protocol. Cells
were held at a holding potential of -40 mV and voltage pulses of 200 ms duration
were applied from -140 mV to +100 mV in 10 mV steps at 1 s intervals. B: Whole
cell currents in a RPMC after the mast cell Ringer (153.7 mM CI") was exchanged for
an extracellular solution containing Na-isethionate (16.7 mM CI", first arrow). The
OR current is markedly reduced between (1) and (2). At the second arrow, the bath
was washed out with mast cell Ringer resulting in restoration of the current (3).
Noise indicates the time taken for solution exchange. Pipette solution contained
KCH3S04.
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5.11 - Effect of Osmolality on the Outwardly Rectifying Current
The ORa conductance in rat BMMCs and RPMCs shares certain similarities with
volume regulated CI" conductances in other cell types (Lewis et al, 1993; Nilius et al,
1994). In these cells, positive transmembrane osmotic pressure (intracellular
osmolality > extracellular osmolality) induces the slow induction of a CI"
conductance. Two possible sources of such an osmotic imbalance exist in
perforated-patch recordings. First, a difference in CI" concentration between the
pipette solution and cytoplasm can result in movement of CI" ions either into or out
of the cell, accompanied by osmotically obliged water. Hence, with pipette solutions
containing 137 mM KC1, as in many of the experiments described above, the pipette
CI" concentration would be higher than that in the cytoplasm and CI" ions would
diffuse into the cell, possibly resulting in cell swelling (Horn and Marty, 1988).
However, when the KC1 was replaced with KCH3S04, the ORa current was still
observed in both rat BMMCs and RPMCs, suggesting that the current was not
induced by movement of CI" and water from the pipette into the cell.
A second potential source of osmotic stress arises because cells subjected to
perforated-patch recordings are very susceptible to small osmotic imbalances
between the cytosol and bath (Axon guide, 1993). This occurs because the cell
volume is not buffered by the large pipette volume as in conventional whole-cell
recordings. Hence, a slight discrepancy in the osmolality of the cytoplasm (which is
usually about 300 mOsm/Kg H20) and the bath solution could result in movement of
water into or out of the cell.
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The osmolalities of the solutions used in these experiments are listed below
(measured with an Advanced Wide-Range Osmometer 3WII, Advanced Instruments
Inc., MA, USA):
The osmolalities of the above solutions provide some evidence that the ORa currents
in rat mast cells developed as a result of cell swelling. For example, the osmolality
of the mast cell Ringer is slightly lower than that expected for the cytosol, so
movement of water, if any, is likely to be into the cell. In contrast, the KC1 pipette
solution used for conventional whole-cell recordings has a lower osmolality than
mast cell Ringer so water would tend to move out of the cell. Due to time
constraints, a full evaluation of the effects of osmolality on the activity of the ORa
current was beyond the scope of these studies. However, in this section, a few
preliminary experiments are described that address two questions. 1) Does a hypo-
osmolar extracellular solution activate an outwardly rectifying CI" current in rat
BMMCs and 2) is the current the same as that observed in perforated-patch
experiments?
The first question was addressed by monitoring the current/voltage relationships of
BMMCs with the conventional whole-cell recording technique as the mast cell
Ringer was exchanged for mast cell Ringer diluted to 67% with distilled water.
Under these conditions, water would tend to move into the cell resulting in swelling.
In 4 out of 4 BMMCs at room temperature, an outwardly rectifying current was
activated when the cell was bathed in 67% dilute Ringer, with a mean conductance of
1.8 ± 1.6 nS (Figure 5.24). Furthermore, the induced current could be inactivated
either by returning the cell to an isosmotic environment (mast cell Ringer, Figure
KC1 Pipette solution
Amphotericin B pipette solution
Mast Cell Ringer






5.24) or by replacing the 67% mast cell Ringer with a 67% low CI" Ringer (originally
containing 16.7 mM CI", Figure 5.25). The latter observation indicates that the
induced current was predominantly carried by CI" ions.
The ORc, current recorded from a rat BMMC with the perforated-patch technique at
25°C was also susceptible to changes in extracellular osmolality. When the bath
solution was replaced with mast cell Ringer containing 100 mM sucrose (real
osmolality 401 mOsm/Kg H20), the current decreased in amplitude and the
conductance decreased from 2.0 nS to 0.8 nS (Figure 5.26). Although these results
represent preliminary observations, they suggest that the ORCI current in rat BMMCs
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Figure 5.24 - Effect of osmolality on whole-cell membrane currents in rat BMMCs,
measured with the conventional whole-cell recording configuration at room
temperature. A: The voltage step protocol. Cells were held at a holding potential of
-40 mV and voltage pulses of 200 ms duration were applied from -140 mV to +100
mV in 10 mV steps at 1 s intervals. B: Continuous pen recording of the whole-cell
currents. At the first arrow, the extracellular solution was changed from mast cell
Ringer to 67% mast cell Ringer, resulting in the development of an outwardly
rectifying current (2). At the second arrow, the mast cell Ringer was replaced,
causing a rapid inactivation of the current (3). The current tracing has been reduced
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Figure 5.25 - Effect of osmolality on whole-cell membrane currents in rat BMMCs,
measured with the conventional whole-cell recording configuration at room
temperature. A: The voltage step protocol. Cells were held at a holding potential of
-40 mV and voltage pulses of 200 ms duration were applied from -140 mV to +100
mV in 10 mV steps at 1 s intervals. B: Continuous pen recording of the whole-cell
currents. At the first arrow, the extracellular solution was changed from mast cell
Ringer to 67% mast cell Ringer, resulting in the development of an outwardly
rectifying current (2). At the second arrow, the 67% Ringer was replaced with a 67%
low CI" Ringer (originally containing 16.7 mM CI"), resulting in rapid inactivation of
the current (3). The current tracing has been reduced in size for the purpose of the
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Figure 5.26 - Effect of osmolality on whole-cell membrane currents in a rat BMMC,
measured with the perforated-patch technique. A: The voltage step protocol. Cells
were held at a holding potential of -40 mV and voltage pulses of 200 ms duration
were applied from -140 mV to +100 mV in 10 mV steps at 1 s intervals. B:
Continuous pen recording of the whole-cell currents. At the first arrow, the bath was
warmed to 25°C, resulting in development of an outwardly rectifying current
between (1) and (2). At the second arrow, during a 25 s break in the tracing, the mast
cell Ringer was replaced with mast cell Ringer containing 100 mM sucrose. The OR
current amplitude and slope conductance were gradually reduced (3). At the third
arrow, during a 50 s break in the tracing, the mast cell Ringer was replaced, resulting
in gradual recovery of the current. The current tracing has been reduced in size for
the purpose of the figure. The pipette solution contained KCH3S04.
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DISCUSSION
Membrane Potentials in rat BMMCs
In previous studies of RBL-2H3 cells, the resting membrane potential was about -90
mV and was set by the inwardly rectifying K+ current at the K+ reversal potential
(Lindau and Fernandez, 1986b). In this study, the membrane potential of rat
BMMCs, which also possessed an IRK current, ranged from -62 mV to +4.5 mV with
a mean and s.d. of -28.5 ± 16.5 mV. These values are very similar to those reported
for mouse BMMCs (Kuno et al, 1995), but appear low compared to RBL-2H3 cells.
A possible explanation for these apparently low values is that a non-specific leakage
conductance (Erev = 0 mV) at the pipette-membrane seal could partially depolarize
the cell. This would be more likely in conditions of low extracellular K+ when the IR
conductance is small (Lindau and Fernandez, 1986b). However, in an intact cell, the
true resting membrane potential would be determined by the K+ reversal potential.
The lack of a detectable IRK in RPMCs explains why the resting potential of these
cells is close to 0 mV (Lindau and Fernandez, 1986b), but whether this accurately
reflects the situation in vivo remains to be determined.
Heterogeneity of ion channel expression in rat mast cells
In the mouse BMMC system, the presence or absence of IRK and ORa currents in
individual mast cells was interpreted as heterogeneity of ion channel expression i.e.
some cells had IRK channels, others had ORcl channels, some cells had both channels
and others had none (Kuno et al, 1995). This interpretation was based on the
observation that mouse BMMCs have the potential to differentiate into different mast
cell phenotypes depending on the microenvironments in which they reside (Nakano
et al, 1985). Hence, individual mast cells within the mouse BMMC population could
have different functional characteristics as reflected by the variation in ion channel
expression. However, rat BMMCs appear to be committed mucosal mast cells and,
unlike mouse BMMCs, do not differentiate to the connective tissue phenotype when
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exposed to fibroblasts or stem cell factor (MacDonald et al, 1996). Therefore,
although variation was found in the presence of the two currents in rat BMMC
populations, it is unlikely to be due to phenotypic heterogeneity of ion-channel
expression. It is more likely that a normal rat BMMC possesses the ion-channels for
both the IRk and ORa currents, and that the heterogeneous distribution of current
patterns within the population results from extrinsic factors (i.e. experimental
conditions) rather than intrinsic factors (i.e. restricted expression of ion channels).
This is highlighted in Table 5.6 which shows the variation in expression of the ORa
conductance in BMMCs under different conditions. Likewise, the inwardly
rectifying current was not seen in some cells in mast cell Ringer, but when the
extracellular K+ concentration was raised, it was present in all cells tested. In both
cases, the lack of a detectable current did not reflect the lack of the appropriate ion
channel. However, although the ORa current was demonstrated in both BMMCs
and RPMCs, the IRK current was only detectable in BMMCs. This may reflect true
heterogeneity between the cell phenotypes as rat BMMCs and RPMCs have distinct
biochemical and functional characteristics. However, the possibility still remains
that the lack of the IRK current may be an artifact of the isolation procedure, similar
to that affecting IgE responses in freshly isolated RPMCs (Taylor et al, 1996).
RPMCs undergo apoptosis on removal from the abdominal cavity, unless stimulated
with the appropriate growth factors (Galli et al, 1994; Horigome et al, 1994), and the
apparent influence of the cytokine SCF on the expression of the ORa current lends
support to this hypothesis.
Activity of the ORa Current in rat BMMCs
In contrast to previous studies (Lindau and Fernandez, 1986b; McCloskey and Oian,
1994; Qian and McCloskey, 1993), this study showed that rat BMMCs possessed an
outwardly rectifying chloride conductance (0RC1) in addition to the previously
described K+ selective inwardly rectifying (IRk;) current. This apparent discrepancy,
which has important physiological significance, can be explained by three different
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hypotheses. First, the results may reflect variations in mucosal mast cell phenotypes.
The BMMCs in this study were grown in lymph node conditioned medium which
contains T-cell-derived cytokines in addition to concanavalin A. These additional
factors could be necessary for expression of the outwardly rectifying chloride
channel which was not observed in either RBL-2H3 cells or mast cells grown in the
presence of IL-3 alone. However, this explanation seems unlikely because the ORcl
current was also present in RPMCs (an example of the connective tissue phenotype)
and these cells were not exposed to the above factors.
A second possibility for the above discrepancy is the apparent dependency of the
ORa conductance on temperature and the maintenance of cytoplasmic integrity.
With the conventional whole-cell recording technique at room temperature (as used
in previous studies) only 3/44 BMMCs showed an ORcl current. However, when the
integrity of the cell's cytoplasm was preserved using the perforated patch-technique,
the ORa current was readily demonstrable both in BMMCs and RPMCs. In
addition, increasing the bath temperature towards physiological values increased the
proportion of cells that possessed the ORa current, although the conductances were
lower with the conventional whole-cell technique. These findings suggest that the
ORcl current may be dependent on an essential intracellular component that is
leached out of the cell during conventional voltage-clamp recordings. The increased
expression of the ORa current when ATP and GTP were included in the pipette
solution in conventional whole-cell recordings lends support to this hypothesis. The
ORC| conductance observed in these experiments is also similar to that induced in
RPMCs when c-AMP is included in the pipette solution (Penner et al, 1988; Dietrich
and Lindau, 1994). For example, the time course for development of the 0RC1
current in RPMCs following "break-in" is similar to that following warming of
BMMCs or RPMCs; the shape of the I/V curve is similar in both cases; and both
currents are blocked by 20pM DIDS. In previous studies of RPMCs (Penner et al,
1988), it was concluded that in vivo a rise in intracellular c-AMP following
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stimulation of the cells with secretagogues or antigen was responsible for activation
of the ORcl current. In this study, neither secretagogues nor exogenous second
messengers were required to elicit the current. This suggests that if c-AMP is the
"missing" cytosolic factor in conventional whole cell recordings, then only basal
levels of the messenger are required to support the ORc, conductance.
The third possibility for the discrepancy in results is the influence of osmolality on
the ORa current. In this study, an ORa current was activated in BMMCs by placing
the cell in a hyposmotic environment, and inactivated by returning the cell to
isosmotic or hyperosmotic solutions. This effect could also explain the results of the
perforated-patch recordings in which small osmotic imbalances between cytosol and
bath could lead to activation of volume regulated CI" channels. The significance of
these findings is discussed below.
In summary, it seems likely that the ORa current in rat BMMCs is dependent on
temperature, a cytoplasmic component and/or differences in transmembrane
osmolality.
Physiological relevance of the ORcl current in rat mast cells
Based on previous studies and the data presented above, two theories have emerged
to account for the function of the 0RCI current in rat mast cells: the CI" potential
clamp hypothesis, and the volume regulation hypothesis. The first hypothesis
originated in studies of RPMCs (Matthews et al, 1989a; Penner et al, 1988). In these
studies, it was suggested that activation of the ORcl current by agonists would shift
the membrane potential of the cell to the CI" reversal potential, assumed to be about
-30 to -40 mV. The membrane potential would then be "clamped" at a sufficiently
negative value to support Ca2+ influx during degranulation. Support for this
hypothesis is provided by studies of RBL-2H3 cells using potential sensitive
indicators such as Zns-oxonal (Mohr and Fewtrell, 1987b; Mohr and Fewtrell, 1987a;
221
Labrecque et al, 1989), and the lipophilic [3H] tetraphenylphosphonium cation
(Kanner and Metzger, 1983; Sagi-Eisenberg and Pecht, 1983). Following
stimulation of the IgE receptor with antigen, RBL-2H3 cells were depolarised within
2 - 3 minutes (Kanner and Metzger, 1983; Sagi-Eisenberg and Pecht, 1983; Mohr and
Fewtrell, 1987a). However, over the subsequent 5 minutes there was a partial
repolarization towards the resting membrane potential (Mohr and Fewtrell, 1987a;
Labrecque et al, 1989). This repolarization could be mediated by the FceRl
receptor-activated CI" current in RBL-2H3 cells (Romanin et al, 1991) in a similar
way to that proposed for RPMCs. Further evidence for the CI" potential clamp
hypothesis is provided by the observations that persistent depolarization (Mohr and
Fewtrell, 1987b) and CI" channel blockade (Romanin et al, 1991) in RBL-2H3 cells
inhibited Ca2+ influx and exocytosis. In addition, studies of rat peritoneal mast cells
showed that CI" uptake was required for optimum histamine release (Glenert et al,
1993). The IA/ curves obtained from rat BMMCs indicate that the ORa current was
activated when the cell was depolarized to potentials more positive than -30mV. If
this occurred during degranulation of BMMCs, then the ORa current would tend to
repolarize the cell as described above.
Despite the evidence for the role of the ORa current in voltage control of the cell
during degranulation, some problems persist with this interpretation. The activation
of the current in RPMCs by agonists such as compound 48/80 or substance P is
slower than the kinetics of secretion in these cells. Also, the CI" channel in RPMCs
can be effectively blocked by DIDS at concentrations that do not inhibit exocytosis,
except at the lowest concentrations of secretagogue (Dietrich and Lindau, 1994).
These observations suggest that the CI" current is not essential for stimulation of
exocytosis, but may enhance secretion following sub-optimal stimulation with
secretagogues. There is also evidence that the repolarization of RBL-2H3 cells that
occurs during degranulation is mediated by an efflux of K+ ions from the cell
(Labrecque et al, 1989; Labrecque et al, 1991). The outwardly rectifying K+ current
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described by Qian and McCloskey (1993) offers a potential mechanism for this
pathway.
The above discussion centres on the role of the ORcl current during degranulation.
In previous studies, the current was activated by agonists and second messengers
known to initiate secretion. However, the results of this study indicate that the 0RC1
current can be active in both rat BMMCs and RPMCs without stimulation with
intracellular or extracellular agonists, and not undergoing degranulation. This
detachment from the process of exocytosis suggests that the current may have an
alternative, or additional, role to that proposed above. If the current was
constitutively active in normal resting cells it would contribute to the resting
membrane potential of the cell, as suggested in mouse BMMCs (Kuno et al, 1995).
The results using the perforated-patch technique at temperatures > 25°C initially
appear to support a constitutively active 0RCI current. However, this technique could
result in the activation of volume-regulated CI" currents as described earlier. Hence,
a second hypothesis for the function of ORa currents in rat BMMCs is a role in
volume regulation.
The ORC| conductance in rat mast cells shares similar properties to volume regulated
CI" conductances in a number of other cell types including RBL-2H3 cells (Nilius et
al, 1994), fibroblasts (Nilius et al, 1994), T lymphocytes (Lewis et al, 1993),
osteoblasts (Gosling et al, 1995), neutrophils (Stoddard et al, 1993), hepatocytes
(Meng and Weinman, 1995), and aortic endothelial cells (Nilius et al, 1994). The CI"
conductances in these cells are thought to be involved in regulatory volume decrease
if the cells encounter a hyposmotic environment (Stoddard et al, 1993), and although
they have broadly similar properties, including outward rectification, there is a
degree of variation between cell types. For example, in mouse fibroblasts, the
volume-regulatory ORcl channel passes a large inward current at negative voltages
(Nilius et al, 1994). In contrast, there was virtually no activation of current at
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negative voltages in RBL-2H3 cells (Ra et al, 1989). The latter observation is in
agreement with the findings reported here for the ORa current in rat BMMCs. The
possibility of volume regulated CI" channels in RPMCs was raised by Dietrich and
Lindau (1994), but this was based on the similarity of the current to CI" currents in
lymphocytes (Lewis et al, 1993) and no experimental evidence was provided. Other
investigators concluded that the c-AMP activated CI" current in RPMCs was not
dependent on changes in cell volume and did not, therefore, play a role in volume
control (Matthews et al, 1989a). The results of this study showing the effects of
changes in transmembrane osmotic pressure on the ORc, current provide the first
direct evidence for the presence of volume regulatory CI" channels in rat BMMCs.
In summary, rat BMMCs possessed an outwardly rectifying CI" conductance in
addition to the previously described K+-selective inwardly rectifying current. The
current was dependent on temperature and the maintenance of cytoplasmic integrity,
and could be activated by a reduction in extracellular osmolality. A similar current
was observed in RPMCs in the absence of external agonists or intracellularly applied
second messengers. The true physiological role of chloride channels in mast cells
awaits further clarification. However, based on these studies, and those previously
reported, two hypotheses remain for the type of CI" channels that are present in mast
cells. First, two types of CI" channel may be present in mast cells: a volume
regulatory channel and an agonist-activated channel; and second, a single type of CI"
channel may be present in mast cells, but it can be activated in a variety of ways,
including by agonists, second messengers and changes in osmolality. The
significance of these hypotheses, and the importance of future work in this area, is




The involvement of mast cells in the pathogenesis of allergic diseases has prompted
extensive investigations into their origin, biochemistry and function (reviewed in
Chapter 1). The realisation that rodents and humans possess at least two phenotypes
of mast cell has generated widespread interest in the possibility of differing roles for
these cells in vivo. Further characterisation of mucosal and connective tissue-type
mast cells in vitro has demonstrated that, at least in rodents, the cells have distinct
functional properties, including the response to cytokines, secretagogues and anti¬
allergic drugs.
The participation of the mucosal mast cell (MMC) phenotype in the inflammatory
response against intestinal helminths is demonstrated by the prominence of these
cells in parasite-infested mucosal tissue, and the finding that MMCs are functionally
active during expulsion of experimental nematode infestations in laboratory rodents
and sheep (reviewed in Miller, 1993b). These observations, suggestive of a direct
protective role for MMCs in the intestinal tract, have prompted studies to further
characterise the properties of these cells in the rat both in vivo (Moqbel et al, 1986;
MacDonald, 1994; Scudamore et al, 1995a) and in vitro (Befus et al, 1982; Pearce et
al, 1982).
The development of techniques to culture rat bone marrow-derived mast cells
(BMMCs), which are morphologically, biochemically and functionally identical to
rat intestinal MMCs (Haig et al, 1982), has provided an opportunity for more
widespread study of the mucosal mast cell phenotype (MacDonald et al, 1989;
MacDonald, 1994; MacDonald et al, 1996). Studies of the IgE-dependent release of
the MMC- and BMMC-specific granule chymase, rat mast cell protease-II (RMCP-
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II), from BMMCs are particularly relevant because this protease may be directly
involved in the process of worm expulsion (Miller et al, 1983; Woodbury et al,
1984), through its capacity to promote epithelial permeability (Scudamore et al,
1995b).
In this study, the release of RMCP-II from individual BMMCs was detected using a
novel ELISPOT assay (Chapter 3). Within a population of BMMCs, only 6 - 24% of
the cells responded to IgE-dependent stimulation, even after sensitisation with
exogenous IgE. This novel finding may represent a key regulatory mechanism, with
the IgE receptor providing a trigger for degranulation, but a number of other factors
determining the final response of individual mast cells. The experiments described
in Chapter 4 identified the cytokine, stem cell factor (SCF), as one of these factors.
SCF enhanced total IgE-dependent mediator release from populations of mature
BMMCs, and, in a similar percentage increase, the proportion of cells that responded
to stimulation. These results suggested that SCF augmented mediator release from
rat BMMCs by primarily activating previously unresponsive cells. Interestingly, this
effect was not observed in BMMCs derived from immature cultures. Therefore,
when taken with the pre-existing data describing the effects of SCF on mucosal mast
cell development (reviewed in Chapter 1), these results allow a model to be proposed
for the role of SCF in the modulation of gastro-intestinal immune responses in vivo.
A simplified scheme outlining the potential role of SCF in gastrointestinal mast cell
responses (based on collective data from a variety of species)
1) Infection with intestinal helminths leads to cytokine production (IL-3, IL-4, IL-9,
IL10) by activated TH2-type cells (Mosmann et al, 1991). These cytokines, and
probably SCF (Newlands et al, 1995), signal the differentiation of mucosal mast cells
from bone marrow-derived progenitors (Haig et al, 1988; Schmitt et al, 1987;
Moellereta/, 1989; Thompson-Snipes et al, 1991; Haig et al, 1994).
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2) The committed mast cell precursors circulate through the bloodstream (Kitamura
et al, 1979; Rodewald et al, 1996) and "home" to the gastro-intestinal tract, possibly
using SCF/c-kit interactions (Adachi et al, 1992; Kinashi and Springer, 1994) and/or
surface integrins (Smith and Weis, 1996) as adhesion molecules.
3) The committed precursors complete their proliferation and differentiation into
mature mucosal mast cells under the continued influence of T-cell-derived cytokines
and SCF (either membrane bound or soluble forms).
4) Production of IL-4 by TH2 cells (Mosmann et al, 1991) and mast cells (Plaut et al,
1989) induces immunoglobulin class switching of B cells from IgM to IgE (Devries
et al, 1993). The parasite-specific IgE binds to high-affinity IgE receptors on the
surface of intestinal mucosal mast cells (similar to the binding to BMMCs of lymph
node conditioned medium-derived IgE - Chapter 3).
5) On reaching maturity, the mucosal mast cells are "primed" by membrane bound or
soluble SCF (and possibly other factors), increasing the probability that they will
degranulate in response to aggregation of the surface IgE receptors by specific
antigen (Chapter 4). An interesting possibility is that the expression of SCF on the
surface of fibroblasts, or the levels of soluble SCF in the local tissue
microenvironment, could also be under the control of cytokines, although this awaits
further study. However, this would provide a mechanism for controlling the
"releasability" of the intestinal mast cell population, with an upregulation of SCF
expression leading to activation of previously quiescent cells, and enhanced mediator
release following IgE-dependent stimulation (Chapter 4).
Although the above scheme is speculative and based mainly on data from in vitro
studies from a variety of species, it provides a framework for understanding the
possible roles of SCF in vivo. In addition, the mechanisms described may also be
involved in the pathogenesis of allergic reponses. Hence, an exciting possibility for
future studies is the development of ELISPOT assays to detect proteases from other
mast cells types in other species. For example, detection of tryptase release from
227
individual human mast cells could be used as an in vitro model of allergic reactions.
The advantage of this method over conventional mediator release assays is that
statistically quantifiable results can be obtained with as few as 5000 mast cells per
assay. Hence, a tryptase ELISPOT assay could be used to investigate the function of
mast cells derived from clinical material such as broncho-alveolar lavage fluid or
skin biopsies. The latter approach would also be extremely valuable in species of
veterinary importance in which it is difficult to obtain large numbers of purified mast
cells. For example, future studies are planned to develop an ELISPOT assay to
detect the release of tryptase from canine mast cells. Such an assay would be useful
for investigating mast cell responses in canine atopic dermatitis, including the
response to various secretagogues, cytokines and anti-allergic drugs.
The release of mediators from mast cells also depends on the activation of ionic
conductances (reviewed in Chapter 1). A critical (and probably the most important)
signal for degranulation is the rise in intracellular Ca2+ following activation of the
Ca2+ influx pathways (Penner et al, 1988; Zhang and McCloskey, 1995). Although
not investigated in this study, these pathways have been demonstrated in rat
peritoneal mast cells (Matthews et al, 1989b), RBL-2H3 cells (Zhang and
McCloskey, 1995) and human basophils (MacGlashan and Botana, 1993) using a
combination of patch-clamp and Fura-2 fluorescence techniques. Similar studies in
the future might identify these pathways in rat BMMCs.
The electrophysiological properties of resting rat BMMCs were described in Chapter
5. As described in previous studies of RBL-2H3 cells (Lindau and Fernandez,
1986b) and IL-3-derived BMMCs (McCloskey and Qian, 1994), rat BMMCs
possessed an inwardly rectifying (IR) K+ current that is probably involved in setting
the resting membrane potential. However, in contrast to the latter studies, rat
BMMCs possessed an outwardly rectifying (OR) CP current. The dependency of the
current on temperature and the maintenance of cytoplasmic integrity suggested that
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an intracellular messenger might be required for its activity. In addition, the effects
of changes in extracellular osmolality suggested that the ORa current in rat BMMCs
was involved in volume regulation, as described for the similar outwardly rectifying
CI" currents in RBL-2H3 cells and a number of other cell types (Nilius et al, 1994).
Hence, one model for the proposed function of the current in vivo is shown below.
A scheme outlining the proposed role of the OR^i current in volume regulation
1) Conditions of extracellular hypotonicity would lead to an influx of water into the
mast cell, resulting in cell swelling. Such conditions might arise following mast cell
activation in the tissues, resulting in sites of inflammation or oedema.
2) Cell swelling leads to activation of the ORc, current (Chapter 5). If the resting
membrane potential of the cell was more negative than the chloride reversal
potential, CI" ions would move out of the cell carrying an inward current until the cell
was depolarised to the CI" reversal potential. In some cells, this depolarisation
activates voltage-dependent K+ channels leading to a concurrent efflux of K+ ions
(Stoddard et al, 1993), although such currents were not observed in rat BMMCs.
3) The movement of CI" ions out of the cell along with osmotically obliged water
reduces the cell volume to its original size (regulatory volume decrease), resulting in
inactivation of the ORc, current.
Despite the evidence for the effect of osmolality on the ORcl current in rat BMMCs,
a number of problems persist with the above interpretation. First, in rat BMMCs
(Chapter 5) and RBL-2H3 cells (Nilius et al, 1994), the ORcl current does not appear
to pass appreciable amounts of inward current at potential more negative than the CI"
reversal potential. However, passage of only small currents may be sufficient to
initiate regulatory volume decrease. Second, the activation of concurrent K+
conductance pathways has not been demonstrated in rat mast cells. And third, an
ORC| current with similar properties has been described in rat peritoneal mast cells
following stimulation with compound 48/80, substance P, or intracellularly applied
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messengers such as c-AMP or GTP-y-S (Matthews et al, 1989a; Dietrich and Lindau,
1994; Janiszewski et al, 1994). A completely different function was proposed for the
latter current as described below.
A scheme outlining the proposed role of the ORg current in voltage control during
degranulation
1) Stimulation of the cell with antigen or external ligands generates G-proteins, IP3
and c-AMP (Gomperts, 1983; Sagi-Eisenberg, 1993; Penner et al, 1988).
2) The Ca2+ influx pathways are activated resulting in a rise in intracellular Ca2+
(Matthews et al, 1989b; Zhang and McCloskey, 1995), the onset of degranulation
(Crews et al, 1981), and depolarization of the membrane potential to beyond the CI"
reversal potential (Kanner and Metzger, 1983; Mohr and Fewtrell, 1987a).
3) Persistent depolarization would decrease Ca2+ entry and inhibit exocytosis (Mohr
and Fewtrell, 1987b). However, the generation of c-AMP and GTP-y-S also
activates the 0RC1 current (Matthews et al, 1989a). At potentials more positive than
the CI" reversal potential, CI" ions move into the cell carrying an outward current.
This shifts the membrane potential towards the CI" reversal potential, thus
maintaining the hyperpolarization-driven Ca2+ influx.
Although some of the data in the above scheme was obtained from RBL-2H3 cells,
there is no direct evidence, as yet, that the above mechanisms operate in rat BMMCs.
Furthermore, in this study, the 0RC1 current was observed in both resting peritoneal
mast cells and BMMCs which were not stimulated with extracellular ligands or
intracellular messengers (Chapter 5). Hence, key questions remain concerning the
role of ORa currents in different mast cell types. Is there more than one type of CI"
channel present in mast cells, each with a different function, or one type with
multiple functions? Can the channels be activated in a variety of ways, including by
messengers or changes in osmolality? Are the channels important in voltage control
during degranulation? Due to time constraints, these questions could not be
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addressed fully in this study. However, future studies are planned to determine more
precisely the nature and function of CI" channels in rat mast cells. These studies
would involve a direct comparison of CI" currents in both rat peritoneal mast cells
and BMMCs and would include: activation of the currents by secretagogues and
intracellular messengers such as c-AMP, ATP, GTP-y-S and Ca2+; effects of
changing osmolality on the ORa current in both cell types; analysis of the CI"
2-
channel permeability to other anions such as SCN", N03", I", Br, S04 , and
glucuronate"; analysis of CI" channel pharmacology by testing various blockers such
as DIDS, NPPB, dideoxyforskolin, tamoxifen, verapamil, and quinine; determination
of the single channel conductance by noise analysis; and analysis of the effect of
extracellular CI" concentration on secretion. Comparative studies such as these could
determine the true role of CI" channels in mast cells. This is a critical question
because a proven role for the 0RCI current in the process of degranulation may
provide a basis for the future development of CI" channel blockers as anti-allergic
drugs.
In conclusion, this study has contributed to our understanding of the function of rat
BMMCs, and suggested factors that may be involved in the immunological and
electrophysiological regulation of intestinal mucosal mast cell function in vivo. It is
hoped that these findings can be extended in future studies of other mast cell types to
further define the regulation of these cells in physiological and pathological
processes. Such studies might lead to novel pharmacological approaches to control
mast cell degranulation in allergic reactions.
231
APPENDIX 1






Dissolve in 1 litre de-ionised, distilled water and adjust pH to 7.2 - 7.3.
Serumless IMDM




714 pi sterile 35% stock solution of BSA (Sigma)
0.5.ml sterile stock solution of human transferrin (Sigma) - 25 mg/ml
50 pi sterile palmitic acid (Sigma) - 10 mg/ml in 100% ethanol)
50 pi sterile oleic acid (Sigma) - 10 mg/ml in 50% ethanol in sterile distilled water
5 pi sterile linoleic acid (Sigma) - 10 mg/ml in sterile PBS
(3-hexosaminidase buffers
A: Substrate buffer - 0.15 M disodium citrate buffer, pH 4.5
7.9 g citric acid
75 ml 1 N NaOH
Dissolve citric acid and make up to 250 ml with de-ionised, distilled water. Adjust
pH to 4.5 with 1 M HC1
B: Stop buffer - 0.2 M glycine-NaOH buffer, pH 10.7
1. 1.88 g glycine + 1.45 g NaCl, dissolved in 125 ml de-ionised, distilled water.
2. 0.4 g NaOH, dissolved in 50 ml de-ionised, distilled water.
To 6.6 ml of (1), add approximately 5.8 ml of (2) until pH reaches 10.7. Keep at 4°C
prior to use.
RMCP-II ELISA coating buffer
1.59 g Na2C03
2.93 g NaHC03
Dissolve in de-ionised, distilled water and make up to 1 litre. Adjust pH to 9.6 (if
necessary). Use for dissolving primary antibody and coating plate.
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RMCP-II ELISPOT buffer and substrate
A: To Prepare Stock AMP solution (2-amino-2-methyl-l-propanol)
1. For 500ml dissolve 35.15mg MgCl2 and 50pl Triton-X-405 in a small volume of
distilled water.
2. Add 47.9ml AMP (Sigma) and mix well.
3. Add distilled water to 90% (450ml). Adjust pH to 10.25 with concentrated HC1.
4. Leave overnight at room temperature and readjust pH. Make up volume with de-
ionised, distilled water and store at 4°C.
B: To Prepare Gel Substrate
5. Prepare a 3% w/v solution of agarose (Type 1, Sigma) in distilled water and
dissolve by boiling.
6. Make up BCIP (5-bromo-4-chloro-3-indoyl phosphate, Sigma) in stock AMP
solution. Weigh out 12.5mg BCIP and dissolve in 200pl dimethylformamide (wear
gloves and perform in fume cupboard).
7. Add 12.5 ml stock AMP. Warm solution to 40°C . Keep agarose melted by
holding at 60°C.
8. Add 3 ml agarose to substrate solution to give final dilution of = 0.6% w/v.
COSHH warning - see risk assessments for AMP, dimethylformamide and BCIP.
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APPENDIX 2
The Effect of Iscove's Modified Dulbecco's Medium on the Survivability of Rat
Peritoneal Mast Cells
Introduction
The purification of rat peritoneal mast cells using Percoll density step gradients was a
simple and reliable method for isolating virtually pure populations of mast cells (see
chapter 2, section 2.11). For the studies described in chapter 5, purified peritoneal
mast cells were used on the day of collection, as well as after 1-2 days in culture in
the presence or absence of stem cell factor (SCF). However, all initial attempts to
maintain peritoneal mast cells in culture (either with or without SCF) ended in
failure. Typically, after 24 - 48 hours, the entire population of cells had a "ghost¬
like" appearence with no distinct cellular outlines, and this was interpreted as cell
death. This appendix describes a series of experiments that were performed to
investigate this problem. The results indicate that the cytotoxicity was caused by the
use of Iscove's Modified Dulbeccos Medium (IMDM) to wash and culture the cells.
Experiment 1 - Effect of SCF concentration on peritoneal mast cell survival
Peritoneal mast cells were purified as described in chapter 2 and resuspended in 10
ml of IMDM/20%HS/PS (standard medium for culturing rat BMMCs). The cells
were washed twice and resuspended in 12 ml of the above medium. 1 ml aliquots of
the cell suspension containing 1.5 x 104 mast cells were added to each well of a 12
well tissue culture plate (Costar, Cambridge, MA, USA), and incubated for 24 hours
with 400, 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.8, 0.4 or 0 ng/ml SCF.
Results - After 24 hours, all the cells in all wells appeared to be dead.
Experiment 2 - Effect of cell density on the survival of rat peritoneal mast cells
Percoll purified peritoneal mast cells were added to cell culture wells in triplicate at
densities of 5xl05, 5xl04, 5xl03 or 5xl02 cells/ml in IMDM/20%HS/PS, and
incubated for 48 hours with 100, 10 or 0 ng/ml SCF.
Results - Most of the cells were dead after 24 hours incubation, and all the cells were
dead after 48 hours.
Experiment 3 - Comparison of Percoll from two different sources
To investigate the effect of different batches of Percoll, peritoneal cells from the
same rat were purified with either a batch of Percoll previously used successfully at
the Moredun Research Institute, UK, or with a batch used for these studies. 1 ml
aliquots of cell suspensions from both purifications containing 1.8 x 104 mast cells
were added to wells and incubated for 48 hours with 200, 100, 50, 25, 12.5 or 0
ng/ml SCF.
Results - All cells from both groups were dead after 48 hours.
Experiment 4 - Use of a different Percoll purification method
To determine if the cells were being damaged during centrifugation in the Percoll
gradient, an alternative protocol was tried which prevents the cells from pelleting on
the base of the tube. Peritoneal lavage cells were layered on top of 10 ml of isotonic
Percoll and centrifuged at 35,000 g for 20 mins. The mast cells, which accumilated
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in the lower 1/3 of the gradient, were washed and resuspended in IMDM/20%HS/PS.
They were then incubated for 48 hours with 200, 100, 50 or 0 ng/ml SCF.
Result - All cells were dead after 48 hours.
Experiment 5 - Comparison of rats from two different sources, and two
different culture media
Peritoneal mast cells were purified from two different rats. One rat was obtained
from Bantam and Kingman, Hull, UK and the other was obtained from the Moredun
Research Institute, Edinburgh, UK. Cells from both groups were resuspended in
either IMDM/20%HS/PS or RPMI/10%FCS at 1 x 105 cells/ml in the presence or
absence of 100 ng/ml SCF.
Results - After 24 hours, the cells in all groups showed good viability when assessed
subjectively. However, after 48 hours, the cells suspended in RPMI/10%FCS were
clearly healthier than those in IMDM. After 36 hours, the cells in IMDM were all
dead, whereas those in RPMI still appeared viable.
Experiment 6 - Effect of washing and resuspending cells in IMDM on the
survival of rat peritoneal mast cells
Percoll purified peritoneal mast cells were either washed three times in
IMDM/20%HS/PS or Hanks balanced salt solution containing 2%FCS, P/S and 10
units/ml heparin (HBSS). Cells were resuspended in RPMI/10%FCS and
quadruplicate aliquots (250 pi) of cell suspensions containing 6.5 x 105 mast cells/ml
were then incubated for 24 hours in the presence or absence of 100 ng/ml SCF.
Results - All the cells washed in IMDM were dead after 24 hours. All the cells
washed in HBSS appeared viable, in both SCF and non-SCF treated groups.
Experiment 7 - To determine the effect of washing cells in various media on the
survivability of peritoneal mast cells
Percoll purified peritoneal mast cells were divided into 7 groups and washed three
times in one of the following solutions, as described in chapter 2, section 2.3.
1. HBSS + 2% FCS + P/S + Heparin
2. HBSS + 20% HS + P/S
3. HBSS + 10% FCS + P/S
4. IMDM + 20% HS + P/S
5. IMDM + 10% FCS + P/S
6. RPMI + 20% HS + P/S
7. RPMI + 10% FCS + P/S
The cells from each group were then resuspended in RPMI/10%FCS/PS and 200pl
aliquots containing 1.6 x 105 viable cells/ml were added to tissue culture wells in
triplicate and incubated for 48 hours in the presence of 100 ng/ml SCF. After 48
hours, the viable cells in each well were counted in a hemocytometer (chapter 2,
section 2.4).
Results - When assessed subjectively, all the cells in groups 4 and 5 appeared to be
dead, whereas cells in all the other groups appeared to be viable. The cell counts in
all wells after 48 hours are compared to the starting cell count in Figure A2.1. The
results indicate that the peritoneal mast cells had died following washing in IMDM,





Figure A2.1 - Viable cell counts of Percoll purified peritoneal mast cells after
washing in various media. Peritoneal mast cells were purified in a two stage density
step Percoll gradient and washed three times in one of the stated media. The cells
were then resuspended in RPMI/10%FCS/PS, and 200 pi aliquots containing 1.6 x
105 viable mast cells/ml were cultured for 48 hours in the presence of 100 ng/ml
SCF. The bars at 48 hours represent the mean ± s.e.m. of viable cell counts from
triplicate wells.
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Experiment 8 - To determine the survivability of peritoneal mast cells in various
media
Percoll purified peritoneal mast cells were washed twice in
HBSS/2%FCS/PS/Heparin and then resuspended in 1 ml of one of the following
media.
1. HBSS + 20%HS + P/S
2. HBSS + 10%FCS + P/S
3. IMDM + 20%HS + P/S
4. IMDM + 10% FCS + P/S
5. RPMI + 20% HS + P/S
6. RPMI + 10% FCS + P/S
Duplicate aliquots (250pl) containing 0.6 x 105 mast cells/ml from each group were
added to tissue culture wells and incubated for 24 hours in the presence or absence of
100 ng/ml SCF. The viable cells in each well were then counted in a
hemocytometer.
Results - The cell counts from each group are compared to the starting cell count in
Figure A2.2. The results provide further evidence for the cytopathic effect of IMDM
on peritoneal mast cells. However, the effect was not as marked as seen following
washing of the cells in IMDM. In this experiment, the cells also appeared to die off
in the RPMI/20% HS but the cause of this was not established.
Experiment 9 - To determine the effect of the Ca2+ concentration of the washing
medium on the survivability of peritoneal mast cells
One obvious difference between the three solutions used in the previous experiments
was the Ca2+ concentration (1.5 mM in IMDM, 0.4 mM in RPMI, 0 mM in HBSS).
To ensure that reduced Ca2+ concentration was not having a "protective" effect
during centrifugation and resuspension, percoll purified peritoneal mast cells were
washed three times in HBSS, HBSS + 1.5 mM Ca2+, or IMDM + 8 mM EDTA. The
cells were then resuspended in RPMI/10%FCS/PS and quadruplicate aliquots were
incubated for 24 hours without SCF.
Results - The cell counts at 24 hours are compared to the starting cell counts in
Figure A2.3. The results indicate that the presence of 1.5 mM Ca2+ during washing
did not have a detrimental effect on the survivability of peritoneal cells, and confirm
once again the cytopathic effect of IMDM.
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Culture Medium
Figure A2.2 - Viable cell counts of Percoll purified peritoneal mast cells after culture
in various media. After washing in HBSS/2%FCS/PS, cells were resuspended in one
of the stated media and cultured for 24 hours in the presence or absence of 100 ng/ml
SCF. Each bar represents the mean ± range of viable cell counts from duplicate





Figure A2.3 - Viable cell counts of peritoneal mast cells after washing in media with
different Ca2+ concentrations. After Percoii purification, cells were washed and
resuspended in one of the three media, and cultured for 24 hours in the absence of
SCF. The bars at 24 hours represent the mean ± s.e.m. of cell counts from
quadruplicate wells. In this experiment, the starting cell counts in the three groups
were not identical and were 0.65xl05/ml, 0.55xl03/ml and 0.8xl05/ml respectively.
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Discussion
This series of experiments demonstrated that washing or culturing Percoll purified rat
peritoneal mast cells in IMDM resulted in cell death within 48 hours. As a result,
IMDM was not used for washing or culturing peritoneal mast cells, and the protocol
used was that shown in chapter 2, section 2.11 i.e. after Percoll purification, cells
were washed in HBSS and then resuspended in RPMI/10%FCS.
The cause of the cytopathic effect remains unknown. It is clearly not due to the
absence of a critical factor in IMDM because the cells were not damaged by washing
or culturing in HBSS. Equally unlikely is the presence of external influences such as
Mycoplasma infection, because the same medium was being used to successfully
grow rat bone marrow-derived mast cells. It therefore seems likely that a component
of the IMDM was having a specific cytopathic effect on peritoneal mast cells, even
after short exposures such as during washing. Both IMDM and RPMI contain over
40 components including inorganic salts, amino acids, vitamins, glucose and buffers.
The concentration of every component differs between the two media, and some
components are present in one and not the other. It was therefore totally beyond the
scope of these studies to attempt to elucidate the factor that was causing the
cytopathic effect. However, these experiments did uncover an unusual phenomenon,
and the results may be of benefit to future investigators.
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APPENDIX 3
Spot counts from ELISPOT assays
Key: Unless stated otherwise, numbers in plate maps = the approximate number of
BMMCs per well.
Numbers in results = the number of spots per well.
- = negative control wells with no cells
© = positive control wells (50 ng/ml RMCP-II)
anti-IgE = goat anti-rat IgE at 1/250
NGS = normal goat serum at 1/250
DNP-BSA = dinitrophenyl-bovine serum albumin at lpg/ml (1/1000).
Buffer = Tyrode's buffer with 1 mM Ca2+/1 mM Mg2+
Chapter 3, Section 3.3
Plate Map: No. of BMMCs per well Results: No. of spots per well
1 2 3 4 5 6 7 8
134 134 134 134 134 134 134 - 9 19 15 18 15 19 14 0
134 134 134 134 134 134 134 - 17 21 24 19 21 19 20 0
DNP-BSA 134 134 134 134 134 134 134 - 21 20 23 18 24 14 24 0
134 134 134 134 134 134 134 - 15 17 30 26 16 21 13 0
134 134 134 134 134 134 134 - 29 12 20 16 9 10 14 0
Buffer 134 134 134 134 134 134 134 © 4 1 2 4 2 1 1 ©
Chapter 3, Section 3.5
Culture containing 38% BMMCs
48 well plate map Results
150 75 38 19 9 5 2 © 28 12 3 2 2 0 0 ©
Anti-IgE 150 75 38 19 9 5 2 © 30 24 16 1 5 0 2 ©
150 75 38 19 9 5 2 - 40 20 9 3 1 0 0 0
150 75 38 19 9 5 2 - 3 2 0 0 0 0 0 0
NGS 150 75 38 19 9 5 2 - 2 0 0 0 0 0 0 0
150 75 38 19 9 5 2 - 0 0 0 0 0 0 0 0
24 well plate map
Anti-IgE 150 75 38 19 9 ©
150 75 38 19 9 ©
NGS 150 75 38 19 9 -
150 75 38 19 9 -
Results
28 12 9 7 0 ©
28 17 3 4 2 ©
1 0 0 0 0 0
2 0 0 0 0 0
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Culture containing 53% BMMCs
Plate map Results
Anti-IgE 210 105 52 26 13 7 3 ©
210 105 52 26 13 7 3 0
NGS 210 105 52 26 13 7 3 -
210 105 52 26 13 7 3 -
42 20 6 9 4 0 3 ©
28 13 15 6 2 2 1 ©
2 4 0 0 0 0 0 0
2 3 0 3 1 0 0 1
Culture containing 95% BMMCs
Plate map - 2 replicate plates
380 190 95 48 24 12 6 -
DNP-BSA 380 190 95 48 24 12 6 -
380 190 95 48 24 12 6 -
380 190 95 48 24 12 6 -
Buffer 380 190 95 48 24 12 6 -
380 190 95 48 24 12 6 ©
Results - Plate 1 Results - Plate 2
64 37 22 15 2 1 1 0
57 34 25 5 5 0 0 1
51 37 26 9 8 6 1 0
69 45 23 12 17 1 0 0
9 9 2 1 0 3 0 0
21 8 1 1 0 1 0 ©
56 21 9 7 2 0 2 0
49 29 18 8 8 2 1 0
56 30 15 9 3 1 0 0
67 38 13 10 7 5 2 0
16 8 4 1 7 0 2 2
18 2 5 3 2 0 0 ©
Culture containing 97% BMMCs
Plate map - 2 replicate plates
390 195 98 49 25 12 6 -
DNP-BSA 390 195 98 49 25 12 6 -
390 195 98 49 25 12 6 -
390 195 98 49 25 12 6 -
Buffer 390 195 98 49 25 12 6 -
390 195 98 49 25 12 6 ©
Results - Plate 1 Results - Plate 2
48 23 13 6 2 1 0 0 56 24 4 3 2 3 0 0
69 37 14 7 9 4 2 0 82 40 31 6 10 3 0 0
59 69 21 5 5 2 2 0 64 43 15 12 6 1 3 0
74 35 13 11 4 2 1 0 95 34 25 15 5 3 2 0
15 15 5 3 1 2 0 1 29 15 9 2 0 2 0 0
11 7 1 1 0 0 0 © 41 10 3 2 0 2 0 ©
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Chapter 3, section 3.6
Plate map - 5 replicate plates
100 100 100 100 100 100 100 -
DNP-BSA 100 100 100 100 100 100 100 -
100 100 100 100 100 100 100 -
100 100 100 100 100 100 100 -
Buffer 100 100 100 100 100 100 100 -
100 100 100 100 100 100 100 ©
Results
Plate 1 Plate 2
7 12 16 11 10 16 5 0 17 6 13 13 6 9 11 0
5 13 20 11 15 5 26 0 11 5 21 12 18 12 16 0
8 15 11 16 17 23 12 0 11 11 14 7 19 20 15 0
9 13 9 21 18 18 17 0 17 12 13 8 11 16 13 0
2 2 3 2 1 3 2 0 0 1 1 5 1 4 2 0
3 1 1 1 2 6 0 © 1 1 1 4 2 1 5 ©
Plate 3 Plate 4
9 15 14 7 13 8 11 0 18 11 13 10 12 13 12 0
8 12 13 9 23 8 14 0 10 18 26 14 25 13 10 0
11 14 11 17 17 8 14 0 7 17 16 16 24 33 17 0
8 22 14 12 22 22 12 0 9 16 12 20 20 16 25 1
1 3 4 2 1 2 3 0 3 3 2 5 1 1 1 0
2 1 0 3 1 1 1 © 3 1 1 2 1 0 0 ©
Plate 5
14 16 12 11 9 9 10 0
15 12 17 19 25 11 16 0
14 14 17 17 27 20 14 0
12 16 18 20 11 27 11 0
4 3 2 4 2 0 0 0
0 2 1 3 2 2 3 ©
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Chapter 3, Section 3.7
Culture containing 66% BMMCs
Plate map Results
Anti-IgE 264 132 66 33 17 8 4 © 38 14 6 5 4 4 0 ©
264 132 66 33 17 8 4 © 42 22 8 10 5 3 1 ©
NGS 264 132 66 33 17 8 4 - 3 0 1 3 0 2 2 1
264 132 66 33 17 8 4 - 2 4 2 2 0 0 0 0
Culture containing 89% BMMCs
Plate map
356 178 89 356 178 89 - -
Anti-IgE 356 178 89 356 178 89 - -
356 178 89 356 178 89 - -
356 178 89 356 178 89 - -
NGS 356 178 89 356 178 89 - ©
356 178 89 356 178 89 - ©
No SCF SCF No cells
Results
6 1 1 10 4 2 0 0
20 5 4 8 6 3 0 0
4 5 4 13 6 2 0 0
11 2 3 1 3 3 0 0
4 0 1 3 2 0 0 ©
2 3 1 4 1 0 0 ©
Chapter 4, Section 4.2
Culture containing 96% BMMCs
Plate map
384 192 96 384 192 96 - -
Anti-IgE 384 192 96 384 192 96 - -
384 192 96 384 192 96 - -
384 192 96 384 192 96 - -
NGS 384 192 96 384 192 96 - ©
384 192 96 384 192 96 - ©
Buffer SCF No cells
Results
10 7 7 16 8 5 0 0
8 7 1 26 18 10 0 0
14 7 0 27 18 8 0 1
9 1 4 3 9 0 2 0
1 5 4 2 3 4 1 ©
1 1 3 5 1 1 1 ©
Culture containing >99% BMMCs
N.B. Plate map - 100 BMMCs per well
Numbers in wells = SCF concentration (ng/ml)
Anti-IgE 400 400 50 50 6.25 6.2 anti-IgE
400 400 50 50 6.25 6.2 anti-IgE
200 200 25 25 3.1 3.1 NGS
200 200 25 25 3.1 3.1 SCF
100 100 12.5 12.5 1.5 1.5 - -
100 100 12.5 12.5 1.5 1.5 © ©
Results: No. spots per well
32 31 36 22 36 18 4 3
30 38 44 37 37 21 6 3
26 29 39 38 25 21 6 3
35 38 39 28 26 18 7 8
30 26 27 34 17 17 0 0
24 26 25 28 19 6 © ©
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Chapter 4, Section 4.3
1st Experiment
N.B. Plate map - 200 BMMCs per well
Numbers in wells = Incubation time (min)
with 50 ng/ml SCF
120 60 30 15 5 0 NGS
120 60 30 15 5 0 NGS
Anti-IgE 120 60 30 15 5 0 anti-IgE
120 60 30 15 5 0 anti-IgE
120 60 30 15 5 0 - -
120 60 30 15 5 0 © ©
Results: No. spots per well
22 44 60 53 38 12 5 3
44 47 52 57 62 13 14 6
24 56 76 66 65 12 6 9
23 51 76 69 55 16 23 3
20 58 81 64 63 21 0 0
24 35 58 57 30 17 © ©
2nd Experiment
N.B. Plate map - 200 BMMCs per well
Numbers in wells = Incubation time (min)
with 50 ng/ml SCF, Buf = cells treated with
buffer alone
30 15 5 0 Buf 30 30 -
30 15 5 0 Buf 15 15 -
DNP-BSA 30 15 5 0 Buf 5 5 -
30 15 5 0 Buf 0 0 -
30 15 5 0 Buf Buf Buf -
30 15 5 0 Buf © © -
Results: No. spots per well
24 20 18 17 2 15 24 0
29 23 26 33 5 18 28 1
24 19 34 14 8 20 19 1
30 26 33 10 10 25 15 1
13 32 29 19 6 7 3 1
17 25 35 22 8 © © 0
Chapter 4, Section 4.4
Plate map - 2 replicate plates for each assay
Key: a,b = SCF/anti-IgE; c,d = SCF/NGS; e,f = buffer/anti-IgE; g,h =
buffer/NGS
400 200 100 400 200 100 a e
Anti-IgE 400 200 100 400 200 100 b f
400 200 100 400 200 100 c g
400 200 100 400 200 100 d h
NGS 400 200 100 400 200 100 - -
400 200 100 400 200 100 © ©
3uffer 50 ng/ml SCF No cells
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Culture 2 - Day 4 (8% BMMCs)
Results - Plate 1 Results - Plate 2
95 49 16 87 56 22 0 3
141 73 23 85 45 46 0 1
107 68 42 147 74 30 1 0
9 4 5 19 8 6 0 0
8 3 1 7 7 6 1 1
3 5 2 3 0 3 © ©
103 41 21 86 66 29 1 3
104 56 24 107 78 39 0 1
79 66 23 119 89 37 1 1
17 2 12 21 10 4 0 0
13 1 1 9 2 0 0 1
9 0 0 2 2 2 © ©
Culture 2 - Day 8 (41% BMMCs)
Results - Plate 1
30 19 11 35 20 10 2 1
39 17 6 24 18 7 0 0
37 11 6 24 24 8 0 0
18 3 3 12 4 3 0 0
7 8 5 10 3 2 0 0
8 4 1 2 5 2 © ©
Results - Plate 2
39 14 7 29 19 14 0 0
20 24 8 27 14 12 0 0
31 13 9 32 20 7 0 0
9 3 5 7 6 3 0 0
5 5 3 7 1 4 1 0
8 3 1 2 3 2 © ©
Culture 2 - Day 11 (64% BMMCs)
Results - Plate 1
38 21 6 58 22 14 0 0
52 22 16 41 26 15 0 0
39 28 6 29 21 - 0 3
6 8 3 8 8 4 0 0
8 6 3 3 4 1 0 0
0 1 2 4 1 0 © ©
Results - Plate 2
49 17 15 33 20 5 0 0
43 25 7 46 21 12 0 0
52 18 7 44 21 14 0 0
6 10 2 6 7 4 1 0
8 4 3 7 7 0 0 0
7 3 1 6 7 2 © ©
Culture 2 - Day 15 (85% BMMCs)
Results - Plate 1
45 17 5 49 16 20 0 0
42 21 11 54 31 17 3 0
39 20 8 38 36 8 1 0
11 8 3 8 7 4 0 0
10 7 8 16 11 0 1 0
12 5 1 10 5 1 © ©
Results - Plate 2
48 19 11 44 27 15 0 0
28 18 9 56 39 21 0 0
44 23 13 43 28 13 0 0
13 4 5 18 6 9 0 0
8 3 3 15 8 2 0 0
8 4 4 14 3 3 © ©
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Culture 2 - Day 18 (92% BMMCs)
Results - Plate 1
46 15 4 65 47 18 1 0
71 32 19 66 51 26 4 0
57 25 18 56 32 27 2 1
33 34 11 49 21 15 0 0
32 22 13 44 34 16 0 1
33 14 10 38 13 10 © ©
Culture 2 - Day 21 (98% BMMCs)
Results - Plate 1
76 46 19 60 49 25 3 0
77 51 24 82 59 29 3 1
51 59 27 77 56 34 3 4
76 61 27 73 30 15 5 0
73 59 26 74 46 14 5 0
57 45 20 57 53 25 ©3 ©
Culture 3 - Day 9 (36% BMMCs)
Results - Plate 1
25 30 10 22 16 15 1 0
45 11 14 38 33 11 3 1
18 21 13 45 32 10 0 0
9 2 2 23 12 2 2 0
5 6 2 5 6 6 2 3
9 3 6 6 3 6 © ©
Culture 3 - Day 17 (87% BMMCs)
Results - Plate 1
32 19 5 57 45 38 1 3
42 20 23 80 46 32 0 2
44 20 5 95 85 30 2 2
17 11 7 20 22 3 4 0
17 17 5 27 13 5 3 3
23 12 6 10 7 2 © ©
Results - Plate 2
43 29 14 59 36 16 1 0
36 20 10 57 31 24 1 0
35 18 18 50 33 17 0 0
26 20 13 37 22 11 0 0
37 18 13 34 39 4 0 0
38 16 11 31 36 15 © ©
Results - Plate 2
76 27 11 88 46 15 2 0
76 48 28 98 60 18 3 0
58 43 20 80 35 21 0 3
58 59 15 77 44 24 0 5
74 43 19 55 41 21 3 3
41 35 17 44 46 18 © ©
Results - Plate 2
41 18 7 33 11 6 1 0
32 14 4 44 46 5 2 0
21 21 9 34 27 9 0 0
13 6 5 12 13 5 0 0
12 6 4 10 5 3 2 2
14 6 3 5 6 4 © ©
Results - Plate 2
16 17 6 46 31 19 2 1
19 25 24 75 44 26 1 0
29 15 5 72 56 36 1 0
16 12 7 30 20 7 0 0
6 17 5 29 10 13 0 0
5 9 6 5 6 9 © ©
Culture 3 - Day 21 (95% BMMCs)
Results - Plate 1 Results - Plate 2
29 13 8 43 22 7 1 0
47 17 9 43 33 8 0 0
45 16 14 45 28 7 1 0
37 15 7 48 22 9 0 0
20 21 8 28 24 5 0 0
27 18 13 20 4 3 © ©
Culture 3 - Day 24 (94% BMMCs)
Results - Plate 1
20 15 4 39 38 22 0 1
38 19 16 61 42 27 0 1
18 22 14 65 41 31 0 0
28 12 11 24 9 8 0 0
22 22 10 24 11 5 0 0
17 18 2 20 8 6 © ©
Culture 3 - Day 28 (99% BMMCs)
Results - Plate 1
108 77 57 100 65 39 0 0
126 75 48 107 89 65 0 0
106 62 46 124 83 42 1 0
124 77 43 106 64 48 1 3
105 93 36 112 53 45 2 1
117 72 41 87 73 39 © ©
39 15 14 36 27 11 1 0
29 23 3 36 16 16 0 1
27 18 17 45 24 12 0 0
32 15 11 27 25 7 0 0
26 9 8 29 13 6 0 0
13 10 7 21 12 9 © ©
Results - Plate 2
43 15 6 31 26 19 0 0
20 28 12 54 35 23 0 0
21 24 10 54 43 27 1 0
14 16 10 21 6 9 0 0
20 8 7 13 10 10 0 0
16 10 4 13 7 3 © ©
Results - Plate 2
81 56 42 114 54 33 0 0
106 66 35 125 69 61 1 0
114 71 43 121 87 37 0 0
109 61 47 119 81 53 0 0
102 84 46 120 51 59 1 1
75 49 23 76 51 27 © ©
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Chapter 4, Section 4.5
Plate map for 2 separate experiments
Key: a,b =DNP-BSA; c,d =Buffer; e,f = SCF/DNP-BSA; g,h = SCF/Buffer
200 200 200 200 200 200 a b
DNP-BSA 200 200 200 200 200 200 c d
200 200 200 200 200 200 e f
200 200 200 200 200 200 g h
Buffer 200 200 200 200 200 200 - -
200 200 200 200 200 200 © ©
50 ng/ml SCF Buffer No cells
Results - Experiment 1 Results - Experiment 2
Culture containing 99% BMMCs Culture containing 99% BMMCs
52 50 38 31 25 28 5 12 29 42 40 27 16 21 - -
48 48 65 36 32 29 9 0 44 39 38 24 41 22 - -
46 57 39 31 27 34 6 12 38 43 43 39 31 43 - -
22 20 21 9 18 11 0 0 3 5 15 2 3 9 - -
10 18 12 12 24 8 4 3 1 7 11 2 7 6 - -
10 14 8 6 5 13 © © 5 3 1 4 1 0 © ©
N.B. Spot counts in negative control wells in experiment 2 were disregarded because
cells were added to the wells in error.
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EFFECTS OF STEM CELL FACTOR ON THE WHOLE-CELL CURRENTS
OF RAT BMMCS
INTRODUCTION
The effects of SCF on IgE-dependent mediator release from rat BMMCs were
described in chapter 4. These results demonstrated that SCF was not, in itself, a
secretagogue for BMMCs, but it significantly enhanced mediator release in response
to anti-IgE or specific antigen. The mode of action of this "priming" effect is
currently not known. However, in other mast cell types, activation of the c-kit
receptor induces the tyrosine phosphorylation of multiple cytosolic proteins (Welham
and Schrader, 1992), and overlap between the IgE and SCF signalling pathways has
been demonstrated in mouse BMMCs (Tsai et al, 1993) and rat peritoneal mast cells
(Koike et al, 1993). Hence, one hypothesis for the priming effect of SCF is that it
modulates the function of ion channels by phosphorylation, thus activating whole-
cell currents. Other ligands that induce whole-cell currents in mast cells without
causing degranulation include ADP and ATP, which induce an outwardly rectifying
K+ current in RBL-2H3 cells (Qian and McCloskey, 1993), and picomolar doses of
substance P, which activate an outwardly rectifying CI" current in rat peritoneal mast
cells (Janiszewski et al, 1994). Both these studies suggested that activation of the
currents might enhance the subsequent response to secretagogues, presumably by
enhancing Ca2+ influx. The purpose of this study was to determine if SCF activated
whole-cell currents in rat BMMCs.
EXPERIMENTAL METHODS AND RESULTS
A5.1 - Efficacy of SCF in the electrophysiological recording chamber
Preliminary experiments were performed to determine if SCF enhanced mediator
release from rat BMMCs under conditions used for electrophysiological studies (i.e.
with electrophysiological solutions in the patch-clamp recording chamber). A
suspension of BMMCs from a culture containing 99% mast cells was sensitised with
mouse IgE (see chapter 2, section 2.15) and resuspended in modified mast cell
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Ringer (instead of the usual Tyrode's buffer). Aliquots of 1 x 105 cells were added to
four separate baths (similar to the recording bath described in section 2.26) in each of
two electrophysiological recording chambers, and stimulated at either room
temperature or 37°C as shown below.
Experimental Design

















The cells were incubated with 50 ng/ml SCF (or Ringers alone) for 5 min before
challenge with DNP-BSA (or Ringers) for a further 30 min. The cells were then
removed from the baths, pelleted by centrifugation, and the pellets and supematants
assayed for (3-hexosaminidase as described previously (chapter 2, sections 2.17 and
2.19).
Figure A5.1 shows that SCF enhanced the percent release of (3-hexosaminidase from
BMMCs challenged with DNP-BSA at 37°C, but not at room temperature. This
result (one of four similar experiments) confirms the previous observations described
in chapter 4, but indicates that mediator release, and its upregulation by SCF, is
temperature dependent. There is a high background release in this experiment
because it was not possible to remove all the BMMCs from the bath, thus
artifactually lowering the concentration of (3-hexosaminidase in the cell pellet.
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70
Buffer Buffer/SCF DNP DNP/SCF
Figure A5.1 - One of four similar experiments showing the effect of SCF on IgE-
dependent (3-hexosaminidase release from rat BMMCs. The cells were sensitised
with mouse IgE, and aliquots of 1 x 105 BMMCs (suspended in 1 ml of mast cell
Ringer) were placed in electrophysiological recording baths. After incubation with
50 ng/ml SCF (or Ringer alone) for 5 min, the cells were challenged with DNP-BSA
(or Ringer alone) either at room temperature or 37°C. Release of ^-hexosaminidase
was enhanced only at 37°C.
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A5.2 - Effect of SCF on the whole-cell currents of rat BMMCs
For these experiments, whole-cell currents were recorded with the perforated-patch
technique as described in chapter 2, section 2.31. This was considered important
because signal transduction through the c-kit receptor probably requires a full
complement of cytosolic messengers and enzymes. After recording the whole-cell
currents for a control period (usually 2-5 min), SCF was added to the bath with a
pipette to a final concentration of 50 - 100 ng/ml. The currents were then recorded
continuously on a pen recorder and observed for the subsequent 10-30 min.
Recordings were obtained from 29 BMMCs before and after the addition of SCF. 7
were obtained at room temperature, 4 at 25°C, 10 at 30°C and 8 at 37°C. SCF did
not activate or change the amplitude of whole-cell currents in rat BMMCs at any of
the indicated temperatures. The presence or absence of the outwardly rectifying CF
(ORa) current was dependent on temperature as described in chapter 5, but its
amplitude was not increased by SCF (Figure A5.2). In addition, there was no
observable effect on the IRK current (Figure A5.2).
DISCUSSION
These experiments demonstrated that SCF had no observable effect on the whole-cell
currents of rat BMMCs. It is unlikely that the negative results reflected experimental
conditions because SCF enhanced IgE-dependent (3-hexosaminidase release from rat
BMMCs under the same conditions as those used for patch-clamping (Figure A5.1).
In addition, the perforated-patch technique was used, thus ensuring that essential
intracellular messengers and enzymes were preserved. It is possible that SCF
activates conductances that are too small to be detected with the solutions and
conditions used in these experiments. For example, Ca2+ imaging techniques would
be required to monitor the influx of Ca2+ through ICrac or non-specific cation
pathways. However, the results indicate that SCF does not activate, or modulate, the
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Figure A5.2 - Typical experiment showing the effect of SCF on the whole-cell
currents of rat BMMCs. A: The voltage pulse protocol. The cell was clamped at a
holding potential of -40 mV and voltage pulses of 200 ms duration were applied
every second from -140 mV to +100 mV in 10 mV steps. B: Continuous pen
recording showing the whole cell currents. At the first arrow, the bath was warmed
to 30°C, resulting in activation of the ORa current. At the second arrow, 50 ng/ml
SCF was added to the bath. There was no observable effect on the amplitude of the
inward or outward currents over the subsequent 10 min period (a 6 min section of the
tracing was removed to produce the figure). Extracellular solution = modified mast
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A comparison of whole-cell currents in isolated
mucosal and connective tissue rat mast cells
P.B. Hill, R.J. Martin and H.R.P. Miller
Departments of Preclinical Veterinary Sciences and
Veterinary Clinical Studies, R(D)SVS, University of
Edinburgh, Edinburgh EH9 1QH
Subpopulations ofmast cells with distinct biochemical and
functional characteristics have been identified in rodents and
man. Based on their anatomical locations, these cells are
designated mucosal mast cells or connective tissue mast cells
and differ in terms of protease content, proteoglycan
content, and response to seeretagogues. Previous studies
have shown that this heterogeneity also extends to their
electrophysiological properties: mucosal-type mast cells
possessed only a K+-seleetive inwardly rectifying current
(McCloskey & Qian, 1994), whereas connective tissue mast
cells did not appear to have whole-cell currents unless
stimulated with secretagogues or second messengers
(Matthews et al. 1989). We recorded whole-cell currents in
fifty-six rat bone marrow-derived mast cells (mucosal
phenotype) and fifty-four rat peritoneal mast cells
(connective tissue phenotype) using the amphotericin B
perforated patch technique. Voltage steps were applied from
—140 to +100 mV from a holding potential of —40 mV. The
pipette solution contained (mxi): 137 KCH3S04 or KC1,
2-7 NaCl, 1 CaCl2, 3 MgCl2 and 10 Hepes; pH 7-3. The
extracellular solution contained (nut): 137 NaCl, 2-7 KC1,
2 CaClj, 5 MgCl2, 10 Hepes and 5'6 glucose; pH 7'3. Bath
temperature was varied between room temperature
(16-20 °C) and 37 °C with a Peltier device.
As previously reported, only the mucosal-type mast cells
exhibited an inwardly rectifying K current. However, in
contrast to previous studies, we found that an outwardly
rectifying chloride current could be demonstrated in both
cell types. Important features of the current were:
(1) activation at potentials more positive than —30 mV;
(2) reduction in current amplitude and chloride conductance
when the extracellular CP concentration was reduced to
16'7 m.u by substituting Na+-isethionate for NaCl;
(3) reversible blockade by the chloride channel blocker DIDS
(20 /tit); (4) dependence on temperature - the current could
be elicited in a significant proportion of cells by increasing
the bath temperature to >25°C; (5) dependence on a
cytoplasmic component - the current was rarely observed
when currents were recorded using the conventional whole-
cell voltage clamp technique; (6) the current was more
commonly observed and was greater in magnitude when
peritoneal mast cells were incubated overnight in the
presence of 10 ng ml-1 stem cell factor, an important
survival factor for connective tissue mast cells; (7) the
current could also be activated by a 33% decrease in
extracellular osmolality.
The results show that an outwardly rectifying chloride
conductance can be observed in both mucosal and connective
tissue-type mast cells without stimulating the cells with
secretagogues or intracellular second messengers. This
current could help to maintain a negative membrane
potential when mast cells degranulate, and may play a role
in volume regulation.
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Effects of temperature and cytoplasmic disruption
on whole-cell membrane currents of rat bone
marrow-derived mast cells
P.B. Hill, R.J. Martin and H.R.P. Miller
Departments of Preclinical Veterinary Sciences and
Veterinary Clinical Studies, R (D)SVS, Idiversity of
Edinburgh, Edinburgh EH9 1QH
In recent studies, rat mucosal type mast cells were shown
to possess only a K+-selective inwardly rectifying current
(IRk) with conventional whole-cell patch clamp techniques at
room temperature (Lindau & Fernandez, 1986; McCloskey &
Qian, 1994). To determine if these results were influenced by
recording conditions, we compared whole-cell membrane
currents obtained from rat bone marrow-derived mast cells
(BMMCs) at various temperatures using the amphotericin B
perforated-patch and conventional whole-cell voltage clamp
techniques. Voltage steps were applied from —100 to +40 mV
from a holding potential of —40 mV. Pipette solutions
contained (mn): 137 KC1, 2-7 NaCl, 1 CaCl2, 3 MgCl2 and
10 Hepes, pH 7-3 (perforated patch) and 137 KC1, 2-7 NaCl,
0-1 CaCl2, 1 MgCl2, 10 Hepes and 1 EGTA, pH 7-3
(conventional whole-cell). The extracellular solution
contained (rm\i): 137 NaCl, 2-7 KC1, 2 CaCl2, 5 MgCl,,
10 Hepes and 5-6 glucose, pH 7-3. Bath temperature was
varied between room temperature (16-20 °C) and 37 °C with
a Peltier device.
The IRk current was present in rat BMMCs at all
temperatures with both recording techniques. In contrast,
an outwardly rectifying (OR) current at potentials more
positive than —30 mV was only observed with the perforated
patch method or if the bath temperature was increased to
>25°C (Table 1). Lowering the extracellular CF
concentration to 50 mil reduced the conductance of the OR
current from 2*7 + 2T to 0-51 + 053 nS (mean + s.D.,
n = 5) and shifted its reversal potential by +31 +21 mV
(mean + s.D., a = 5). The chloride channel blocker DIDS
decreased the OR current conductance from 2-7 + 2-2 to
IT + To nS (mean + s.D., n= 5), also indicating that the
OR current was carried by CF ions.
Table 1. Percentage of BMMCs showing the OR current under
various experimental conditions
16-20 °C 25-37 °C
Cytoplasm disrupted: 0% (n = 30) 40% (n = 5)
conventional WCR
Cytoplasm preserved: 26 % (n = 91) 68% (n = 59)
perforated patch
WCR, whole-cell recording.
The results indicate that detection of certain whole-cell
currents depends upon experimental methodology. The effect
of temperature and cytoplasmic disruption suggests that the
ORcl current is dependent on a cytoplasmic messenger but it
does not require stimulation of the cell with secretagogues
for ito activation. Activation of the ourrent by depolarization
suggests that it may contribute to the repolarization of the
membrane potential that occurs following stimulation of
mast cells with antigen, thus allowing sustained Ca2+ entry-
essential for exocytosis.
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Abstract Rat mucosal type mast cells are thought to
possess only a K+-selective inwardly rectifying (IRK)
current in the resting state. We used rat-bone-marrow-de-
rived mast cells (BMMCs) as a model of mucosal mast
cells and recorded whole-cell membrane currents from
cells perforated with amphotericin B. Under these condi¬
tions, both inwardly rectifying (IR) and outwardly recti¬
fying (OR) currents were observed. The reversal poten¬
tial and conductance of the IR current depended on the
extracellular K+ concentration, indicating that the chan¬
nel was K+ selective. The OR current was not affected by
changes in extracellular K+ concentration, but lowering
extracellular Ch concentration reduced the conductance
and shifted the reversal potential in a positive direction.
The OR current was not affected by K+ channel blockers,
but was reversibly blocked by the chloride channel
blocker 4,4'-diisothiocyanato-2,2'-stilbenedisulphonate
(D1DS), again indicating a CL conductance. The IRK
current was also detected in the majority of cells using
the conventional whole-cell recording configuration at
room temperature. In contrast, the ORa current was only
observed in 7% of recordings made at room temperature
with the conventional whole-cell voltage-clamp mode,
but was detected in 66% of cells if the bath temperature
was increased and the integrity of the cell's cytoplasm
was preserved by using the perforated-patch technique.
Under similar conditions, the ORCI current was also
present in rat peritoneal mast cells, a connective tissue
phenotype previously thought to have no whole-cell cur¬
rents in the resting state. The role of this current and fac¬
tors affecting its activation are discussed.
P. B. Hill (IS) ■ R. J. Martin
Department of Preclinical Veterinary Sciences,
Royal (Dick) School of Veterinary Studies,
The University of Edinburgh,
Summerhall, Edinburgh, EH9 1QH. Scotland
H. R. P. Miller
Department of Veterinary Clinical Studies,
Royal (Dick) School of Veterinary Studies,
The University of Edinburgh, Scotland
Key words Mast cells • Whole-cell currents •
K+ channels • CL channels ■ Inward rectifier
Introduction
Recent electrophysiological studies have suggested that
mast cells can possess two types of ion channel that reg¬
ulate the resting membrane potential: an inwardly recti¬
fying K+ (IRk) current f 18, 22, 28] and an outwardly rec¬
tifying CL (ORC|) current [14], The presence or absence
of these currents depended on the phenotype of the mast
cell (connective tissue or mucosal), and on the species
from which the cells were derived. In mouse bone-mar-
row-derived mast cells (BMMCs), which can differenti¬
ate into different phenotypes, both currents were ob¬
served either concurrently or individually [14]. Rat
BMMCs [22] and RBL-2H3 cells [18, 28], both mucosal
phenotypes, only possessed the 1RK current in the resting
state. In contrast, neither the IRK nor the ORa currents
were present in resting rat peritoneal mast cells, an ex¬
ample of the connective tissue type [18, 22].
Other membrane currents have been described to oc¬
cur in rat mast cells but only when various second mes¬
sengers were included in the pipette solution or when the
cell was stimulated with secretagogues. These messenger
or ligand-activated channels include: Ca2+-permeable
channels [13, 20]; cation-selective channels [3, 13, 20];
outwardly rectifying K+ channels [22, 28]; and outward¬
ly rectifying chloride channels [2, 21, 27, 30]. These
channels have been implicated in the process of degranu-
lation, because their activity was only detectable follow¬
ing stimulation of the cells and not in the resting state.
The conventional whole-cell recording configuration,
as used in the previous studies, causes dialysis of the in¬
tracellular milieu and loss of many cytoplasmic compo¬
nents including solutes and messengers [10, 26]; in ad¬
dition the above-described experiments were performed
at room temperature. To determine if these factors influ¬
enced the electrophysiological properties of mast cells,
we measured whole-cell currents of mucosal and con-
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nective tissue type rat mast cells at various temperatures
using the amphotericin-B-perforated-patch technique.
We report that an outwardly rectifying chloride current,
previously described to occur only in rat mast cells
stimulated with secretagogues, is present in both mucos¬




Male Wistar rats between 175 g and 200 g (Moredun Research In
stitute, Edinburgh. UK) were exsanguinated whilst deeply ana-
sthetized with halothane and used as donors of bone marrow, peri¬
toneal cells and for preparation of lymph node conditioned medi
urn (LNCM). The preparation of bone-marrow-derived cultured
mast cells and the production of LNCM have been described [6],
Briefly, femoral bone marrow cells from healthy rats were cul¬
tured at 2.5xl05 to 5xl05 cells/ml in Iscove's Modified Dulbec-
co's Medium (IMDM, Gibco-BRL, Paisley, UK) supplemented
with 20% horse serum (Advanced Protein Products, Brierley Hill,
UK), penicillin (100 IU/ml), and streptomycin (100 pg/ml). The
cells were stimulated with batch-tested LNCM at 10-25% v/v, and
re fed every 2 5 days. The percentage of mast cells was deter
mined by differential counts (100 cells) of Lcishman's stained
cytoccntrifugc preparations. Mature cultures (n - 12) ranging in
age from 13 to 37 days and each containing more than 85% mast
cells were used for these experiments, with consistent results.
Cells taken at this stage of culture can be regarded as mature as
judged by the degree of cytoplasmic granularity and in their con
tent of the mucosal mast-cell-specific protease, rat mast cell prote-
ase-Il [81.
Peritoneal mast cells were collected by peritonea] lavage with
Hanks Balanced Salt Solution (HBSS) containing 2% fetal calf se¬
rum (FCS), penicillin/streptomycin and 10 units/ml heparin. Cells
were washed twice, re suspended in 30% Pcrcoll and layered on
top of a two-stage Percoll density step gradient consisting of 4 ml
of 1.09 g/ml over 2 ml of 1.1 g/ml. After centrifugation at 500 g
for 20 min, a pellet containing >95% mast cells was obtained. The
cells were washed three times in HBSS and re-suspended at a con¬
centration of 2xl05 to 4xl05 cells/ml in RPMI medium (Gibco-
BRL) containing 10% FCS. Peritoneal mast cells were either used
on the day of collection, or were incubated for 24 18 h in the
presence or absence of 10 ng/ml recombinant rat stem cell factor
(rrSCF164), an important mast cell survival, growth and differentia¬
tion factor [5J.
Solutions and reagents
For amphotericin-B-perforated-patch recording, the pipette solu¬
tions contained (in mM): 137 KC1 or KCH3S04, 2.7 NaCl, 1
CaCR, 3 MgCR, 10 HEPES (pH 7.3) and for conventional whole-
cell recording (in mM): 137 KC1 or KCH3S04, 2.7 NaCl, 0.1
CaCL, 1 MgCL, 10 HEPES, 1 EGTA (pH 7.3). Mast cell Ringer
was used as the extracellular solution and contained (in ntM): 137
NaCl, 2.7 KC1, 2 CaCl2, 5 MgCL, 10 HEPES, 5.6 glucose
(pH 7.3). In some experiments, NaCl was replaced with KC1 to
make extracellular solutions containing 10, 50, 90, 137 or 165 mM
KC1. Low CP solutions containing 51 and 14 mM CL were made
by substituting Na acetate and K acetate for NaCl and KC1 respec¬
tively, and a low CL solution containing 16.7 mM CL was pre
pared by substituting Na-isethionate for NaCl. Amphotericin B
was obtained from Calbiochem, UK, and the channel blockers
4,4' diisothiocyanato 2,2' otilbcncdisulphonate (DIDS), 1 amino
pyridine, and tetraethylammonium chloride (TEA) were obtained
from Sigma, Poole, UK. rrSCF164 was kindly provided by Dr.
Keith Langley of Amgen, Thousands Oak, Calif., USA.
Whole-cell recordings
For electrophysiological recording, mast cells were re-suspended
in mast cell Ringer, plated onto glass coverslips, and incubated at
37°C for up to 7 h before being placed in the recording chambor.
Both mast cell phenotypes adhered to untreated glass without need
for further immobilization. Any contaminating macrophages in the
preparations could be discerned by their large size and lack of cy
toplasmic granularity. Pcrforatcd-patch recordings were performed
using amphotericin B to permeabilize the membrane as described
elsewhere [29], Briefly, 2 pi of a 50 mg/ml stock solution of am¬
photericin B in dimethylsulphoxide (DMSO) (Sigma) was added
to 0.5 ml of pipette solution to yield a final concentration of
200 pg/ml. Sylgard-coated pipettes were heat polished to resis¬
tances between 0.5 and 2.5 MQ and their tips were filled to
-1-150 pm with pipette solution free of amphotericin B. Pipettes
were then back fdled with the amphotericin B/pipette solution be¬
fore being used immediately to obtain a gigaohm seal. Perforation
of the membrane patch, as revealed by the appearanco of slow ca
pacitance transients, occurred within 5-25 min and recordings
were only made when the access resistance fell to less than
25 MO. Capacitance transients were cancelled using capacitive
cancellation circuitry on the amplifier which yielded the whole-
cell capacitance and access resistance. Conventional whole-cell
voltage-clamp recordings were performed as described [7], and
the results were compared to those obtained with the perforated
patch technique.
Whole cell voltage clamp recording (in both configurations)
was performed with a patch clamp amplifier (EPC 7, List). The
reference electrode was an Ag AgCl wire which, in ion substitu
tion experiments, was connected to the bath solution through an
agar bridge containing 150 mM KC1. In control experiments, junc¬
tional potentials that developed at this interface were less than
1 mV and no corrections were made. When the KC1 in the pipette
solutions was replaced with KCH3S04, large junctional potentials
developed at the pipette solution/pipette electrode interface. These
could not be cancelled using the pipette offset potential circuitry
on the amplifier. To overcome this problem, a fine open-ended
plastic tube containing 150 mM KC1 in 5% agar was placed over
the pipette electrode which acted as an agar bridge between the
electrode and the pipette solution (modified from [1]). The zero-
current potential before formation of the gigaohm seal was set to
0 mV. Voltage pulses of 200 ms duration were applied every sec¬
ond from -100 mV to +40 mV in 10-mV steps from the holding
potential of -40 mV. In some experiments, this protocol was ex¬
tended from -140 mV to +100 mV to accentuate the currents (see
Results and legends). The voltage pulses and mombrane currents
were stored digitally on video tape and on a continuous pen re
cording. Currents were fdtered at 2 kHz by an 8-pole Bessel filter,
digitized with an analogue-digital converter (CED 1401, Cam¬
bridge, UK), and stored with the voltage pulses on a personal
computer for later analysis. Current/voltage (I/V) relationships
were generated and analysed with the CED voltage-clamp soft¬
ware in which currents were sampled at 1 kHz and averaged over a
20-ms period. In most cases, the currents were sampled in the
middle of the 200-ms pulse. However, if there was evidence of
time-dependent inactivation, the currents were sampled in the re¬
gion of the peak. Leak currents determined from the linear range
of the IIV curve were subtracted before calculating slope conduc¬
tances using a least squares fit to data points between -140 mV to
-100 mV and +80 mV to +100 mV. Due to the magnitude of in¬
ward currents in high-K+ buffers, conductances in these conditions
were calculated in the range -100 mV to -80 mV.
Bath temperature was varied between room temperature
(16-20°C) and 37°C with a Peltier device (Firbank Electronics,
UK). We found that, at 37°C, the stability of the pipottc membrane
seal was unreliable, often resulting in breakdown of the prepara¬
tion. We therefore increased the temperature of the extracellular
solution in the recording chambor in approximately 5°C incre
ments, and recorded the whole-cell currents at 25°C, 30°C and
37°C if possible. Each temperature change took approximately
2 min. For some of the statistical analysis, data acquired at the
three temperatures havo boon grouped and results reported for the
range 25-37°C. Solution changes were made by perfusion and as¬
piration of the bath (chamber volume 4 ml) which took from 30 s
to 2 min depending on flow rate. During solution exchange, the
perfusate passed over the activated Peltier element before reaching
the cells; the bath temperature typically decreased by 2-3 °C dur¬
ing this time but this did not affect the current recordings de¬
scribed here.
Statistical analysis
Conductances are expressed as mean ± SD. Comparisons between
conventional whole-cell recordings and perforated-patch record¬
ings were made by unpaired Student's f-tests. Conductances at
room temperature (16-20°C) were compared to those in the range
25-37°C by paired or unpaired Student's /-tests, depending on
whether recordings were obtained in both ranges from the same
cell. Because of small group sizes with non-parametric distribu¬
tions, conductances at each temperature increment were compared
using Kruskal-Wallis and Mann-Whitney tests.
Results
Whole-cell currents in rat BMMCs
I/V relationships obtained from 79 rat BMMCs perforat¬
ed with amphotericin B and warmed to temperatures be¬
tween 25 and 37°C showed two types of voltage-depen¬
dent current. An inwardly rectifying (IR) current was
Fig. 1A-C Whole-cell membrane currents recorded from ampho¬
tericin B perforated rat bone marrow derived mast cells (BMMCs)
with accompanying leak-subtracted current/voltage (//^relation¬
ships. Cells were clamped at a holding potential of -40 mV and
voltage pulses of 200 ms duration were applied from -100 mV to
+ 40 mV in 10-mV steps at 1-s intervals. A Inwardly rectifying
current. B Outwardly rectifying current. C Concurrent inwardly
and outwardly rectifying currents
B
rapidly activated by hypcrpolarizing potential steps
(Fig. 1 A), and an outwardly rectifying (OR) current was
seen in cells depolarized to positive potentials (Fig. IB).
At potentials between -100 mV and +40 mV, the OR
currents were instantaneous and sustained, but at higher
potentials the current exhibited time-dependent inactiva-
tion (see later). A total of 37 cells (47%) showed the in¬
wardly and outwardly rectifying currents concurrently
(Fig. 1C). An additional 15 cells (19%) showed only the
outward current, and in 14 cells (18%) only the inward
current was observed. In some cells (16%), no voltage-
dependent currents were observed and the IIV relation¬
ship represented a basal leak conductance. Both the IR
and OR currents were observed when recording with pi¬
pette solutions containing either KC1 or KCH3S04, sug¬
gesting that movement of CI" from the pipette into the
cell was not responsible for induction of the currents.
The IR and OR conductances in the range of 25-37°C
were 1.74 ± 1.1 nS (n = 41) and 2.21 ± 1.4 nS (n = 31)
respectively. The capacitance of rat BMMCs was
4.8 ± 1.5 pF (mean ± SD, n = 116), but this did not cor¬
relate with the IR or OR conductances, suggesting that
the currents were not directly dependent on membrane
area. The mean leak conductance in the range of 25-37°C
was 0.75 ± 0.62 nS (n = 53).
Ionic selectivity of the currents
The IR currents observed to occur in our rat BMMCs were
very similar in appearance to those described to he present
in RBL-2H3 cells [18, 28], rat BMMCs grown in the pres¬
ence of interleukin-3 (IL-3) [22], and cultured mouse
BMMCs [14], in which the currents were characterized as
a K+-selective inward rectifier. Our IIV curves were char¬
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Fig. 2A, B Effect of extracellular K+ concentration on inwardly
rectifying currents. A Whole-cell I/V curves of a BMMC in six
different concentrations of extracellular K+. There is a positive
shift in reversal potential as the extracellular K+ increases from
2.7 mM to 165 mM. B Reversal potentials (E rev) plotted against
log10 extracellular K+ (mM). The line is a least-squares fit to the
data. The slope of 52 mV/decade is close to that predicted for a
K+-selective membrane
-140 -100
Fig. 3 Effect of extracellular CF concentration on the outwardly
rectifying current. When the extracellular CI- concentration is de¬
creased from 153.7 mM to 51 mM by substituting Na-acetate for
NaCl, the outwardly rectifying conductance is markedly decreased
and the reversal potential shifts in a positive direction (arrows)
than the K+ reversal potential and typically contained a re¬
gion showing a small outward current just positive to the
reversal potential, as shown in Fig. 1A. To investigate the
proportion of cells showing the IR current, we first exam¬
ined I/V relationships from 21 BMMCs in extracellular so¬
lutions containing 2.7 and 10 mM K+. In mast cell Ringer
(2.7 mM K+) 15 cells (71%) showed the IR current, but
when the extracellular K+ was increased to 10 mM the
current was present in all 21 cells (100%). When the ex¬
tracellular K+ was increased from 2.7 mM to 165 mM
(with a corresponding decrease in the Na+ concentration),
the reversal potential of the I/V curves shifted in a positive
direction (Fig. 2A). The linear relationship between rever¬
sal potential and log extracellular K+ concentration with a
least squares slope of 52 mV/decade indicates that the
conductance is essentially K+ selective (Fig. 2B). The
slope conductance measured between -100 mV and
-80 mV also increased with extracellular K+ and was
1.48 ± 0.7 nS in 10 mM K+(/? = 9), 4.27 ± 1.4 nS in
50 mM K+ 0? = 9), 5.50 ± 2.3 nS in 90 mM K+(n = 5),
6.24 ± 2.8 nS in 137 mM K+(n = 7), and 5.8 ± 4.0 nS in
165 mM K+(n = 3). An increase in conductance with in¬
creasing extracellular K+ concentration also indicates that
the current is predominantly carried by K+ ions.
The OR current was not affected by changes in extra¬
cellular K+ concentration. However, when the extracellu¬
lar Cl~ concentration was reduced to 51 mM by substitut¬
ing Na acetate for NaCl, the OR conductance decreased
by 82 ± 8.5% (Fig. 3), from a mean of 2.7 ±2.1 nS to
0.51 ± 0.53 nS (n = 5). In three cells bathed in extracellu¬
lar solution containing 14 mM CF the peak OR conduc¬
tance was reduced to 0.24 nS in one cell and completely
abolished in the other two cells. If cytosolic CF was in¬
variant during solution exchange, the shift in reversal po¬
tential predicted by the Nernst equation for a threefold
decrease in extracellular CF concentration would be
28 mV for a membrane selectively permeable to CF. Re¬
ducing the extracellular CF concentration from
153.7 mM to 51 mM resulted in a positive shift in the re¬
versal potential of the OR current by 31 ±21 mV (n = 5,
Fig. 3 arrows). The deviation from theory resulting in a
large standard deviation may reflect changes in intracellu¬
lar CF concentration occurring during the exchange (cy¬
tosolic CI is not known in perforated-patch experiments
and varies until a Donnan equilibrium is established be¬
tween pipette and cell). The OR conductance was also de¬
creased when Na isethionate was substituted for NaCl to
yield an extracellular solution containing 16.7 mM CF
(3.39 ± 2.3 nS to 0.88 ± 1.2 nS, n = 4), and this effect was
reversible on washout of the bath (Fig. 4B).
The OR current was not affected by 100 pM 4-amino-
pyridine or 25 mM TEA (not shown), but the OR conduc¬
tance was reversibly decreased by the chloride channel
blocker D1DS. Addition of 20 pM DIDS to the extracellu¬
lar solution reduced the OR conductance by 69 ± 23%
from a mean of 2.8 ± 2.0 nS to 1.0 ± 1.3 nS (n = 7). Figure
4C shows a typical experiment in which the OR conduc¬
tance decreased after addition of 20 pM DIDS to the bath,
but partially recovered after the blocker was washed out.
All of these observations indicate that the OR currents in
rat BMMCs are predominantly carried by CF ions.
Dependence of the OR CF conductance on bath
temperature and cytoplasmic integrity
The OR chloride conductance has not been described
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Fig. 4 Effect of extracellular CI concentration and DIDS on
whole-cell membrane currents in BMMCs. A The voltage step
protocol. Cells were held at a holding potential of -40 mV and
voltage pulses of 200 ms duration were applied from -140 mV to
+ 100 mV in 10-mV steps at 1-s intervals. B,C Typical continuous
pen recordings of the I/V relationships. Below each trace are the
original superimposed currents evoked by the 25 voltage steps la¬
belled by each encircled number. B Whole-cell currents in a
BMMC after the mast cell Ringer (153.7 mM Cl~) was exchanged
for an extracellular solution containing Na-isethionate (16.7 mM
C\~, first arrow). The outwardly rectifying (OR) current, showing
time-dependent inactivation at potentials above +60 mV, is mark¬
edly reduced between encircled number J and encircled number 2.
At the second arrow, the bath was washed out with mast cell
Ringer resulting in restoration of the current (encircled number 3).
Noise indicates the time taken for solution exchange. Pipette solu¬
tion contained KCH3S04. C Effect of DIDS on the OR current. At
the first arrow, 20 pM DIDS was added to the bath resulting in
gradual diminution of the OR current. At the second arrow, the
DIDS was washed out of the bath resulting in recovery of the OR
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Fig. 5 A Perforated-patch experiments showing the effect of in¬
creasing bath temperature on 31 BMMCs that showed the OR
chloride (ORcl) current at 25-37°C. The distribution of ORa con¬
ductances at room temperature (16-20°C) is shown by the black
bars and those between 25 and 37°C by the white bars. The shift
of the distribution to the right indicates activation of the current by
the rise in temperature. B Activation of the ORa current in a cell
warmed from room temperature to 30°C. UV relationships are
shown at intervals following activation of the Peltier device. The
cell was clamped at a holding potential of -40 mV and voltage
pulses of 200 ms duration were applied from -100 mV to + 40 mV
in 10-mV steps. Leak currents were subtracted
tigated using conventional whole-cell recording tech¬
niques [18, 22], We wished to determine if our results
were influenced by recording conditions, so we com¬
pared 117 perforated-patch recordings obtained at room
temperature (16-20°C) with our results at the warmer
temperatures in the range of 25-37°C. At room temper¬
ature, 23% of amphotericin-B-perforated BMMCs dis¬
played both IRk and ORcl currents concurrently, with a
further 49% showing only IRK currents. In marked con¬
trast to the results obtained at 25-37°C, only 3% of
BMMCs displayed exclusively outward currents. Out of
117 cells, 25% appeared quiescent, displaying neither in¬
ward nor outward currents. The IRK and ORcl conduc¬
tances at room temperature were 1.22 ± 0.7 nS (n = 56)
and 1.25 ± 0.9 nS (n = 20), respectively, both signifi¬
cantly lower than those recorded at 25-37°C (P<0.005).
The difference between these results and those de¬
scribed earlier is primarily attributable to the increased
proportion of cells showing ORcl currents at 25-37°C
(26% at room temperature compared to 66% at
25-37°C). This effect is illustrated in Fig. 5A, which
shows the effect of warming on the distribution of ORcl
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Table 1 Effect of recording
conditions on the ORa conduc¬
tance. The probability of ob¬
serving the conductance in¬
creases as the conditions ap¬
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conductances in 31 BMMCs that showed the ORcl cur¬
rent at 25-37°C.
The effect of warming on the ORcl current was also
demonstrated in individual cells by monitoring the I/V
relationships as BMMCs were warmed. Figure 5B
shows the development of the ORa current in a typical
cell following activation of the Peltier device. The tem¬
perature at which the ORcl current developed varied
from cell to cell; in most BMMCs, the current devel¬
oped at either 25 °C (n = 20) or 30°C (n = 22), but in
some cells the current only appeared at 37°C (n = 6).
The median OR conductance also increased with each
temperature increment but the difference between the
three temperatures did not reach statistical significance,
probably due to small group sizes. In cells that exhibit¬
ed the ORC| current, the time from the start of warming
to development of the peak conductance ranged from
132 to 696 s with a mean and SD of 309 ± 132 s
(/? = 21). These figures indicate that the ORcl conduc¬
tance continues to increase even after the elevation of
temperature has been completed. This delay would
most likely arise if the current was dependent on a cy-
tosolic factor. The OR current was typically stable for
long periods, and in one cell it was monitored for
60 min without deterioration. However, we could not
determine if the effect of warming was reversible be¬
cause our Peltier device did not allow rapid cooling of
the bath. Taken together, these results clearly indicate
that detection of the ORc, current is more likely if the
temperature of the cells is increased towards physiolog¬
ical values.
We then examined conventional whole-cell record¬
ings from BMMCs to determine if maintenance of cyto¬
plasmic integrity was also important for demonstration
of the ORcl current. UV relationships showed that 41 out
of 44 BMMCs at room temperature (93%) displayed the
IRk current, with a mean slope conductance of
0.83 ± 0.5 nS (n - 22). A small OR conductance
(0.87 ± 0.6 nS) was also present at room temperature in
3 out of 44 cells, but only in those experiments in which
KCH3SO4 was used in the pipette solution (n = 13).
When cells were warmed to 25-37°C, 3 out of 14
BMMCs showed some OR conductance but it was much
lower than that measured in perforated-patch recordings
(0.69 ± 0.1 nS).
A summary of the effects of temperature and cyto¬
plasmic disruption on the activation of the OR conduc¬
tance in BMMCs is shown in Table 1. The results clearly
indicate that the ORcl current is dependent both on tem¬
perature and the degree of cytoplasmic integrity.
Whole-cell currents in rat peritoneal mast cells
The OR chloride current in rat BMMCs was similar to
that described to occur in rat peritoneal mast cells
(RPMCs) when cAMP was included in the pipette solu¬
tion or when the cells were stimulated with secretago-
gues [2, 11, 21], To determine if an ORcl could also be
detected in resting RPMCs, we used the perforated-
patch technique to obtain I/V relationships from cells at
room temperature and in the range 25-37°C. Figure 6B
shows the development of an OR current in an RPMC
warmed to 25°C and the abrupt decrease in current am¬
plitude and slope conductance following addition of
20 pM DIDS to the bath. In five similar experiments,
20 pM DIDS reduced the mean OR conductance by
53 ± 28% from 1.7 ± 0.96 nS to 0.75 ± 0.53 nS (n = 5).
A similar effect was observed when RPMCs showing
the OR conductance in mast cell Ringer were perfused
with an extracellular solution containing 16.7 mM Cl_
(Fig. 6C), again indicating that the conductance was CI"
selective. As in rat BMMCs, the expression of the ORa
current was variable and depended on recording condi¬
tions. Out of 40 RPMCs, 10 (25%) showed the OR cur¬
rent between 25 °C and 37°C, in contrast to 9 out of 55
cells (16%) from which recordings were made at room
temperature. The slope conductance also increased with
temperature from 1.15 ± 0.36 nS (n = 9) to
1.51 ± 0.86 nS (n = 10), although the difference did not
reach statistical significance. The ORa was also more
commonly observed in RPMCs that had been incubated
for > 24 h with 10 ng/ml rrSCF164. From 55 RPMCs re¬
corded at room temperature, 12 cells had been incubat¬
ed with rrSCF164; the ORcl was present in 5 cells from
this subgroup (42%) in contrast to 4 out of the remain¬
ing 43 cells (9%). The mean OR conductance was high¬
er in the rrSCF164 treated group (1.3 ± 0.4 nS vs
0.96 ± 0.23 nS) but again the difference was not statis¬
tically significant.
In accordance with previous reports [18, 22], we
could not demonstrate a K+-selective IR current in
RPMCs under our experimental conditions. In three
cells bathed in high-K+ Ringer (50 mM), there was no

































Fig. 6A-C Effect of temperature, DIDS and extracellular CI- con¬
centration on whole-cell membrane currents in rat peritoneal mast
cells (RPMCs). A The voltage step protocol. Cells were held at a
holding potential of -40 mV and voltage pulses of 200 ms dura¬
tion were applied from -140 mV to +100 mV in 10-mV steps at 1-
s intervals. B After warming the cell to 25 °C (first arrow), an out¬
wardly rectifying (OR) current develops that exhibits time-depen¬
dent inactivation at potentials greater than +60 mV (encircled
number 2). At the second arrow, 20 pM DIDS was added to the
bath resulting in a sudden diminution of the OR current (encircled
number 5). Pipette solution contained KCH3S04. C Whole-cell
currents in an RPMC after the mast cell Ringer (153.7 mM CP)
was exchanged for an extracellular solution containing Na-isethio-
nate (16.7 mM CI", first arrow). The OR current is markedly re¬
duced between (encircled numbers I and 2). At the second arrow,
the bath was washed out with mast cell Ringer resulting in restora¬
tion of the current (encircled number 3). Noise indicates the time
taken for solution exchange. Pipette solution contained
kch3so4
Discussion
Activity of the ORa in rat mast cells
In this study, we characterized whole-cell currents of rat
BMMCs grown in the presence of cytokines derived
from concanavalin-A-stimulated T-lymphocytes. These
cells have not been studied electrophysiologically but
they have been extensively characterized biochemically
and immunologically and in all respects so far studied
they are identical to intestinal mucosal mast cells [19,
23]. They may, therefore, represent a better model for
electrophysiological studies of mucosal mast cells than
RBL-2H3 cells [18] or mast cells grown in the presence
of rat recombinant IL-3 [22]. In contrast to the latter
studies, we report that rat BMMCs possess an ORcl in
addition to the previously described K+-selective inward¬
ly rectifying (IRK) current. This discrepancy may result
from variations in cell phenotype; the additional growth
factors and concanavalin A in the LNCM culture system
could be necessary for expression of the outwardly recti¬
fying chloride channel which was not observed to occur
in either of the other cell types. However, this explana¬
tion seems unlikely because the ORcl was also present in
RPMCs (an example of the connective tissue phenotype)
and these cells were not exposed to the aforementioned
factors.
A more likely possibility for the discrepancy de¬
scribed is the apparent dependency of the ORc, conduc¬
tance on experimental conditions. We found that with the
conventional whole-cell recording technique at room
temperature (as used in previous studies) only 3 out of
44 BMMCs showed an ORc, current. However, when the
integrity of the cell's cytoplasm was preserved using the
perforated-patch technique, the ORcl current was readily
demonstrable both in BMMCs (see Table 1) and RPMCs
(Fig. 6). In addition, we found that increasing the bath
temperature towards physiological values increased the
proportion of cells that possessed the ORcl current, al¬
though the conductances were lower with the conven¬
tional whole-cell technique. These findings suggest that
the ORcl may be dependent on an essential intracellular
component that is leached out of the cell during conven¬
tional voltage-clamp recordings. A similar effect was re¬
cently reported for the immunoglobulin E (IgE) receptor-
activated calcium conductance in rat mast cells, which
could only be detected using perforated-patch recordings
performed at 37°C [33],
The ORcl conductance observed in our experiments is
similar to that induced in RPMCs when cAMP is includ¬
ed in the pipette solution [2, 27]. For example, the time
course for development of the ORcl current in RPMCs
following "break-in" is similar to that following warm¬
ing of BMMCs or RPMCs; the shape of the I/V curve is
similar in both cases; and both currents are blocked by
20 pM DIDS. In previous studies of RPMCs [27], it was
concluded that in vivo a rise in intracellular cAMP fol¬
lowing stimulation of the cells with secretagogues or an¬
tigen was responsible for activation of the ORcl current.
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In our cells, neither secretagogues nor exogenous second
messengers were required to elicit the current. This sug¬
gests that if cAMP is the "missing" cytosolic factor in
conventional whole-cell recordings then only basal levels
of the messenger are required to support the ORa con¬
ductance.
The ORcl conductance in rat mast cells also shares
certain similarities with a volume-regulated Cl~ conduc¬
tance in T-lymphocytes [17]. In our experiments, the
ORCI conductance was also observed when pipette KC1
was replaced with KCH3S04, suggesting that the current
was not induced by movement of pipette CP and osmoti-
cally obliged water into the cell during perforated-patch
recordings. It was also concluded in previous studies that
the cAMP-activated CI current in RPMCs was not de¬
pendent on changes in cell volume [21 ].
However, cells subjected to perforated-patch record¬
ings are very susceptible to small osmotic imbalances
between cytosol and bath which could lead to activation
of volume-regulated CI channels. The effect of osmolar-
ity on the activation of ORa in BMMCs and RPMCs,
and the relationship between the currents described here
and in previous studies, therefore awaits further study.
Variation in expression of whole-cell currents
In the mouse BMMC system, the presence or absence of
IRk and ORc, currents in individual mast cells was inter¬
preted as heterogeneity of ion channel expression [14].
We also found variation in the presence of the two cur¬
rents in our cell populations, but we favour an alternative
explanation to heterogeneity of ion channel expression.
We suggest that a normal rat BMMC possesses the ion
channels for both the IRK and ORn currents, and that the
heterogeneous distribution of current patterns within the
population results from extrinsic factors (i.e. experimen¬
tal conditions) rather than intrinsic factors (i.e. restricted
expression of ion channels). This is highlighted in Table
1, which shows the variation in expression of the ORa
conductance in BMMCs under different conditions.
Likewise, the IR current was not detected in some cells
in mast cell Ringer, but when the extracellular K+ con¬
centration was raised it was present in all cells tested.
Hence, with both the ORa and the IRK, the lack of a de¬
tectable current did not reflect the lack of the appropriate
ion channels. However, although we demonstrated the
0RCI current in both BMMCs and RPMCs, the IRK was
only detectable in BMMCs. This may reflect true hetero¬
geneity between the cell phenotypes as rat BMMCs and
RPMCs have distinct biochemical and functional charac¬
teristics. However, the possibility still remains that the
lack of the IRK current may be an artefact of the isolation
procedure, similar to that affecting IgE responses in
freshly isolated RPMCs [32], RPMCs undergo apoptosis
on removal from the abdominal cavity, unless stimulated
with the appropriate growth factors [5, 9], and the appar¬
ent influence of the cytokine rrSCF164 on the ORa cur¬
rent lends support to this hypothesis.
Physiological relevance of the IRK and the ORcl currents
in rat mast cells
Previous studies have shown that the IRK is involved in
regulation of the resting membrane potential [14, 18]. As
seen in Fig. 1. the current is rapidly activated in BMMCs
by hyperpolarizing potential steps, which in vivo would
prevent further hyperpolarization. Note also the presence
of the slight outward current "bump" in the IRK I/V curve
just positive to the reversal potential. This would tend to
restore the resting membrane potential if the cell was
slightly depolarized from the K+ reversal potential. The
IRk current therefore provides a mechanism that would
prevent excessive hyperpolarizations, and resist small de¬
polarizations, of the cell. The lack of a detectable IRK in
RPMCs explains why the resting potential of these cells
is close to 0 mV [18], but whether this accurately reflects
the situation in vivo remains to be determined.
The ORcl current in our cells was only activated when
the cell was depolarized to potentials more positive than
-30 mV (Fig. IB, C). This suggests that in vivo the ORa
current could be activated by large fluctuations in resting
membrane potential or by depolarization, as occurs fol¬
lowing stimulation of tumour mast cells following stimu¬
lation with antigen [ 12, 24, 31 ]. In RBL-2H3 cells, anti¬
gen-mediated depolarization is followed by a repolariza¬
tion towards the resting membrane potential [15, 24], a
process considered to be due to efflux of K+ ions from
the cell [16]. We suggest that the influx of CL ions that
follows activation of the ORn [4] would also tend to re-
polarize the cell, thus restoring a negative membrane po¬
tential. The ORc, current in rat BMMCs could therefore
serve two functions: (1) to regulate the resting membrane
potential, as in mouse BMMCs [14] and (2) to counteract
the depolarization of the cell during degranulation, thus
maintaining the driving force for Ca2+ entry [21, 25].
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Stem cell factor enhances immunoglobulin E-dependent mediator release
from cultured rat bone marrow-derived mast cells: activation of previously
unresponsive cells demonstrated by a novel ELISPOT assay
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SUMMARY
Mucosal mast ceils (MMC) are important effector cells in the immune response against
gastrointestinal nematodes. We used cultured rat bone marrow-derived mast cells (BMMC) as
an in vitro model of MMC to study the effects of the multifunctional cytokine stem cell factor
(SCF) on immunoglobulin E (IgE)-dependent secretion of granule mediators. SCF (<1000ng/ml)
was not a direct secretagogue for these cells, but it significantly enhanced IgE-mediated secretion
of the granule constituents rat mast cell protease-11 (RMCP-11) and ^-hexosaminidase from
mature BMMC in a dose-dependent manner (>10ng/ml). Maximum up-regulation of secretion
occurred after cells were pretreated with SCF (50 ng/ml) for 5 minutes before challenge with anti-
IgE, but the effect then declined and was absent in cells incubated with the cytokine for 3 to 24 h. In
a novel ELISPOT assay developed to identify individual BMMC secreting RMCP-II, the
proportion ofmature BMMC responding to anti-IgE was significantly increased by treatment with
SCF. To investigate this effect further, the percentage release of RMCP-II and /J-hexosaminidase
from populations of mature BMMC was directly compared to the proportion of individual cells
releasing RMCP-II as detected by ELISPOT. The release of both mediators was enhanced by SCF,
and the increased percentage release reflected both an increased proportion of secreting cells, and
enhanced mediator release from individual cells. These results suggest that SCF can enhance IgE-
dependent mediator release from BMMC not only by augmenting the secretory response from
individual cells, but also by activating previously unresponsive cells.
INTRODUCTION
Intestinal mucosal mast cells (MMC) in the rat differ from
connective tissue mast cells (CTMC) in their response to
secretagogues,1 and in their content of granule proteases.2
Unlike rat CTMC, which contain rat mast cell protease-I
(RMCP-I), rat MMC contain the granule chymase rat mast
cell protease-II (RMCP-II), which is released into the blood¬
stream and gut lumen during immune expulsion of the
intestinal parasites Nippostrongylus brasiliensis and Trichinella
spiralis? 8 RMCP-II increases gut epithelial permeability via a
paracellular route, possibly by effects on junctional complex
proteins.6
Isolation of rat MMC from the gut is laborious and can give
Received 8 September 1995; accepted 28 September 1995.
Abbreviations: BMMC, bone marrow-derived mast cells; RMCP-
11, rat mast cell protease II; SCF. recombinant rat stem cell factor.
Correspondence: P. B. Hill, Department of Preclinical Veterinary
Sciences, Royal (Dick) School of Veterinary Studies, Summerhall,
Edinburgh, EH9 1QH, UK.
variable results.1'7'8 By contrast, rat bone marrow-derived mast
cells (BMMC), which exhibit many features of rat MMC,9'10
can be grown in the presence of an interleukin-3 (IL-3)-rich
T-cell-conditioned medium." '2 Like MMC in vivo, rat BMMC
release substantial quantities of RMCP-II when activated
immunologically,13 and accordingly can be considered as an in
vitro model of rat MMC.
Many aspects of mast cell development and function are
influenced by stem cell factor (SCF), the ligand for the c-kit
tyrosine kinase receptor. This cytokine influences chemotaxis,
adhesion, survival, proliferation, differentiation and matura¬
tion of mast cells.14'17 SCF can also induce and/or enhance
mediator release from CTMC, including mouse skin,18 rat"1 or
mouse20 peritoneal, and human lung21 or skin22 mast cells.
In this study, we evaluated whether SCF had any effects on
the secretory function of rat BMMC. We found that although
SCF is not a secretagogue for these cells, it enhances immuno¬
globulin E (IgE)-dependent mediator release from rat BMMC.
Using a novel enzyme-linked immunospot (ELISPOT) assay to
identify individual cells releasing RMCP-II, we show for the
first time that only a proportion of a BMMC population
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respond to immunological stimulation. Furthermore, we found
that enhancement ofmediator release by SCF is associated with
an increase in the proportion of individual cells secreting
RMCP-II, suggesting that the cytokine functions in part by
activating previously unresponsive cells. Our findings also
suggest a modulatory role for SCF in gastrointestinal immune
responses.
MATERIALS AND METHODS
Cultured bone marrow mast cells (BMMC)
The preparation of bone marrow-derived mast cells and the
production of lymph node conditioned medium (LNCM) have
been described.12 Briefly, femoral bone marrow cells from male
Wistar rats were cultured at 2-5-5 x 105 cells/ml in Iscove's
Modified Dulbecco's medium (IMDM, Gibco-Brl, Paisley)
supplemented with 20% horse serum (Advanced Protein
Products, Brierley Hill), penicillin (lOOIU/ml), and streptomy¬
cin (lOOjUg/ml). The cells were stimulated with LNCM at 10-
25% v/v, and refed every 2-5 days. Percentage mast cells was
determined by differential counts (400 cells) on Leishman's-
stained cytocentrifuge preparations. BMMC proliferated
rapidly initially, representing 85% of cells after approximately
15 days. After this, the percentage of BMMC increased slowly
to almost 100% before cell viability declined. Before use,
BMMC were washed three times by centrifugation (200g) and
resuspension, counted using a haemocytometer and assessed
for viability by nigrosine exclusion. Unless stated otherwise,
cells were used from cultures containing > 95% mast cells with
>95% viability. Mean RMCP-II concentration in individual
mast cells, determined by enzyme-linked immunosorbent assay
(ELISA)23 of freeze/thawed cell pellets, increased from
3-4 ± 0-3pg/cell at day 4 to 30-4 ± 3pg/cell at day 28 (data
from two cultures).
Reagents
Cell suspensions were washed and diluted in Tyrode's buffer
(TB, containing (in ium): NaCl 137, glucose 5-6, KC1 2-7,
NaH2P04 0-4, HEPES 10, bovine serum albumin 0-25% w/v,
pH7-3). SCF and secretagogues were diluted in Tyrode's
buffer/1 mM Ca2 + /1 mM Mg2+ (TB + ). Recombinant rat SCF
(2-2mg/ml) was kindly provided by Dr Keith Langley of
Amgen Inc., Thousands Oaks, CA. Preparation of purified
RMCP-II, murine monoclonal anti-RMCP-II and sheep anti-
RMCP-II for use in ELISA and ELISPOT assays has been
described.23 ELISPOT substrate buffer (AMP buffer) com¬
prised 1-0m 2-amino-2-methyl-l-propanol (Sigma), 0-7 mM
MgCl2 and 0 01% v/v Triton-X-405, pH 10-25. The ELISPOT
substrate was 5-bromo-4-chloro-3-indoyl phosphate (BCIP,
Sigma). The final substrate solution was prepared as
described,24 and comprised 1 mg/ml BCIP in AMP buffer
with 0-6% w/v agarose (Type 1, Sigma).
Immunological stimulation ofmediator release from BMMC
Two IgE-mediated stimulation protocols were used. In some
experiments, cells were challenged directly with goat anti-rat
IgE (provided by Dr E. Hall, Glasgow Veterinary School, UK),
because cultured rat BMMC maintained in LNCM are
ordinarily exposed to 1-2/ig rat IgE per ml,25 and binding of
this endogenous IgE to BMMC was detected throughout
culture by flow cytometry (not shown). In other experiments
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(see legends), IgE binding was increased (shown by flow
cytometry) by passively sensitizing the BMMC with mono¬
clonal mouse IgE anti-dinitrophenyl (DNP) (SPE-7, Sigma).
BMMC were washed three times in TB, incubated with 10/ig
mouse IgE/106 cells in TB/4mM EDTA for 1 h at 37°, and
washed again three times in TB. In these experiments, DNP-
bovine serum albumin (BSA) (Calbiochem, Nottingham) was
used for challenge.
Percentage mediator release from BMMC populations
Triplicate or quadruplicate aliquots (0-5 ml) containing 0-8-
1 x 106 BMMC were incubated with various concentrations of
SCF (diluted in TB +) or TB + control for various periods at 37°
in a shaking water bath. After the addition of appropriately
diluted antibodies or antigen in 0-5ml TB4", the cells were
incubated at 37° for a further 30min. Goat anti-rat IgE (algE)
was used at an optimal dilution of 1 : 250, and DNP-BSA at a
concentration of 10/(g/ml. Normal goat serum (NGS, 1 :250)
was used as a control for algE, and TB+ as a control for DNP-
BSA. Cells were pelleted by centrifugation (12 000 #) at 4° and
transferred to an iced water bath. After collection of super-
natants, cell pellets were resuspended in 1 ml TB and subjected
to three freeze-thaw cycles in methanol/dry ice to fracture
plasma membranes and release remaining mediators. Super-
natants and pellets were stored at —70° until assayed for
RMCP II23 and /i-hexosaminidase.'3
Enumeration ofRMCP-II release from individual BMMC by
ELISPOT assay
We developed a modification of the technique originally
described by Sedgwick and Holt24 for the enumeration of
antibody-secreting cells. Forty-eight-well cell culture plates
(Costar, Cambridge, MA) were incubated overnight at 4° with
150/d/well mouse monoclonal anti-RMCP II (1 /rg/ml) in
phosphate-buffered saline (PBS), pH 7-5. After washing twice
with PBS/0-05% Tween 20 (PBS/T20), remaining binding sites
were blocked by adding 200^1/well 1% non-fat milk (Marvel,
Premier Brands, Stafford) in PBS and incubating for 1 h at 37°.
The plate was washed four times in PBS, and 125/d of a
BMMC suspension was added to each well (diluted in TB to
provide between 100 and 400 cells/well). Examination of wells
under phase contrast microscopy confirmed the presence of a
single cell suspension. RMCP II (50ng/ml) was added to two
wells as a positive control, and wells containing no cells were
included as negative controls. Cells or controls were incubated
with SCF as described above, followed by 125 /d appropriately
diluted algE, DNP-BSA, NGS, or TB for 30min at 37°. After
four washes in PBS/T20 to remove the cells, plates were
sequentially incubated with 150/d/well 1:1000 sheep anti-
RMCP-II and 150/d/well 1 : 10000 donkey anti-sheep IgG-
alkaline phosphatase conjugate (Sigma), both diluted in PBS/
T20/4% BSA. Incubations were for 1 hr at 37° and plates were
washed four times after each incubation in PBS/T20. Finally,
200/d ELISPOT substrate (heated to 40°) was added to each
well, and the plate was left overnight at room temperature (18-
22°) to allow colour development.
Assay sensitivity was assessed by determining the lowest
concentration of purified RMCP-II that could be detected in a
1 p\ droplet. Twofold serial dilutions of RMCP-II from 500 pg/
p\ to 0-03 pg//d were added to plates using a 1 /d pipette, and
incubated for 30min at 37°. Specific binding of RMCP-II
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to antibody-coated wells was determined by adding serial
dilutions of RMCP-II in 1 //I droplets to wells coated with
PBS, rabbit polyclonal anti-RMCP-I, and mouse monoclonal
anti-RMCP-II. (The mouse monoclonal anti-RMCP-II used in
this assay is specific for RMCP-II, and does not cross-react with
RMCP-I.23) Plates were then developed as described above.
Bound RMCP-II released from individual BMMC resulted
in the development of discrete blue spots in ELISPOT assays.
These were counted under a bright light without magnification.
Variation in spot size was noted in all assays, but was not
quantified.
Positive (50ng/ml RMCP-II) or negative (no cells) control
wells were diffusely blue or clear respectively. The sensitivity of
the assay was lOpg RMCP-II/pl, indicating sufficient sensi¬
tivity to detect RMCP-II-release from individual cells. Binding
of RMCP-II occurred only in wells coated with anti-RMCP-II.
No spots developed in wells coated with PBS or anti-RMCP-I,
thus confirming that RMCP-II was bound specifically by wells
coated with homologous antibody.
Statistical analysis
Analysis of variance (ANOVA) and unpaired Student's /-tests
were used to compare treatment groups. The data were
analysed using Minitab statistical software. Results are
reported as mean ± SEM.
RESULTS
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Figure 1. The effect of stem cell factor (SCF) on //-hexosaminidase
release from BMMC. The BMMC (106 per tube; n - 3) were pre-
incubated with SCF at 10, 100, or 1000 ng/ml, or with buffer alone, for
15 min before addition ofgoat anti-rat IgE (algE) or normal goat serum
(NGS) at 1/250 final dilution for a further 15min. Each bar represents
the mean ± SEM of triplicate release assay tubes. *Significant
difference from cells treated with buffer alone (P < 0-005).
SCF enhances IgE-dependent mediator release from
mature BMMC
Preincubation of BMMC populations with SCF at 10, 100
or 1000 ng/ml for 15 min resulted in a highly significant
(P < 0-005) enhancement of IgE-dependent //-hexosaminidase
release, from 19% without SCF preincubation to a mean of
47% in cells challenged with algE (Fig. 1). In a separate
experiment, SCF did not enhance mediator release at concen¬
trations of 0-001 to 1 ng/ml, but again significantly increased
secretion when used at 10 and 100 ng/ml (not shown). When
mature BMMC were incubated with SCF (50 ng/ml) for 5, 15,
or 60min, or 3 or 24 h before challenge with algE, maximal
enhancement of RMCP-II or //-hexosaminidase release
occurred after a 5min preincubation, but the effect declined
thereafter was not statistically significant in BMMC that had
been treated with SCF for 3 or 24 hr (Fig. 2). Incubation with
SCF (10, 100, 1000 ng/ml) did not cause direct release of
//-hexosaminidase from BMMC in the absence of anti-IgE,
suggesting that SCF was not a direct secretagogue for these cells.
SCF enhances the proportion of BMMC that release RMCP-II
in response to anti-IgE
We first verified that the number of spots counted in ELISPOT
assays were correlated to cell density by assaying twofold
dilutions of BMMC from 150BMMC/well to 10 BMMC/well.
The number of spots in wells treated with anti-IgE increased
linearly with increasing cell density (r = 0-99, P < 0 001), with
a mean of 21% BMMC releasing RMCP-1I, compared to a
background release from only 0-3% of BMMC treated with
NGS (Fig. 3).
We then used the ELISPOT assay to determine whether
preincubation with SCF altered the proportion of BMMC
within a population that responded to stimulation with anti-
IgE. The proportion of BMMC releasing RMCP-II was
increased by preincubation with SCF in a concentration- and
time-dependent manner. Concentrations of 50 or 25 ng/ml
resulted in the highest proportion of cells responding (35 ± 5 or
36 ± 3% respectively), compared to 4 ± 0-7% of cells treated
with anti-IgE alone (Fig. 4a). In subsequent assays, a SCF
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Figure 2. Time course of the effect of SCF on IgE-dependent RMCP-II
release from BMMC. The BMMC (106 per tube) were preincubated
with 50 ng/ml SCF or buffer alone for various times followed by algE or
NGS at 1/250 final dilution for 30 min. Each bar represents the
mean ± SEM of triplicate release assay tubes. *Significant difference
from cells treated with algE for equivalent time periods (P < 0-05). //-
hexosaminidase release (not shown) was highly correlated with RMCP-
II release (r = 0-976, P < 0-001).
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Figure 3. Relationship between cell density and number of spots/well
determined by assaying serial dilutions of cell suspensions from
150cells/well to lOcells/well. BMMC from a culture containing 38%
mast cells were challenged with goat anti-rat IgE (solid circles) or
normal goat serum (solid triangles). Each point represents the
mean ± SEM of individual spot counts in five wells. Correlation
coefficient between cell density and number of spots in wells challenged
with anti-rat IgE = 0-99, P < 0 001.
The effect of SCF was shown to be time dependent by
incubating BMMC with 50ng/ml SCF for 5, 15, 30, 60, or
120min before challenge with anti-IgE (Fig. 4b). A 30-min
incubation resulted in the highest proportion of cells releasing
RMCP II (34 ± 2%), but this was not significantly different
from the results obtained after a 5-min incubation (26 ± 3%);
both values were highly significant when compared to results
for cells treated with anti-IgE alone (8 ± 1%, P < 0 01 for
either comparison). SCF therefore increased the proportion of
BMMC that detectably responded to anti-IgE at concentra¬
tions and incubation times similar to those that enhanced total
mediator release as described in the initial experiments. For all
subsequent assays, BMMC were incubated with SCF for 5min
before addition of the secretagogue (anti-IgE or antigen) or
control.
Effects of SCF on mediator release from BMMC populations
at various stages of culture
ELISPOT assays (100 cells/well) were performed throughout
the course of two BMMC cultures to determine whether the
response to SCF might be related to maturity of the culture.
The response of BMMC to anti-IgE and SCF fell into two
categories. In four experiments performed using cultures
containing 8, 36, 41, or 64% BMMC, a highly significant
(P < 0 001) proportion of BMMC responded to anti-IgE alone
when compared to NGS controls, but addition of SCF had no
significant effect (Fig. 5a). In contrast, SCF significantly
increased (P < 0 001) the proportion of BMMC responding
to anti-IgE in 4 out of 5 experiments performed using cultures
containing 85, 87, 92, 94, or 95% mast cells (Fig. 5b).
Mediator release in response to anti-IgE apparently
decreased as the cultures matured, but this effect may partially
be due to increased spontaneous release of RMCP-II (compare
Figs. 5a and 5b); in some experiments, the proportion of
BMMC responding to anti-IgE was not significantly different
from background release in negative controls (NGS versus
odgE in Fig. 5b). At no stage did SCF alter the response of cells
treated with NGS. This finding provided additional evidence
that, in isolation SCF had no detectable secretagogue activity in
these BMMC populations.
Effects of SCF on release of RMCP-II from individual
BMMC compared with percentage mediator release by the
entire population of BMMC
We wished to determine whether an SCF-dependent increase in
mediator release by a BMMC population as a whole might
reflect an increase in the proportion of secreting cells as opposed
to increased amounts of mediator release from the responding
BMMC. We therefore compared results from ELISPOT assays
to those obtained in conventional mediator release assays,
using aliquots of the same cell populations. In addition, we
wished to determine whether passive sensitization of cells with
IgE would enhance the response ofmature BMMC populations
to immunological stimulation. Accordingly, we sensitized
BMMC from a mature culture with mouse IgE anti-DNP,
incubated the sensitized cells with SCF (50ng/ml for 5min
before challenge) or buffer as a control, and then stimulated the
BMMC with DNP-BSA. For each experiment, the percentage
release of RMCP-II and /I-hexosaminidase from 0-8 x 106
BMMC was compared to the proportion of BMMC from the
same population that released RMCP-II as determined by
ELISPOT (Fig. 6). In these experiments, mean specific IgE-
dependent release of RMCP-II or /^-hexosaminidase (% release
from DNP minus % release from control) in the absence of
SCF was 9 ± 0-5% and 12 ± 0-3% respectively (P < 0 01 vs.
results with buffer alone). After pretreatment with SCF, the
cells' response to antigen-mediated stimulation increased
significantly (P < 0 001) to 26 ± 1% or 36 ± 3% for RMCP-
II and /(-hexosaminidase respectively. In the ELISPOT assays,
a mean of 14 ± 1% individual IgE-sensitized BMMC released
RMCP-II in response to DNP-BSA alone, and this increased
significantly {P < 0-01) to 21 ± 1% after pretreatment with
SCF. Background release from cells treated with buffer alone
was 3 ± 0-3%. These results suggest that SCF enhances
mediator release from BMMC both by activating previously
unresponsive cells and by augmenting the secretory response in
degranulating cells.
DISCUSSION
In all respects so far studied, rat BMMC represent the in vitro
analogues of rat intestinal MMC. Importantly, BMMC release
RMCP-II following IgE-mediated stimulation, and therefore
provide a useful model for studying the mechanisms involved in
mediator release.13 We initially explored the effects of SCF on
the IgE-mediated secretion of RMCP-II and /(-hexosaminidase
from populations of mature BMMC (from cultures containing
70
>95% BMMC). We found that, in contrast to mouse" or
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Figure 4. (a) The effect of SCF concentration on RMCP II release from BMMC in response to anti-IgE. Cells from a culture
containing > 99% BMMC were incubated with varying concentrations of SCF for 5 min before challenge with anti-IgE. Percentage of
cells that detectably released RMCP-II was determined by ELISPOT. Each bar represents the mean ± SEM of spot counts from four
wells, (b) Release of RMCP-II from anti-IgE treated BMMC (200 BMMC/well, from a culture containing, >99% mast cells) after
incubation with SCF (50 ng/ml) for varying periods of time. The graphic illustrates the increased number of spots in wells after 5, 15, or
30 min preincubation with SCF, compared to 60 or 120 min, or control wells (no SCF). Scale marker = 1 cm. Bars represent the
mean ± SEM of spot counts from six wells.
rat19-26 peritoneal mast cells, or mouse18 or human22 skin mast
cells, SCF did not directly induce mediator release from rat
BMMC under our experimental conditions. However, pre-
treatment of BMMC with SCF (> 10 ng/ml) for 5 min before
challenge with anti-IgE resulted in an approximately 2-5-fold
increase in mediator release (from 19% to 47%). Enhancement
of IgE-dependent mediator release by SCF was maximal after
short preincubations (5 min) and was not evident after
incubations over 3 hr. This effect has also been reported for
human skin22 and lung21 mast cells, and is most likely due to
internalization of c-kit receptor/SCF complexes following
ligand binding.27
In studies of mast cell function, it is customary to report
the effects of secretagogues or cytokines on mast cell
secretion in terms of percentage release of various media¬
tors.13'20'22'28-31 Typically, in accord with our own findings,
secretagogue-activated mast cell populations specifically release
10-50% of the stored mediators present in the cells. We were
interested in how values for specific mediator release might
reflect the extent to which individual BMMC within a
population respond to IgE-dependent stimulation, and whether
SCF-dependent enhancement in mediator release reflected
individual cells releasing more mediator, or increased numbers
of cells responding to stimulation.
Using the ELISPOT assay, we demonstrated for the first
time that the majority (80-90%) of the BMMC populations
were refractory to stimulation by either anti-IgE or specific
antigen, but the proportion of responding cells was significantly
increased by pretreatment with SCF. However, when the results
of ELISPOT assays and conventional mediator release assays
were directly compared (as in Fig. 6), the increase in percentage
total mediator release (approximately threefold) was greater
than the increase in the proportion of responding cells
(approximately 1-5-fold). Our results suggest that SCF
up-regulates secretion from mature BMMC in two ways: first,
by activating previously unresponsive cells as clearly shown by
© 1996 Blackwell Science Ltd, Immunology, 87, 326-333
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Figure 5. The effect of SCF on IgE-dependent RMCP-II release from
individual BMMC derived from cultures at different stages of maturity.
Cells were incubated in the presence (50 ng/ml for 5 min) or absence of
SCF before challenge with anti-IgE. (a) Representative result from a
culture containing less than 85% (i.e. 64%) mast cells. There was a
significant effect of anti-IgE (algE) compared to normal goat serum
(NGS, A, P < 0-001), but SCF had no significant effect on the release of
RMCP-II either with or without anti-IgE challenge. Similar results were
obtained with cultures containing 8, 36, and 41% mast cells, (b)
Representative result from a culture containing more than 85% (i.e.
94%) mast cells. The number of cells responding was significantly
increased after incubation with SCF (*P < 0 001). Similar results were
obtained from cultures containing 85, 87, 92, and 94% mast cells. In this
experiment, the responses of BMMC to anti-IgE or normal goat serum
were not significantly different. Each bar represents the mean ± SEM of
the spot counts from nine wells from each of two separate ELISPOT
assays.
the ELISPOT assays; and second, by enhancing mediator
release from individual cells. The latter conclusion was also
suggested by an increase in spot size from cells treated with
SCF, but we did not attempt to quantify this effect.
We also used the ELISPOT assay to investigate the effect of
SCF on the secretory pattern of individual BMMC at various
stages during culture. Pretreatment of BMMC with SCF
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Figure 6. (a) Conventional mediator release assay showing percentage
release of /Mtexosaminidase and RMCP-II from entire populations of
BMMC (from a culture containing >99% mast cells) tested in two
separate experiments. BMMC were sensitized with mouse monoclonal
IgE anti-DNP and then stimulated with DNP-BSA in the presence
(50 ng/ml for 5min before challenge) or absence of SCF. Each bar
represents the mean ± SEM from quadruplicate aliquots of 0-8 x 106
BMMC. (b) ELISPOT assays measuring the proportion of BMMC that
released RMCP-II, performed in parallel to the experiments in (a) using
aliquots of the same cell populations. Each bar represents the
mean ± SEM of spot counts from nine wells from each of two separate
ELISPOT assays. The increased mediator release in the conventional
assay (a) is clearly associated with an increase in the number of cells
responding to immunological stimulation as demonstrated in the
ELISPOT assay (b). A, significant difference from buffer or buffer/SCF
(P < 0-01); Significant difference from cells stimulated with DNP alone
(P < 0-05).
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BMMC (i.e. from cultures containing at least 85% mast
cells), but did not up-regulate secretion from cells derived from
immature cultures containing less than 85% mast cells. The
lack of an effect of SCF on IgE-dependent mediator release
from immature populations of BMMC might have reflected
effects of'contaminating cells' in these preparations. Immature
cultures contain other bone marrow-derived cells (especially
macrophages), which could potentially influence the effects of
cytokines on mast cells. Alternatively, lower expression of the
SCF receptor (c-kit) in developing cells, or differences between
mature and immature BMMC in the intracellular mechanisms
necessary for transducing the signal, may have contributed to
the apparent lack of SCF responsiveness in these populations.
Whether the different effects of SCF on BMMC at various
stages of growth/maturation in vitro reflect a similar phenom¬
enon in vivo remains to be determined.
Activation of the FceRl receptor in mast cells leads to
extensive tyrosine phosphorylation of intracellular intermedi¬
ates which are critically involved in signal transduction.32"35
Activation of the c-kit receptor by SCF also leads to tyrosine
phosphorylation of multiple cytosolic proteins,36 and overlap
between the two signalling pathways has already been
demonstrated in mouse bone marrow-derived cultured mast
cells37,38 and rat peritoneal mast cells,26 suggesting some
overlap in the mechanisms by which degranulation can be
triggered via the FceR 1 or the c-kit receptor. Our results suggest
that, in rat BMMC, SCF can prime the cell for subsequent
activation via the IgE receptor, but cannot directly induce
degranulation. To address the possibility that SCF was in some
way compensating for sub-optimal binding of endogenous IgE,
the BMMC were sensitized with IgE anti-DNP and challenged
with DNP. In these experiments (Fig. 6), pretreatment with
SCF resulted in similar increases in both the proportion of cells
responding to antigen and in the total amount of released
granule mediators as was previously observed in cells stimu¬
lated with anti-IgE without prior addition of exogenous IgE.
These results suggest that the effect of the cytokine was not
dependent on the degree of IgE binding.
Why do some cells remain refractory to IgE-dependent
stimulation even after preincubation with SCF? Failure of a cell
to respond to IgE-mediated stimulation could result from a
deficiency at any stage of the signal transduction pathway,
including inadequate FcbR 1 expression, insufficient IgE, lack of
intracellular transduction proteins, reduced intracellular cal¬
cium stores and/or reduced ion channel expression. Expression
of FceRl in mouse bone marrow-derived mast cell cultures
coincides with granule formation,39 suggesting that cultured
mast cells possess IgE receptors at the onset of maturation. In
addition, rat BMMC have surface bond endogenous IgE
throughout culture (confirmed by flow cytometry), and there¬
fore FceRl receptors, but these could be sub-optimal in some
cells. However, when cells were passively sensitized with
exogenous IgE, which increased occupancy of the IgE
receptors, a refractory population still remained indicating
that failure to respond was not related to the degree of IgE
binding. In rat basophil leukemia (RBL-2H3) cells40,41 and
human basophils and mast cells,42,43 stimulation of populations
of cells via the FceRl resulted in variable intracellular calcium
fluxes and oscillations. In addition, correlation of intracellular
calcium fluxes with mediator release from individual cells
indicated that a sustained rise in intracellular calcium, seen only
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in a proportion of the cells, was required to initiate secretion
(T. D. Kim, personal communication). Similar heterogeneity in
intracellular calcium responses could explain the large propor¬
tion of BMMC that fail to respond to immunological
stimulation in our study.
In summary, we showed that the cytokine, SCF, enhanced
mediator release from a population ofmature BMMC, and this
up-regulation was shown to be due to both activation of
previously unresponsive cells and augmentation of the secre¬
tory response in individual cells. The many similarities between
rat BMMC and rat MMC suggest that SCF may also be
involved in regulation of mast cell responses in the gut, acting
as a modulator of gastrointestinal immune responses.
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